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This study aims to compare the efficiency of conventional liposomes and surfactant-enriched 
vesicles (surfactosomes) using the hydrophilic drug salbutamol sulphate (SBS) and the 
hydrophobic drug beclometasone dipropionate (BDP) for pulmonary delivery via nebulisation. 
Initially liposomes and surfactosomes with or without cholesterol were prepared using thin film 
method and were compared for their VMD, span and drug entrapment. Their drug retention on 
extrusion through 5µm, 2µm, 1µm and 0.4µm polycarbonate membrane using mini-extruder 
was also studied. It was observed that liposomes were more stable than surfactosome.   
Particulate based proliposome technology was also used to study their potential for generating 
stable and inhalable dispersions. Mannitol was used as the carbohydrate carrier and on 
hydration; proliposomes and prosurfactosomes have generated liposomes and surfactosomes 
respectively. The VMD, span and zeta potential of the vesicles, and drug entrapment and drug 
retention on extrusion were studied. It was seen that lower proportions of SBS were entrapped 
using proliposome technology; hence, further extrusions through 5µm and 2µm were avoided. 
In vesicle with BDP, inclusion of cholesterol has decreased the drug entrapment and 
crystallisation of mannitol was observed.  
Nebulisation of liposomes and surfactosomes with and without cholesterol was studied using 
PARI LC sprint air jet nebuliser, Aeroneb pro and Beurer iH50 vibrating mesh nebulisers. Two 
stage (Twin) impinger was used to study the potential suitability of the generated vesicles for 
inhalation. VMD, span and zeta potential of vesicles before and after nebulisation was studied. 
BDP delivery and retention in both stages of the twin impinger was also studied. It was found 
that surfactosomes without cholesterol delivered maximum BDP to the twin impinger. 
Nebulisers suitable for all four formulations were also studied. Beurer iH50 delivered maximum 
BDP via liposomes with and without cholesterol, Aeroneb Pro delivered maximum BDP via 
surfactosomes with cholesterol to upper impinger while PARI LC sprint delivered maximum 
BDP via surfactosomes with cholesterol. VMD and span of aerosols generated from all three 
nebulisers were also studied. 
Stability of liposomes and surfactosomes prepared using proliposome technology was studied. 
VMD, span, zeta potential and BDP retention before and after spray drying and freeze drying 
were investigated. It was concluded that liposomes and surfactosomes were equally stable when 
spray drying was used whereas liposomes were more stable that surfactosomes when freeze 
drying was conducted. X-ray diffraction, scanning electron microscopy and transmission 
electron microscopy were used to analyse the characteristics of proliposomes and 
prosurfactosomes. A reduction in size and crystallinity was observed after spray drying and 
freeze drying of the formulations. Stability was also studied on storing proliposome and 
prosurfactosome in different environmental conditions like 5-6°C, room temperature and 40°C 
for a period of 3 months. It was concluded that both proliposomes and surfactosomes were most 
stable in 2-8°Cwhereas least stable in 40°C. Proliposomes were more stable than 
prosurfactosomes regardless of the storage temperature. 
Formulation and characterisation of novel prosurfactosomes and comparing it with conventional 
liposomes for pulmonary drug delivery is the novelty of this thesis.  
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Phospholipids are major components of cell membranes. They are made from a glycerol 
backbone, phosphate headgroups and fatty acid chains. They act as building blocks of 
every cell (Cevc and Paltauf, 1995). A phospholipid molecule consists of diglycerides, a 
phosphate group and an organic molecule like choline as shown in Figure 1.1. 
Diglyceride is glycerine which has two fatty acid chains and covalently bonded to 
glycerol via ester linkage. Glycerol is part of the hydrophilic head and it also helps the 
fatty acid tail to connect to phosphate headgroup. The carbon 3 of glycerol consists of 
polar headgroup, i.e. water soluble and carbon 1 and 2 consists of fatty acid which 
forms the non-polar tail i.e. lipid soluble (Berg et al., 2002). Hence, phospholipids are 
described as amphipathic molecules owing to their polar and non-polar moieties (Lasic, 
1988). Phospholipids are made of diverse headgroups, and diverse degree of saturation 
and length of hydrocarbon chains. It has been found that when phospholipids are 
combined with water they form hollow spheres (Bangham et al., 1965). Hydrophilic 
head contacts the aqueous medium forming the outside and inside of the vesicles that 
are in contact with the aqueous environment. Hydrophobic tails mutually attracts and 
remain sandwiched in between the polar moieties. This arrangement avoids the contact 
of hydrophobic tail with water. These phospholipids have a phenomenal property of 
self-assembling when dispersed in aqueous media that are free from detergents and co-
solvents. 
 




Micelles are spherical amphipathic molecule aggregates which arrange themselves in a 
way that protects their hydrophobic moieties from the aqueous environment. Micelles 
have very small particle size of about 50nm. Micelles contain polar head moiety on their 
outer side which contacts with the surrounding water and non-polar tail which is 
orientated towards the inner side away from the aqueous phase. Micelles create a highly 
hydrophobic microenvironment within their core which helps in maximum 
entrapment/solubility of hydrophobic drugs. This may increase the bioavailability of the 
drug (Wei et al., 2009).  
1.3. Vesicles 
Vesicles are small membrane enclosed sack which has the ability to transport materials 
across biological barriers (Honeywell-Nguyen and Bouwstra, 2005). These vesicles are 
separated from the surrounding with phospholipid layers and can be divided into range 
of types depending on their morphology such as unilamellar or multilamellar vesicles. 
Their membrane is similar to the plasma membranes, thus, they tend to fuse with the 
desired cell and release their contents into the cytoplasm.  Vesicles can carry both 
hydrophilic and lipophilic molecules and, thus they are extensively used for various 
purposes like drug delivery, drug targeting, protection of proteins against degradation, 
controlled drug release and protection of drug against metabolism (Sudhamani et al., 
2010a). Most commonly described vesicles in pharmacy are niosomes and liposomes 
(Honeywell-Nguyen and Bouwstra, 2005) .  
1.4. Niosomes 
Niosomes are non-ionic surfactant vesicles that are used in drug delivery to entrap a 
solute in a manner analogous to liposomes (Sudhamani et al., 2010b). Niosomes are 
usually formed using a mixture of non-ionic surfactants of the alkyl or dialkyl 
polyglycerol ether class and cholesterol followed by hydration in aqueous media. The 
surfactants used are uncharged single chain molecules, unlike liposomes which may 
have charged double chained phospholipids. As shown in Figure 1.2, niosomes can 
entrap both hydrophilic and lipophilic drugs, either in the aqueous core or in vesicular 
membranes made of lipid materials (Srinivas et al., 2010). They have many properties 
similar to liposomes in delivering drug to various regions of the body. They are more 
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stable and made of materials that are cheaper than those made to manufacture 
liposomes. The size of niosomes is observed using microscopic techniques to be in the 
range of 10nm to few micrometers. Niosomes have disadvantages like tendency of 
aggregation, fusion, hydrolysis and leakage of encapsulated drugs from niosomes to the 
surrounding aqueous environment (Sudhamani et al., 2010b). 
 
Figure 1.2 Structure of Niosome (Taken from Sudhamani et al., 2010). 
 
1.5. Liposomes 
Liposomes are hollow phospholipid vesicles normally dispersed in hydrophilic solvent. 
Liposomes are formed due to the self-assembly of phospholipids in the presence of an 
aqueous environment as seen in Figure 1.3. A liposome surrounds an aqueous internal 
core that may contain drug molecules and sustain their release. Liposomes are regarded 
as successful carriers for a wide range of drugs having different water solubility (Lopes 




Figure 1.3 Structure of Niosome (Taken from Sudhamani et al., 2010) 
        
Liposomes were first discovered by Alec D Bangham in 1961 in England while he was 
studying phospholipids and blood clotting (Sharma et al., 2009). Some liposomal drug 
formulations such as Doxil
®
 (PEGylated liposomal doxorubicin) and Daunoxome
®
 
(daunorubicin citrate liposome injection) have already been used in clinic (Huang et al., 
2010b). Liposomes have also been extensively investigated as carriers for antimicrobial 
drugs, steroidal drugs and vaccines. As shown in Figure 1.4, a liposome can be used to 
deliver many materials into the body. The size of liposomes ranges between 25nm and 
20µm (Kozubek et al., 2000). Liposomes act as delivery vehicles for drugs, genetic 
materials, enzymes and other macromolecules and facilitate the uptake of these 
materials by living cells (2004). These vesicles have unique structures which are 
capable of entrapping hydrophilic, lipophilic, amphiphilic and charged hydrophilic 
drugs (Prajapati et al., 2011). Due to the amphipathic nature of liposome, it can entrap 
hydrophilic drugs into its aqueous phase and incorporate hydrophobic drugs in its 
phospholipid bilayers (Lopes et al., 2004, Huang et al., 2010b). Unilamellar liposomes 
are preferred for entrapping hydrophilic drugs whereas multilamellar liposomes are 
preferred for entrapping lipophilic drugs. Due to the presence of large range of 
phospholipids with various combinations and characteristics to prepare liposomes, drug 
delivery and targeting using liposomes may vary with accordance to the materials used 
to manufacture the liposomes. Liposomes can have various molecules attached to their 
surface such as the polymer polyethylene glycol or antibodies. Liposomes may also 
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have the ability to fuse with cell membranes, thus, releasing the entrapped drug into the 
internal components of the target cell. This is illustrated in Figure 1.5. 
 
Figure 1.4 Use of liposomes to deliver different materials into the body (Taken from Wikipedia) 
http://en.wikipedia.org/wiki/Liposome 
 




For liposomes to form, the hydration procedure must be undertaken at a temperature 
significantly exceeding the temperature at which phospholipid passes from the gel phase 
(Lß’) to the liquid crystalline phase (Lα) where its flexibility is higher. This temperature 
is called the phase transition temperature(Tm) which is a characteristic for each 
phospholipid depending on the type of its polar head-group and the length and degree of 
saturation of its hydrophobic alkyl chains. As demonstrated in Figure 1.6, when aqueous 
phase is added to a thin film of phospholipid, the hydration of the outer monolayer 
predominates compared to the inner layers. This results in the expansion of the polar 
headgroups of the phospholipid molecules and formation of blisters. Aqueous phase 
penetration through these “blisters” results in formation of phospholipid bilayers (Lasic, 
1988). The most commonly used liposomes are composed of synthetic lipids (Misra et 
al., 2009). 
 
Figure 1.6 A schematic representation for the formation of MLVs on hydration of a dry phospholipid thin 
film (Taken from Lasic, 1988).   
1.6. Role of Cholesterol 
Cholesterol can be included in the mixture that forms the bilayers because of its effect 
on the physical properties, for instance cholesterol may exhibit the following properties 
when included in liposomes: 
1. Acts as a fluidity buffer and intercalates with phospholipid molecules (Charnvanich 
et al., 2010).  
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2. Enhances the liposome rigidity and stability in vitro and in vivo (Benson, 2010, 
Samad et al., 2007). 
It has been studied that cholesterol tends to dry the lipid/water interface of vesicular 
membranes  and enhances close contact and increases van der Waals interactions 
between adjacent lipid molecules. This contributes to the reduced membrane 
permeability and prevention of leakage on using cholesterol in the liposomal 
formulation (Wang et al., 2006). 
1.7. Zeta potential for stability of colloids 
Zeta potential is an electric charge usually carried by colloidal suspensions or 
emulsions. This net charge of the particle affects the distribution of counter ion 
surrounding the interfacial region close to the surface (Attwood and Florence, 2012). 
The separation of charge that occurs in the interface of two phases in the colloidal 
system is called electrical double layer as it consists of two layers with opposite charge. 
This may be due to the ionisation of substance on surface, preferentially absorbed ions 
of one sign or due to preferential ion adsorption of deliberately added chemicals. 
Many important properties of the colloidal system is determined by its electrical charge 
directly or indirectly. This charge distribution determines the interaction energy 
between the particles in colloidal system and its aggregative stability (Olton, 2008). 
Electrostatic repulsion between the particles determined its zeta potential. The greater 
the zeta potential the more is the repulsion between particles and more stable will be the 
system. Derjaguin, Landau, Vervey, and Overbeek (DLVO) developed a theory which 
deals with the stability of colloidal system in 1940s. They suggested that the stability of 
the colloidal system depends on the total potential energy function when particles are in 
Brownian motion. When the repulsive power is more than attraction the particles may 
resist aggregation and flocculation, thus, increasing the stability of the system (Kirby 
and Hasselbrink, 2004).  
1.7.1. Basic theories of double diffusion layer 
There are many theories and models proposed by which zeta potential of a colloidal 
system emerged from.  
Helmholtz model (1879) where Helmholtz put the concept of double layer at the 
surface of metal in contact with electrolyte (Anchordoguy et al., 1987). His model 
suggested linear potential drop from the surface. However, he did not take into account 
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ion diffusion, adsorption on the surface and solvent/surface interactions (Gregory, 
2006). It was followed by Gouy-chapman model (1909- 1913) where the surface was 
considered flat, infinite, uniformly charged and ions were considered as point charge. 
This model also considered the exponential potential decrease from the surface 
(Abdelwahed et al., 2006, Oldham, 2008, Stojek, 2010). It was further modified by the 
Stern model (1924) which was a combination of Helmholtz’s theory of rigid layer and 
Gouy-Chapman’s theory of diffuse layer (Anchordoguy et al., 1987). He made 
assumptions like finite size of ions and ion cannot approach the surface at the distance 
smaller than the magnitude of ionic radius (Abdelwahed et al., 2006). It also introduced 
the slipping place at the boundary of diffuse layer (Gregory, 2006). Further 
developments were made to the stern model by Graham model (1940) where he 
proposed the existence of three regions. The inner Helmholtz plane (IHP), the outer 
Helmholtz plane (OHP) and the diffuse layer (Grahame, 1947). 
1.7.2. Double diffusion layer model 
The liquid layer surrounding the charged particle exists in two layers: stern layer 
(strongly bound region) and diffusion layer (loosely bound region). This is illustrated in 
Figure 1.7. The stern layer is the inner sub layer that is formed close to the surface and 
where the counter-ions are specifically adsorbed. The outer part is called the diffusion 
layer. There is another characteristic distance called slipping plane which is associated 
with the tangential motion of the liquid relative to the surface. This plane separates the 
stern charge from the diffuse charge around the particle. When the particle moves due to 
Brownian motion, ions within the slipping plane moves with the particle whereas the 
ions beyond the slipping plane do not travel with particle. The potential at this boundary 
is zeta potential (Attwood and Florence, 2012). The zeta potential of the particle varies 
with distance from the surface uses the concept of diffusion double layer. The decay 
increases exponentially with distance from the shear plane. The inverse of the decay 
constant is a distance called the Debye double layer thickness. The higher the ionic (free 
salt) concentration, the faster the decay and smaller the double layer thickness (Kirby 




Figure 1.7 Model of double diffusion layer (Attwood and Florence, 2012) 
 
1.7.3. Origin of zeta potential 
The origin of zeta potential is due to the following factors 
i. Ionisation of surface groups 
Dissociation of acidic group on the surface of particle tends to give a negative charge to 
the particle surface, whereas the basic group tends to give a positive charge to the 
particle surface. pH at which the net electric is zero is called as iso-electric point. The 
magnitude of charge depends on pH of the solution as well as the strength of the acidic 
and basic group. 
ii. Differential loss of ions from the crystal lattice 
If an ionic compound starts dissolving its ions, the particle may acquire surface charge. 
If the positive and negative ions dissolve in equal quantity, the particle will be 
uncharged. However, if the positive ion is dissolved more than the negative ion it will 





iii. Absorption of charged species 
Surfactant ions may be specifically adsorbed onto the surface of a particle. Cationic 
surfactant gives positive charge whereas anionic surfactant gives negative charge to the 
surface (Everett, 1988, Berg, 2010) 
1.7.4. Factors affecting zeta potential 
i. pH 
pH of the sample is the most important factor affecting the zeta potential in aqueous 
medium. In Alkaline suspension, the particle tends to aquire more negative charge 
whereas in acidic suspension the particle aquires positive charge. Therefore a zeta 
potential versus pH curve will be positive at low pH and lower or negative at high pH. 
The point in plot where the zeta potential is zero is called the isoelectric point. 
ii. Ionic strength 
The concentration of ion and its valency in solution determines the thickness of the 
double layer. The high ionic strength compresses the electric double layer. The ion with 
higher valency compresses the layer more than ion with low valency. 
  
iii. Concentration of formulation component 
The concentration of different individual substance in the formulation can affect the zeta 
potential of the product. Hence, this can help in formulating a product with maximum 
stability (Everett, 1988, Hunter and White, 1993).  
1.7.5. Different phospholipids affecting zeta potential 
The type of phospholipid added does have a major effect on the zeta potential of the 
formulation. Surface charge is based on the structure of the lipid. Phosphotidyl choline 
(PC), also called as lecithin, at physiological pH is a neutral zwitter ion. Similarly, 
phosphotidylethanol amines are neutral zwitter ions at physiological pH 7.4. However, 
phosphotidyl serine (PS) and phosphotidyl glycerol (PG) were found to have negative 
charge at physiological pH and tend to increase the negative zeta potential of the 
vesicle. PG and PS based vesicles usually exhibit a net charge of -1 (Yandrapati, 2012).  
It was demonstrated that lipid vesicles made of acidic phospholipids (PS, PG) possessed 







neutral pH (Yandrapati, 2012). Synthetic lipids like DPPC and DMPC possess neutral 
to slightly negative surface charge (Wang, 2000). Hence, the surface charge of the 
vesicles can be altered by changing the lipid or mixing them together. 
1.8. Types of liposomes 
As shown in Figure 1.8, liposomes can be classified according to their lamellarity into 
multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), large unilamellar 
vesicles (LUVs) and oligolamellar vesicles (OLVs). Table 1.1 gives an overall review 
of the types of liposomes and their approximate size. 
 
Figure .1.8  Schematic representation of different types of liposomes with different lamellarity 
(Taken from Bochot et al., 2000) 
 
 
Table 1.1 Vesicle Types with their Size and Number of Lipid Layers (adapted from Samad et al., 
2007) 
Vesicle type 
Abbreviation Diameter size Number of 
lipid bilayers 
Multilamellar vesicles 
MLVs More than 0.5µm More than 5 
Oligolamellar vesicles 
OLVs 0.1-1µm 2-3 
Multivesicular liposomes 
MVLs More than 1µm Multi 
compartmental 
structure 
Small unilamellar vesicles 
SUVs 20-100nm 1 
Large unilamellar vesicles 
LUVs More than 100nm 1 
13 
 
1.8.1. Multilamellar vesicles (MLVs) 
Multilamellar vesicles (MLVs) have several lipid bilayers (up to 14) in “onion-like” 
layers. Each layer is separated from the next one by a space of aqueous solution as 
shown in Figure 1.9. An MLV typically has a VMD larger than 0.5µm. MLVs are 
generally prepared by hydrating a thin film of phospholipids followed by vigorous 
shaking via vortex mixing, sonication or hand shaking (Lasic, 1988). The aqueous phase 
added should have a temperature above the phase transition temperature (Tm) of the 
lipid system used in the formulation. The preparation protocol of MLVs should be 
controlled to obtain liposomes with relatively narrow size distribution. MLVs can also 
be prepared from preformed SUVs or LUVs by controlled fusion, freeze-thawing or 
dehydration-rehydration methods. MLVs are generally preferred for entrapping 
lipophilic drugs because of the large number of bilayers they have in which lipophilic 
molecules can be incorporated. 
 
Figure.1.9 Onion like structure of multilamellar liposomes (Taken from Sciences, 2012) 
 
1.8.2. Oligolamellar vesicles (OLVs) 
MLVs possessing only two or three phospholipid bilayers may be referred to as 
oligolamellar vesicles (OLVs). They are 0.1-1µm in size (Samad et al., 2007). OLVs 
can be made using reverse phase evaporation and are thus, sometimes called reverse 
phase evaporation vesicles (REVs) (Szoka and Papahadjopoulos, 1978). They are made 
by formation of water in oil emulsion by brief sonication of an aqueous phase/buffer 
and phospholipid dissolved in an organic solvent (diethylether or isopropylether or 
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mixture of isopropyl ether and chloroform). The organic phase is evaporated under 
reduced pressure to form a viscous gel. This in turn forms a mixture of OLVs and LUVs 
by removal of residual solvent by continued rotary evaporation under reduced pressure 
(Dua et al., 2012). The aqueous phase is added at this point.   
1.8.3. Small unilamellar vesicles (SUVs) 
Small unilamellar vesicles (SUVs) are made of single phospholipid bilayer and have a 
size range of 20-100nm (Kozubek et al., 2000). SUVs are prepared by injecting an 
ethanolic solution of phospholipid in an aqueous phase above the phase transition 
temperature of the phospholipid (Batzri and Korn, 1973b). Alternatively, probe or bath 
sonication of MLVs is a common technique employed for formation of SUVs (Lasic, 
1988). SUVs can also be made by detergent depletion technique in which MLVs are 
dissolved in detergent which is later removed by dilution, dialysis, chromatography, 
adsorption, ultrafiltration or centrifugation to form SUVs (Brunner et al., 1976, Lasic, 
1988). 
1.8.4. Large unilamellar vesicles (LUVs) 
LUVs have single lipid bilayer and have a size ranging from 0.1 to 1µm. LUVs can also 
be of cell size (Kozubek et al., 2000). LUVs can be utilised for provision of higher 
entrapment of hydrophilic drugs. Injection of ether solutions of phospholipids into water 
warmed to a temperature above the Tm of the dissolved phospholipid(s) yields LUVs 
(Batzri and Korn, 1973a). Reverse phase evaporation method causes the production of 
both OLVs and LUVs (Szoka and Papahadjopoulos, 1978). In this method, a buffer is 
used for the formation of w/o emulsion of phospholipid. The organic phase is removed 
using rotary evaporator and a gel containing LUVs is obtained by sonication. It can also 
be made by ethanol injection of phospholipids in an aqueous phase (Lasic, 1988). Even 
LUVs can be prepared from preformed MLVs by size extrusion as extrusion decreases 
the lamellarity of the liposome (Berger et al., 2001a).   
1.9. Advantages of using liposomes over traditional 
drug delivery systems 
Liposomal drug delivery systems has many advantages like reduced toxicity, sustained 
drug release, manipulation of drug pharmacokinetics, targeting specific tissues and 
protection of encapsulated drugs from enzymatic degradation. 
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1.9.1. Reduced toxicity 
Liposomes are non-toxic, biodegradable and non-immunogenic drug carriers because 
they are prepared from phospholipids which are very similar to the components of the 
biological membranes and respiratory tract surfactants (Huang et al., 2010a). Due to 
advancement in the research of preparation and formulation of liposomes, many 
liposome preparations can provide greatly enhanced drug encapsulation. Drug 
encapsulation in liposomes may prevent drug toxicity or attenuate adverse effects by 
retaining and improving the therapeutic effect of the drug. This is achieved by 
sustaining the drug release from the liposomes and enhancing the targeting of the drug 
to the desired tissue. 
1.9.2. Sustained delivery system 
Following inhalation of liposomal aerosols, they may provide sustained release of the 
drug, which help in localising the drug action (e.g. in the lung) for prolonged durations 
in the respiratory tract tissue (Huang et al., 2010a). The drug encapsulated in the 
liposome’s central aqueous core has to pass across each bilayer of the liposome to be 
released, thus this provides the sustained release property and reduces the need for 
frequent dose administration (Chrai et al., 2001). It is hence, expected that liposomes 
made from many bilayers might be desirable for provision of prolonged drug release. 
1.9.3. Alteration of the Pharmacokinetics of drugs  
Drug encapsulation in liposomes may significantly alter the pharmacokinetic and 
pharmacodynamic properties of the drug, thus, enhancing drug uptake, delaying drug 
clearance and avoiding frequent drug administration (Gibbons et al., 2011, Alino et al., 
1999). 
1.9.4. Avoidance of side effects and local irritation 
Liposomes target specific cell type, thus, minimising the uptake of the encapsulated 
drug by organs other than the targeted one. When given via inhalation, liposomes may 
reduce drug levels in the systemic circulation, hence minimising the potential of adverse 




1.9.5. Protection for the encapsulated drug 
Drug or material encapsulated inside liposomes is protected from direct contact with the 
external environment until it is released from the liposomes; this may minimise or 
prevent degradation of the drug because its encapsulation in the liposome can protect it 
from the external enzymatic environment (Samad et al., 2007, Sharma et al., 2009).  
1.10. Drawbacks of conventional liposomes 
Liposomes have been extensively studied for parenteral, transdermal, nasal and 
pulmonary drug delivery. Liposomes have been used for potential application in 
transdermal drug delivery for treatment of various diseases like cardiovascular diseases, 
Parkinson’s disease, Alzheimer’s disease, depression, anxiety, skin cancer, female 
sexual dysfunction, post-menopausal bone loss and urinary incontinence (Patel et al., 
2009). The use of liposomes for transdermal delivery is limited because of the barrier 
provided by the outer most layer of skin epidermis called stratum corneum. The 
conventional liposomes do not have great flexibility, thus, it becomes difficult for them 
to pass through small skin openings. The rigid property of liposomes also causes 
problems in treating pulmonary diseases like asthma, pneumonia, chronic obstructive 
pulmonary disorder and acute lung injuries, because rigid vesicles may not be 
adequately aerosolised because of their resistance against nebulisation (Saari et al., 
1999, Darwis and Kellaway, 2001). Hence, it became necessary to form a more flexible 
liposome to overcome these problems which is called elastic vesicles or Transfersomes 
(Prajapati et al., 2011). 
1.11. Transferosomes termed as “surfactosomes” 
This new class of liposomes termed Transfersomes was first registered by the German 
company IDEA AG by Gregor Cevc in 1991 (Benson, 2010, Prajapati et al., 2011). 
Transferosomes are ‘the carrying body’; In Latin, the word ‘Transferre’ means a “to 
carry across’ and the Greek word ‘soma’ means ‘body’. In this study transferosomes are 
termed as surfactosomes in order avoid the usage of trademark word. Transferosomes 
have been previously studied extensively for skin delivery. It was observed to be more 
elastic than conventional liposome which helps it to pass through stratum cornuem of 
skin with less leakage of drug. Along with phospholipids, these transferosomes are also 
composed of surfactants such as sodium cholate, deoxycholate, Span, Tween and 
dipotassium glycyrrhizinate in appropriate ratios (Trotta et al., 2002). These surfactants 
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act as ‘edge activators’ to destabilise the lipid bilayers and increases deformability and 
flexibility of the vesicles (El Maghraby et al., 1999). Due to its flexible nature, 
transferosome can squeeze through channels that are one-tenth of its diameter (Benson, 
2010). The flexibility of transferosome minimises the risk of bilayer rupture and 
subsequent drug leakage (Prajapati et al., 2011). Incorporation of the ‘edge activator’ in 
the form of surfactant was the basic principle of Cevc’s original Transferosome 
approach.Transferosomes  have better penetration ability through the skin and is highly 
adaptable, ultra flexible, stress-responsive, when compared with conventional liposomes 
(Patel et al., 2009). They are also permeable, having ‘softened’ bilayers. They also have 
the capability to self-optimize and self-repair themselves, thus, becoming able to 
squeeze through small gaps between the cells despite their large size (Dubey et al., 
2008). This high deformability gives better penetration of intact vesicles as shown in 
Figure 1.10 (Prajapati et al., 2011), enabling them to cross various cellular barriers 
efficiently. Since then, huge amount of research has been conducted to investigate on 
these surfactosomes under different titles like transferosomes, flexible vesicles, 
ultradeformable vesicles and elastic vesicles. 
In this study a similar system for pulmonary drug delivery has been hypothised and 
studied for its usefulness. Transferosomes are renamed as surfactosomes for pulmonary 
delivery. Here, surfactosomes are believed to be more elastic/flexible than conventional 
liposomes, hence, can carry drug without much leakage when passed via nebulisers for 
pulmonary drug delivery.  Like liposomes, surfactosomes possess an aqueous core 
surrounded by the lipid bilayers..  
 
Figure.1.10 Schematic representation of vesicular penetration via two micropores (Taken from Prajapati 




The term surfactant designates a substance which exhibits some surface and interfacial 
activity. Surfactants are anionic surfactants, non-ionic surfactants or cationic 
surfactants. These surfactants, also termed “edge activators”, have been reported to 
confer elastic properties to lipid vesicles, allowing dramatically improved flexibility and 
adaptability to deliver agents to the target. In many vesicle-based formulations, non-
ionic surfactants have been used (Mahale et al., 2012). The packing characteristics of 
lipids in the bilayer are affected by the type of surfactant and thus, efficient drug 
delivery system can be engineered by selecting the right surfactant with the right lipid in 
the right proportion. 
Hydrophilic/ lipophilic balance (HLB) gives a measure of the physicochemical 
properties of surfactants in terms of their affinity for or solubility in water or lipid. HLB 
values are 4.3, 15 and 16.7 for Sorbitan monooleate (Span 80), Polyoxyethylene 
sorbitan monooleate 80 (Tween 80) and sodium cholate respectively (El Maghraby et 
al., 2004). Based on these HLB values, the affinity for lipids is expected to be in the 
order of Span 80 ˃ Tween 80 ˃ Sodium cholate (i.e. the surfactant with highest HLB 
value has the lowest affinity to lipid). Considering the distribution between lipid and 
aqueous components, there will be an effective molar ratio (Re) of surfactant to lipid. 
This effective molar ratio describes the actual amount of surfactant in liposomes relative 
to the lipid concentration (El Maghraby et al., 2004).  
1.12.1. Sorbitan Monooleate (Span) 
Span 80 is known as commercial name of sorbitan monooleate containing several kinds 
of esters. Span 80 has a relatively small head-group compared with Tween 80, as it 
lacks the Polyoxyethylene units. It has an HLB of 4.3, is lipophilic and immiscible with 
water and thus, its lipid to water distribution coefficient is high (El Maghraby et al., 
2004). 
1.12.2. Polyoxyethylene sorbitane monooleate (Tween) 
Tweens are probably the most commonly used non-ionic surfactants in pharmaceutical 
industry. Tween 80 is a non-ionic surfactant with a large head-group and an HLB value 
of 15, is miscible with water, thus, it is expected that Tween 80 will distribute more in 
the water compared to lipid. Tween 80 comprises a partial oleic acid ester of sorbitol-
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derived cyclic ether, condensed with 20 ethylene oxide units per molecule (Simoes et 
al., 2005).  
1.12.3. Sodium cholate 
Sodium cholate (cholic acid) is a water-soluble bile-salt. An expansion of the vesicles 
takes place and momentary defects are induced in liposomal membranes on addition of 
sodium cholate to lipid bilayers. It leads to enhanced permeability for molecules 
(Subuddhi and Mishra, 2007). Number of factors like chemical nature and concentration 
of the bile salt, molecular structure of the lipids, and size and  shape, type of buffer and 
pH and temperature of the dispersion may affect the interaction of bile salts (e.g. sodium 
cholate) with the phospholipid vesicles (Subuddhi and Mishra, 2007). 
1.13. Anti-asthma drugs 
There are many anti-asthma drugs. In this review, the discussion is limited to the model 
bronchodilator salbutamol sulphate (SBS) (Figure 1.10) and model prophylactic steroid 
beclometasone dipropionate (BDP) (Figure 1.11). These two drugs are probably the 
most commonly used in the treatment of asthma. 
1.13.1. Salbutamol sulphate (SBS)  
Salbutamol sulphate (SBS) is a selective β2 adrenoreceptor agonist having 
bronchodilatory effect (Tanwar, 2007). Its chemical structure demonstrates its 
hydrophilic characteristics and is shown in Figure 1.11. It is useful in therapeutic 
management of bronchial asthma, chronic bronchitis and emphysema (Huang et al., 
2010a). SBS can be used in various dosage forms like peroral tablets, injections or 
aerosols. Many side effects are observed when this drug is given in conventional oral or 
injectable formulations. When taken orally it is readily absorbed from the 
gastrointestinal tract. It also undergoes first pass metabolism in the liver (Tanwar, 
2007). Hence, the preferred route of delivery is via inhalation for its effect on lungs or 
slow intravenous injections for direct effect on bronchial smooth muscles (Huang et al., 
2010a). SBS is widely used as amorphous spray dried product for inhalation (Corrigan 
et al., 2004). As the plasma half-life of the drug ranges from 4 to 6 hours, the 
recommended dose frequency is every 4 to 6 hours (Bendas and Tadros, 2007). Thus, its 
short biological half-life and short duration of action are the main drawbacks (El-Gendy 
et al., 2009). Hence, it is necessary to formulate a controlled release drug delivery 
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system for SBS to avoid the frequent administration of the drug and potentially 
minimise its adverse effects. The use of liposomes for SBS may constitute one form of 
sustained delivery formulations for SBS (El-Gendy et al., 2009).  
Major side effects of SBS are manifested by skeletal muscle tremors, tachycardia and 
other types cardiac arrhythmias. The side effects are reversible. Some rare side-effects 
include urticaria, angioedema, hypotension, and collapse have also been reported 
(Lulich et al., 1986) 
 
 
                           Figure.1.11 Chemical structure of salbutamol sulphate 
 
1.13.2. Beclometasone dipropionate (BDP) 
Beclometasone dipropionate (BDP) is a water-insoluble (i.e. hydrophobic) steroid 
(Figure 1.12). BDP is highly soluble in chloroform, and freely soluble in acetone and in 
ethanol. However, is only slightly soluble in water (i.e. 49.39mg/L). Thus, when 
incorporated into the phospholipid of liposomes it is expected to associate more with the 
lipid bilayers instead of the aqueous spaces. For treatment of asthma, it is convenient to 
deliver BDP as aerosols from aqueous suspension via nebulisation for the treatment of 
asthma and other inflammatory lung diseases (Batavia et al., 2001) especially in the 
initial stage of treatment (Zeng et al., 2000). Direct administration of steroids like BDP 
to the lung has been found to cause localised side-effects manifested by oral candidiasis 
and dyspnea. Hence, the use of liposomes formulation of BDP may have an advantage 
over microcrystalline BDP suspensions since liposomes can provide sustained release 
and proper solubilisation matrix for this drug. Delivery of BDP to the lung via 
nebulisation using liposomes has been reported to be highly suitable (Saari et al., 1999, 
Darwis and Kellaway, 2001).  
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A proportion of BDP tends to crystallise in liposomal formulations due to the 
incompatible steric fit between the steroid and the liposome bilayers and its limited 
solubility in phospholipids. This observation has been reported upon the detection of 
large amounts of crystalline steroid after extrusion and during storage of the BDP 
liposome formulations (Batavia et al., 2001). Moreover, there are many concerns about 
giving corticosteroid drugs like BDP in large doses since systemic side effects of this 
drug like adrenocortical suppression, skin changes (thinning, bruising) and cataract have 
been reported (Zeng et al., 2000). Therefore, ideally maximised targeting of the 
administered dose of BDP to the site of action in the respiratory tract should be 
achieved in order to obtain a localized therapeutic effect minimised amount gaining 
access to the systemic circulation (Zeng et al., 2000).  
 
   Figure.1.12 Chemical structure of Beclometasone dipropionate (BDP)  
 
1.14. Instability of liposomes and surfactosomes in 
aqueous media 
The chemical and physical properties of liposomes and surfactosomes are critical 
parameters affecting the performance of drug loaded into the vesicles. These vesicles 
are very unstable in aqueous media. Instability manifestations are vesicle aggregation, 
bilayer fusion, and phospholipid hydrolysis and oxidation with concomitant leakage of 
the originally entrapped drug (Ahn et al., 1995). This could greatly shorten the shelf-life 
of formulation, or change the pharmacokinetic profile of the encapsulated material. 
Many formulation ingredients like buffer, solvent and pH modifier may also affect the 
stability of liposomes. Hydrolysis of ester bonds linking the fatty acids to glycerol 
backbone and peroxidation of unsaturated acyl chains are the main chemical instabilities 
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affecting liposomal phospholipids (Shaji and Bhatia, 2013). Hence, storage of these 
vesicles as dry powders has been considered to improve their stability during storage 
(Desai et al., 2002a). Many techniques are employed to manufacture dry powders of 
liposomes like freeze drying (Lu and Hickey, 2005) and spray drying (Lo et al., 2004). 
Alternatively, proliposome technology is an approach used to manufacture stable 
phospholipid formulations that can generate liposomes upon constitution with aqueous 
phase prior to administration by patient (Payne et al., 1986b, Perrett et al., 1991). 
1.14.1. Freeze drying (lyophilisation) 
Freeze drying is commonly known as “lyophilisation” and is considered a promising 
means of extending the shelf-life of liposomes. As freeze drying is a low temperature 
process it is unlikely to cause thermal degradation of liposomes (Pikal, 2006). This 
process offers protection against various conditions that might cause liposomal 
instability in aqueous dispersions, thus, yielding a product with a greatly extended shelf-
life (Crommelin and Van Bommel, 1984, Bridges and Taylor, 2001). Lyophilisation is a 
drying process which converts solutions of thermo-labile materials into solids having 
sufficient stability for distribution, storage and aerosol delivery (Lu and Hickey, 2005, 
Pikal, 2006). Freeze drying can be viewed as a three-step process consisting of freezing, 
primary drying and secondary drying. In freeze drying, most of the water is converted 
into ice during the freezing stage. Ice is subsequently removed by direct sublimation in 
the primary drying stage. Most of the unfrozen water is then removed in the secondary 
drying stage by desorption (Pikal, 2006). 
Freeze drying equipment is relatively expensive and long processing time is needed to 
produce dry liposomes (Pikal, 2006). Both freezing and drying may cause instability 
problems and stress to liposomes as a result of the induced structural or functional 
damage to the vesicles during freezing and drying. This in turn leads to leakage of the 
encapsulated drug on rehydration, thus compromising integrity of liposome 
formulations (Bridges and Taylor, 2001). Liposome bilayers depend for their stability 
on hydrogen bonding between water molecules and the polar head groups of the 
phospholipid molecules in liposomes. The process of drying leads to loss of water 
which leads to changes in the bilayer behavior and loss of liposome integrity. This 
further leads to bilayer damage, fusion or vesicle aggregation, ultimately leading to loss 
of the previously entrapped material (Bridges and Taylor, 2001). Freezing may cause 
phase transition changes, osmotic stress and expansion of the bilayers due to ice 
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formation (Bridges and Taylor, 2001). To maintain the same particle size distribution of 
liposomes after lyophilisation and rehydration, cryoprotectants should be added before 
freeze drying (Bridges and Taylor, 2001).  
1.14.1.1. Cryoprotectants and lyoprotectants 
Delivery of drugs using colloidal vectors and nanoparticles is very efficient. Physical 
and chemical instabilities of these vectors are the major obstacles found on their storage 
in aqueous suspensions for extended periods (Henriksen et al., 1994).  To improve the 
physical and chemical instability of these substances, removal of water molecules is 
very important (Grahame, 1947). This is most commonly achieved by freeze drying in 
pharmaceutical field which converts solution/suspensions into solids by vacuum 
desorption or sublimation, thus, improving stability (Henriksen et al., 1994). This 
process creates stress during freezing and drying step like solute concentration, 
formation of ice crystals, pH changes etc. (Wang, 2000). Cryoprotectants are added to 
protect them from freezing stress and lyoprotectant from drying stress. 
Carbohydrates are favoured to be used during lyophilisation because they are 
chemically non-toxic and can be easily vetrified. Most of them also have transition 
temperature above -30°C making them more favourable (Gregory, 2006). 
Cryoprotectants and lyoprotectants were initially studied with proteins. There are two 
theories regarding the mechanism of stabilisation during freeze drying: ‘vitrification’ 
and ‘water replacement theory’ (Olton, 2008). 
Vitrification theory 
Crystallisation of ice during lyophilisation may induce a mechanical stress on particles 
leading to destabilisation, especially on fragile systems like nanoparticles. It has been 
suggested in previous studies that cryoprotectants directly interact with the bilayer and 
is associated with it throughout the freezing process to maintain bilayer integrity 
(Anchordoguy et al., 1987). Sugars like trehalose, mannitol, sucrose and glucose are the 
popular cryoprotectants and are known to vetrify at certain temperatures denoted Tg’ 
(Grahame, 1947). Vitrification is solidification of liquids without crystallization, a state 
in which it comprises a glassy state as the system is amorphous with no organised 
structure but possesses the properties of a solid. During vitrification, the viscosity of the 
solute in increased by concentrating it (critical viscosity) which inhibits the coming 
together of water molecules to form ice (Grahame, 1947). These cryoprotectants tend to 
immobilise the nanoparticles with their glassy matrix and protect them against 
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mechanical stress of ice crystals formed during freezing. The point at which this occurs 
is called the glass transition temperature (Tg’). Freezing must be carried out below the 
Tg’ of the amorphous sample. Concentration of these sugars play an important part in 
level of stabilisation afforded. This regime completely eliminates ice formation inside 
and outside the nanoparticle, thus preserving its shape (Grahame, 1947). During drying 
when the ice is removed by sublimation, it leaves behind a highly porous glass with 
nanoparticles embedded it them. Thus, it can be hypothesised that the rigidity of glassy 
matrix prevents the damage of nanoparticles from ice crystal and also prevents 
molecular aggregation by inhibiting molecular motion (Olton, 2008). 
Water replacement theory 
Lyoprotectant helps in stabilisation of nanoparticles by water replacement hypothesis 
where there is a formation of hydrogen bond between the OH group of lyoprotectant 
and the polar groups on the surface of nanoparticles at the end of drying process. These 
bonds serve to replace water when the water is lost during the process of drying, thus, 
helps to maintain structure (Olton, 2008). This satisfies the hydrogen bonding 
requirement of nanoparticle. This may keep the nanoparticles in pseudo hydrated state, 
thus, helping to preserve the native structure of nanoparticles by serving as water 
substitutes (Grahame, 1947). 
1.14.2. Spray drying 
Spray drying is a one-step process of drying that can have applications in designing 
liposome dry powders. Spray drying is a versatile technology which can have multiple 
applications and employed to manufacture a range of products including pharmaceutical 
and nutritional (Gasper et al., 2007). This process has the ability to produce spherical 
micro-particle powders with good flow properties, high porosity and low density. Thus, 
“respirable” dry powdered liposomes have been manufactured using the spray drying 
technology (Lo et al., 2004). Spray drying has many benefits like control over particle 
size, density and degree of crystallinity, improved bioavailability and product stability 
and rapid drying of thermo-sensitive materials (Gasper et al., 2007). Typical spray 
drying sequences that occur within fractions of a second are atomization of feed into a 
spray, spray-air contact, moisture evaporation of the sprayed droplets, and separation of 
the dried particles from the air (Lo et al., 2004). The spray drying technique dries the 
drug-loaded liposomes in order to retain their contents during storage (Charnvanich et 
al., 2010). High temperature process in spray drying may lead to thermal degradation of 
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protein activity which is a major concern. This activity loss occurs due to protein’s 
sensitive structural alteration by heat (Lo et al., 2004). Thus, optimization of the 
operating parameters in spray drying is essential. Stabilizing adjuvants can be included 
to protect the drug integrity during spray drying. In spray drying the most commonly 
used stabilizing adjuvants are carbohydrates such as sucrose, mannitol, lactose, 
trehalose, and polyols (Lo et al., 2004).              
1.14.3. Particulate based proliposomes 
To overcome the instability issue of liposomes, a delivery system called proliposomes 
was introduced by Payne and co-workers (1986). Proliposome technology represents an 
economic and convenient alternative to freeze- drying and spray drying to prepare 
liposome precursors that can generate liposomes with high entrapment efficiencies by 
addition of aqueous phase and shaking prior to administration. Proliposome of two 
types: Particulate based proliposomes (Payne et al., 1986) and ethanol based 
proliposomes (Perrett et al., 1991)  
According to Payne et al. (1986a;b), particulate-based proliposomes are the free flowing 
granular product which are composed of phospholipids, cholesterol (optional), drug and 
carbohydrate carrier, which on addition of aqueous phase (e.g. buffer solution) gets 
converted into an isotonic dispersion of MLVs (Payne et al., 1986a). Particulate-based 
proliposomes has been regarded as potentially most efficient and cost effective in 
commercially producing precursors for generating liposomes on large scale (Shaji and 
Bhatia, 2013). In our laboratory, proliposomes have been prepared by mixing lipid, drug 
and carbohydrate carrier in an organic solvent within a round bottom flask. The flask is 
then attached to a rotary evaporator under vacuum. On the evaporation of all the organic 
solvent, particulate proliposomes are formed. This is different from the traditional 
method introduced by Payne and co-workers (1986a) which relies on coating the 
carbohydrate carrier with the lipid solution upon injection through a feed-tube line to 
coat the carrier following evaporation of the organic solvent. The advantage of the 
method adapted in our laboratory is the avoidance of lipid losses in the tube-line and the 
risk associated with possible “splash” of the organic solvent during injection into the 
feed-line. There are different types of carbohydrates used in the preparation of 
proliposomes such as sorbitol, mannitol, lactose, sodium chloride and glucose (Payne et 
al., 1986a).  
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Different types of proliposomes have been prepared and experimented. Katare et al 
formulated an effervescent particulate based proliposomes using fluid bed method. They 
formulated effervescent proliposomes to produce liposomes with narrow size 
distribution, and high entrapment of non-steroidal anti-inflammatory drugs such as 
ibuprofen and indomethacin (Katare et al., 1990, Katare et al., 1991, Katare et al., 
1995). Desai et al studied the effect of jet-milling following blending carrier and lipid to 
form proliposomes. Formation of liposomes after dispersing it in water was established 
(Desai et al., 2002b, Desai et al., 2003). Deshmukh and co-workers studied the 
efficiency of proliposomal bead formulations for cromolyn (BCS Class III compound). 
Distearylphosphatidylcholine, cholesterol and the surfactant Tween 80 were spray-
coated onto beads of the anti-asthma drug cromolyn sodium. Vesicle formation and 
drug entrapment efficiency using the beads were evaluated using Caco-2 cells and 
everted rat intestinal sac model. This study concluded that the phospholipid-surfactant 
proliposomal beads have offered an effective method for oral delivery of Cromolyn 
(Deshmukh et al., 2008). Proliposomes were formed in enteric-coated beads and 
glyburide was used as a model drug. The beads were enteric coated with Eudragit L-
100. These proliposome beads proved to be more stable, enhanced drug dissolution and 
produced liposomes on hydration for oral administration (Kumar 2001). Chen and Alli 
in 1987 created proliposomes by coating Nonpareil beads (sugar spheres) with 
phospholipids. On hydration with aqueous phase these beads formed liposomes. These 
new types of proliposomes were termed as “bead-based proliposomes” (Chen and Alli, 
1987). 
1.14.4.  Prosurfactosomes 
Like proliposomes, prosurfactosomes also termed as protransferosomes are made up of 
lipid and drug along with surfactant coated with carbohydrate carrier. On hydration, 
prosurfactosomes becomes surfactosomes also termed as transferosomes.  Gupta and 
Trivedi (2012) have prepared cisplatin-loaded protransferosomes for topical drug 
delivery. These protransferosomes were surface modified using gelling agents and block 
co-polymers. They were evaluated for stability on storage for 6 months (Gupta and 
Trivedi, 2012). Ajay and Kumar investigated ketoprofen protransferosomes for 
sustained and efficient transdermal drug delivery. Sodium cholate was used as 
surfactant and nine different formulations with or without cholesterol were evaluated for 
the entrapment efficiency and release profile of the drug (Ajay and Vinit, 2013). Jain et 
al investigated protransferosomes of norgestrel for transdermal delivery. They were 
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characterised for different parameters like drug loading capacity, vesicular shape, size 
and size distribution, degree of vesicle deformability, transit time and formulation 
stability at 40ºC and room temperature (Jain et al., 2003). It was concluded that 
protransferosomes are better than proliposomes for transdermal drug delivery.                              
1.15. Pulmonary drug delivery 
Inhalation of drugs for treating local lung diseases such as asthma, cystic fibrosis and 
chronic obstructive pulmonary disease (COPD) has been considered for long decades or 
even centuries. The advantages of pulmonary drug delivery rather than using oral 
delivery are 
i.  High concentration of medication is delivered to the desired site in the lung 
ii. Systemic side effects are avoided or minimised 
iii. Rapid therapeutic response is achieved 
iv. Drugs bypass the therapeutic barriers like first pass liver metabolism and gastric 
absorption 
v. Therapeutic effect is achieved with lower doses 
vi. Pulmonary inhalation represent a non-invasive route for drug delivery  
The respiratory system as shown in Figure 1.13 starts from the nose and ends in the 
alveolar sacs. The respiratory tract can be classified into nasopharyngeal and 
oropharyngeal region which is also called the extrathoracic region which extends from 
the nose to larynx and is also referred as “upper airways”. This is followed by the 
tracheo-bronchial region and alveolar region. The tracheo-bronchial region extends 
from the trachea to terminal bronchioles and is also referred to as “central airways”. The 
alveolar region consists of bronchioles, alveolar ducts and alveoli; this region is referred 
as “lower respiratory airways” or “deep lung”. In this region the gas exchange takes 




Figure.1.13 A schematic representation of the human respiratory system (Hofmann, 2011)      
 
1.16. Pulmonary drug delivery devices 
Inhalation of drugs via aerosols is desirable for drug administration in the treatment of 
respiratory diseases (Morice et al., 2002). Drug inhalation may allow high 
concentrations of therapeutic molecules to be targeted to the site of action within the 
lung, thus systemic adverse effects can be minimised. Drug delivery devices must be 
chosen according to the specific drug formulation and the region of the lung to be 
targeted. Modern technology has provided various devices for administration of 
aerosolised drug to the respiratory tract via inhalation. Current delivery devices 
available for inhalation therapy are pressurised metered-dose inhalers (pMDIs), dry 





1.16.1.  Pressurised metered dose inhalers (pMDIs) 
Pressurised metered dose inhalers (pMDIs) were developed in 1955 by Dr. George 
Maison (Khilnani and Banga, 2008). pMDIs are used to deliver a measured amounts of 
medication via aerosol to the respiratory airways. Within a canister made from 
aluminium or stainless steel, the drug is dispersed or dissolved in a liquefied propellant. 
The main parts of a pMDI device as shown in Figure 1.14 are the canister, a metering 
valve and an actuator (mouthpiece). The canister contains a mixture of propellants, 
surfactants, preservatives and the drug (Khilnani and Banga, 2008). The canister is solid 
and tough to maintain high interior atmospheric pressure and has the capacity of holding 
15-30ml of liquefied formulation. The propellant is used for dispersing or dissolving the 
drug under high pressure within the canister (Ledermuller et al., 2003). The propellant 
is a liquid of very low boiling point (e.g. < 20°C), hence it is maintained in the liquid 
status under very high pressure condition within the canister. Liposomal formulations 
are mostly used after dissolution of phospholipid in a suitable propellant. During the 
actuation of pMDIs, the propellant is exposed to the atmospheric pressure which leaves 
the drug in the form of inhalable dry aerosol particles (Khilnani and Banga, 2008). The 
metered valve helps in the measurement of volume of fluid containing drug to be 
released from the device for inhalation (Tien et al., 2001).  
 






Major disadvantage of pMDIs is the need for inhalation coordination by the patient. 
Another disadvantage is the use of propellant like chlorofluorocarbon (CFC) which is 
found to deplete the ozone layer. This in turn increases the risk of skin cancer, immune 
suppression and global warming. Another drawback includes nose breathing and 
coughing by high flow velocity. 
1.16.2.  Dry Powder inhalers (DPIs) 
Dry powder inhalers (DPIs) have been in the market since early 1970s. There are 
different types of DPIs like Spinhaler, Rotahaler, Diskhaler and Turbuhaler. These 
devices provide aerosolised drug only when the patient actively inhales (Khilnani and 
Banga, 2008). Dry liposomes prepared for administration using DPI devices are made 
by freeze drying or spray drying or by loading micronised drug on carbohydrate carrier 
particles. Unlike pMDIs, the use of DPIs does not require coordinated patient inhalation 
(Khilnani and Banga, 2008). The powdered formulation within the device is converted 
into aerosols by the airflow during active inspiration, resulting in induction of a shear 
that causes delivery of the powder from the device (Ledermuller et al., 2003). The 
negative pressure generated by the patient inspiration causes the drug particle to pass 
through the airflow. As the drug formulation is in powder form, it is physically and 
chemically more stable compared to corresponding liquid formulations and delivery 
becomes easy, accurate and reproducible. However, the major disadvantage includes the 
demand for rapid drug aerosolization which can occur upon strong inspiration. This is 
difficult to achieve in patients with low inspiratory power or flow rate (e.g. children and 
old patients). Another disadvantage is provided by the atmospheric humidity and rapid 
change of temperature. This may lead to aggregation of dried drug particles, thus, 
(Ledermuller et al., 2003) reducing the delivered fraction of the drug (Khilnani and 
Banga, 2008). Some constrains in the use of DPIs include size and size distribution of 
drug particles, shape of carrier, and drug porosity and crystallanity (Telko and Hickey, 
2005). Many studies have shown that DPIs are preferred over pMDIs as they are 
propellant-free and actuation breath synchronization is not required (Morice et al., 
2002). 
1.16.3.  Nebulisers 
Nebulisers are neither propellant based nor they need patient coordination during drug 
inhalation. Nebulisers can be used to deliver high drug doses in a relatively short time 
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(Khilnani and Banga, 2008). Most of the polydispersed aerosols produced by nebulisers 
are 1-5µm in diameter; this range is suitable for deposition in the lung (O'Callaghan and 
Barry, 1997, Ledermuller et al., 2003). Some nebulisers rely on compressed air for 
atomisation while others use ultrasonic energy and vibrating mesh (Bridges and Taylor, 
2001). Nebulisers are preferred devices over pMDIs and DPIs for delivery of liposome 
formulations. They can provide high doses of drugs to the lung and minimum effort 
with no coordination are required. Conventional techniques can be used to produce 
liposomes in nebulisers without any further processing except for removal of 
unentrapped drug (O'Callaghan and Barry, 1997). However, nebulisation has many 
disadvantages like inefficient delivery of drug to the lungs, large residual amount of 
drug in nebuliser and the wastage of drug during exhalation in the surrounding air; 
however all these disadvantages have been minimised with the revolutionary novel 
designs of many nebulisers currently available in the market. Some aerosol particles are 
too large for deposition in the lungs and some are too small to sediment and thus are 
exhaled (O'Callaghan and Barry, 1997). The effectiveness of drug delivery by nebuliser 
depends on various factors like particle size, formulation properties, nebuliser type and 
patient inhalation pattern. 
There are three types of nebulisers: 
a. Air-jet nebulisers 
b. Ultrasonic nebulisers 
c. Vibrating-mesh nebulisers 
1.16.3.1. Air-jet nebulisers 
Air-jet nebulisers consist of mouth piece, medication bottle and source for compressed 
gas (e.g. gas compressor) to effectively convert liquid medications into “respirable” 
aerosols as shown in Figure 1.15.  Jet nebuliser uses the principle of Bernoulli Effect 
(O'Callaghan and Barry, 1997). In jet nebulisers, the mouth piece is connected to the 
medication bottle (i.e. nebuliser reservoir) into which the medication liquid is filled. A 
gas compressor is used (Ledermuller et al., 2003) which on operation supplies 
compressed gas through the “venturi” nozzle of the nebuliser reservoir to convert drug 
into aerosols. The air pressure on top of medication fluid decreases and gas velocity 
increases. Negative pressure is produced at this point at the other end of the gas feeding 
tube. This results in the suction of medication liquid via “Bernoulli Effect”, leading to 
formation of aerosol droplets from the liquid dispersions under the influence of surface 
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tension (O'Callaghan and Barry, 1997, Elhissi and Taylor, 2005). The viscosity of the 
drug dispersion is directly proportional to nebulisation time (McCallion et al., 1996). 
The VMD of droplets is 15-500µm and the output efficiency depends on the baffle, 
“venturi” orifice and gas velocity and pressure (Newman and Clarke, 1983, Dennis et 
al.,1990, O'Callaghan and Barry, 1997). Large droplets produced impacts with the 
baffles within the nebuliser and falls back into the reservoir while the smaller ones can 
be released from the nebuliser because they are capable of escaping the baffling system 
of the nebuliser. The VMD of the aerosol droplet is directly proportional to the size of 
“venturi” nozzle and pressure of compressed gas (Khilnani and Banga, 2008). The use 
of nebulisers amongst children and infants is simple and easy when compared with DPIs 
and pMDIs (O'Callaghan and Barry, 1997). During jet nebulisation of liposomal 
suspensions, disruption of liposomal membranes may occur due to mechanical shearing 
by the nebuliser. VMD of liposomes, aerosol droplet VMD and gas pressure are the 
major determinants of vesicle stability during jet nebulisation (Leung et al., 1996).  
 
Figure 1.15 Design of conventional Air jet nebuliser. (O’Callagham and Barry, 1997) 
 
 Nebulisers can be divided into conventional, continuous open-vent and breath-
enhanced open vent nebulisers. 
 
Conventional nebulisers generates a fixed flow of gas containing aerosol. It 
continuously produces aerosols regardless of patient’s inhalation or exhalation, thus, 




In open vent nebulisers, there is a generation of negative pressure by the expansion of 
compressed air which sucks air and fluid into to the chamber via the vent for 
atomisation. This pushes more aerosols out to be inhaled by patients. This results in 
short nebulisation time and reduced droplet VMD due to greater solvent evaporation 
(O'Callaghan and Barry, 1997).  This results in continuous air flow into the chamber 
pushing more small particles to be inhaled. The nebulisation time is reduced but the 
total amount of drug inhaled is similar to that using conventional jet nebulisers. 
Children and patients with low inspiration may fail to adapt to the high flow rate of this 
nebuliser and this can result in great losses of aerosol during exhalation.  
  
In breath assisted open vent nebulisers like Pari LC Plus, there is a vent for air flow 
in the top and compressed gas flow at the bottom. The vent nebulisers work only during 
inspiration, thus, reducing aerosol and drug waste during expiration. (O'Callaghan and 
Barry, 1997).  
1.16.3.2. Ultrasonic nebulisers 
Ultrasonic nebulisers use ultrasonic energy to convert liquid into aerosol (Leung et al., 
1996, Taylor and McCallion, 1997). In ultrasonic nebulisers, the energy required for 
aerosolisation (i.e. atomisation) of liquid is provided by the high frequency vibrations of 
a piezoelectric crystal (1-3Mz) that is located at the lower part of the device (Taylor and 
McCallion, 1997). As the vibrations become intense, they create fountain of droplets as 
shown in Figure 1.16. Large droplets are created in the apex while the smaller ones are 
created in the base from which the smallest droplets are converted to aerosol. Air driven 
by an in situ fitted fan within the nebuliser takes the small aerosol droplets to the 
mouthpiece side for inhalation by the patient (Elhissi and Taylor, 2005).  
 
Figure.1.16 Schematic diagram of an ultrasonic nebuliser (Taylor and McCallion, 1997) 
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Two types of aerosol generation mechanisms are proposed which are the capillary wave 
theory and cavitation bubble formation (Torchilin and Weissig, 2007). They are 
diagrammatically represented in Figure 1.17 (A) and (B). 
In capillary wave theory, it is proposes that droplets are formed from the capillary 
waves produced at the surface of the liquid. The formation of capillary jet is directly 
proportional to the frequency of the sound provided. 
In cavitation bubble theory the liquid is atomised by hydraulic shocks which are 
produced by implosion of cavitation bubbles (Taylor and McCallion, 1997). Low 
frequency energy is desirable to create bubbles inside the formulation. 
Ultrasonic nebulisation increases the temperature of nebuliser fluid by around 15°C. 
This may lead to chemical degradation of heat-sensitive drugs such as proteins and 
delicate structures such as liposomes  (Leung et al., 1996). However, looking at the 
positive side, the increase in temperature may promote the solubility of poorly water 
soluble drugs (Steckel and Eskandar, 2003). This nebuliser also has higher dead volume 
with larger aerosol VMD and fluid output as compared to jet nebuliser (Taylor and 
Hoare, 1993) 
 
Figure.1.17 Generation of aerosol in ultrasonic nebuliser using (A) Cavitation bubble theory (B) Capillary 




1.16.3.3. Vibrating mesh nebuliser 
Vibrating-mesh nebuliser is the most recent type of nebuliser that has become 
commercially available in market (Dhand, 2002, Elhissi and Taylor, 2005). Vibrating-
mesh nebulisers consist of a vibrating mesh with fine multiple apertures thought which 
the liquid drug solution or suspension is passed through to be atomised into slow 
moving fine aerosol droplets with narrow size distribution (Dhand, 2002). Vibrating-
mesh nebulisers are also highly efficient, portable, user friendly, silent in operation, 
hand-held and battery operated. In these nebulisers, baffles are not required as the 
droplet size is controlled by the micro-sized mesh pores of the nebuliser (Newman and 
Gee-turner, 2005). 
Different vibrating-mesh nebulisers employ different mechanisms of aerosol operation, 
and can be classified into passively vibrating-mesh nebulisers and actively vibrating-
mesh nebulisers. 
Passively vibrating-mesh nebulisers  
In passively (low energy) vibrating-mesh nebuliser, the piezoelectric crystal is attached 
to a transducer horn to which high frequency ultrasonic waves originated from a 
piezoelectric crystals are passed and transmitted to the mesh plate. This causes passive 
movements of the mesh which results in extrusion of the drug fluid through the mesh 
apertures, resulting in generation of aerosols (Dhand, 2002). The Omron MicroAir 
NEU22 nebuliser works using this principle (Newman and Gee-turner, 2005). 
 
Actively vibrating-mesh nebulisers 
In actively vibrating-mesh nebulisers, a micropump system employs an aerosol 
generator which produces aerosols. An electric current is applied which leads to the 
vibration of the ceramic vibrational element. This in turn leads to the upward and 
downward movement of the mesh. There are around 1,000 micro-pores in the mesh 
plate and the medication is usually positioned above the domed aperture plate. This 
ultimately leads to the generation of aerosols by the micropump action of the mesh, 
which extrudes drug fluid through the apertures. Aeroneb Pro, Aeroneb Go and 
Aeroneb Solo are examples of nebulisers that use this mechanism of operation. Beurer 
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iH 50 also uses a similar operating mechanism and is classified as an actively vibrating-
mesh nebuliser.  
With the Aeroneb Pro nebulisers, shown in Figure 1.18, shorter time is needed to 
complete nebulisation and almost all the medication fluid present in this nebuliser is 
aerosolised, ending up with negligible residual volume (Dhand, 2002). Moreover, there 
is no increase in the temperature of the medication fluid; hence, this nebuliser is 
potentially appropriate for delivery of peptide and protein drugs. This technology may 
suffer from a disadvantage like the possible blockage of some apertures and the high 
price of the nebuliser compared to jet nebulisers. 
 
                       
 
Figure 1.18 Aeroneb pro nebuliser and its vibrating mesh membrane (Fink, 2001) , www.aerogen.com 




Beurer iH 50 is another actively vibrating mesh nebuliser utilising a different 
mechanism of operation. It can be used to treat diseases like asthma and bronchitis. In 
Beurer iH 50, the medication is atomised using a high tech vibrating membrane. It 
works with the latest membrane oscillation technology. The vibrating membrane is 
partially porous, thus, allowing only small particles of medication to pass through. It has 
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a high nebulization capacity of 0.25 ml/min (Beurer, 2014). This device is small, 
portable and has been reported to be suitable for use while travelling (Health, 2014) 
(Figure 1.19).  
 
Figure 1.19 Beurer IH50 vibrating mesh nebuliser (Beurer, 2014) 
http://www.beurer.com/web/uk/products/nebulization/nebulization/IH-50 
 
1.17. Apparatus to analyse aerosol characteristics 
The pharmacokinetic profile of inhaled drug is affected by its site of deposition in the 
respiratory airways. Absorption profile of a drug in the upper airways is different from 
its absorption in the deep lung. To determine the deposition of a drug in various 
pulmonary regions, pulmonary deposition models have been established and approved 
officially. For example the Two-stage impinger is an in vitro aerosol deposition model 
designed to study the likelihood of particles to deposit in lungs; this apparatus is 
approved by the British Pharmacopeia (BP) and United States Pharmacopeia (USP). 
1.17.1. Twin (Two-stage) Impinger 
Inhaled drug particles via nebulisers are deposited in different areas of the respiratory 
tract, depending on the aerodynamic size of the particles (Miller et al., 1992). Two-stage 
impinger, also called Twin impinger, is a two-stage size separation device for assessing 
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the deposition profile of drug aerosolised using oral inhalation devices (Figure 1.20). 
Both stages are defined by the aerodynamic particle size cut-off characteristics 
(Hallworth and Westmoreland, 1987).  
The Two-stage impinger consists of a series of glassware through which vacuum is 
applied to pass air across the two stages of the impinger. The vacuum is applied to draw 
the air through the instrument and is adjusted at a flow rate of 60L/min. At this flow 
rate, the cut-off diameter between the two stages is 6.4 µm; hence particles smaller than 
this size will deposit in the lower stage and be described to be in “fine particle fraction” 
(FPF) or “respirable” fraction, and this fraction is expected to be therapeutically useful.  
Thus, the use of the twin impinger helps to determine the fraction of drug particles 
collected in the first stage of impinge (representing the upper airways) and the second 
stage (representing the lower airways) (Miller et al., 1992). There are two main 
disadvantages associated with the use of the twin impinger. Firstly, the sample is 
divided only in two categories (i.e. “respirable” and “irrespirable”). Secondly, the 
vacuum applied through the apparatus may result in some solvent evaporation, hence 
the “respirable” fraction might be overestimated for liquid aerosols  (Miller et al., 1992). 
This impinger, however, is very useful for the routine quality assessment and testing of 
aerosols produced (Hallworth and Westmoreland, 1987). 
 





1.18. Mechanisms of particle deposition 
Lung is a prime organ of exposure for a variety of air-borne particles. On inhalation, 
these particles may deposit in different regions of the respiratory system. The deposition 
of inhaled aerosols helps in determining any change in the dimensions of airways and 
alveoli, thus, could act as a diagnostic approach (Darquenne, 2006). The ability of a 
particle to reach lower respiratory airways depends on its aerodynamic size.  There are 
three principal mechanisms by which particles are deposited in the lung. These are 
inertial impaction, gravitational sedimentation and infusion/Brownian diffusion. The 
mechanism of particle deposition depends on the size of the particle. To a less extent 
electrostatic precipitation and interception are also additional deposition mechanisms.  
1.18.1. Inertial impaction 
This mechanism of particle deposition is followed by particles larger than 5µm (Hilman, 
1991). This occurs when the particle has to change its pathway due to airway 
bifurcations (Darquenne, 2006) which occurs when the particle’s momentum is too 
large to change its course according to the airway(Hussain et al., 2011), resulting in 
particle deposition by impacting the walls of the airways at the point of deflection. 
Chance of impaction is directly proportional to the size of particle, air velocity and 
particle density (Heyder, 2004). The main site of deposition by inertial impaction is the 
upper respiratory tract like nose, mouth and pharynx.  
1.18.2. Gravitational sedimentation 
In gravitational sedimentation, the settlement of particle depends on the action of 
gravitational force. Particles reach their terminal settling velocity when the gravitational 
force equals the opposing viscous resistive forces of the air (Hussain et al., 2011). The 
probability of particle deposition by sedimentation is directly proportional to the particle 
size and particle density (Darquenne, 2006) and inversely proportional to the air flow. 
Gravitational sedimentation generally takes place for particles ranging in size between 
0.5µm - 5µm (Darquenne, 2006). This mechanism of particle deposition is dominant in 






1.18.3. Brownian diffusion 
In Brownian diffusion, deposition is due to random collision of particles with gas 
molecules. Particles having aerodynamic size smaller than 0.5µm may deposit by 
Brownian diffusion (Hussain et al., 2011) . In airways like bronchioles and alveolar 
region where the air flow is very low or absent this mechanism of deposition is 
observed. Deposition of particles by Brownian diffusion is inversely proportional to 
particle size. Brownian diffusion is dominated in the alveolar regions of the lung due to 
longer residence time and smaller airways  (Darquenne, 2006).  
1.18.4. Interception 
Deposition via interception is common in particles like fibres where the length to 
diameter ratio is large. This type of deposition may happen when the edge of particle is 
in contact with the airway wall while the remaining is in the air space (Darquenne, 
2006). The chance of particle interception is inversely proportional to the diameter of 
respiratory airway. 
1.18.5. Electrostatic precipitation 
Electrostatic precipitation occurs when charged particles are inhaled. Some surfaces of 
airways are charged and hence these particles may be electrostatically attracted. This 
results in a greater deposition of the charged particles rather than the neutral ones. 
Particle deposition by electrostatic precipitation is not regarded as a common 
mechanism of deposition (Darquenne, 2006). 
1.19. Clearance of deposited particles 
There are two mechanisms of particle clearance in the lung; mucociliary clearance in 
the upper respiratory airways and clearance by alveolar macrophages in lower 
respiratory airways (Stuart, 1976). 
1.19.1. Mucociliary clearance 
Mucociliary clearance is the primary mode of particle clearance in nasopharynx and 
tracheobronchial tree against all types of inhaled particles (Stuart, 1976, Clarke and 
Pavia, 1980). This region contains goblet cells and ciliated columnar cells. The goblet 
cells are responsible for the production of mucus that serves for entrapment and 
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conveyance of deposited particles which is propelled out of the respiratory system by 
the cilia (Stuart, 1976). Various insoluble materials are cleared using this mechanism. 
Mucociliary clearance is a continuous process used to eliminate particles immediately 
following their deposition (Wilkey et al., 1980). 
1.19.2. Alveolar clearance 
Insoluble particles deposited below ciliated airways are eliminated via slow 
phagocytosis and conveyance within pulmonary macrophages which is ultimately 
cleared into the gastrointestinal tract (Brain and Blanchard, 1993). These pulmonary 
macrophages are the immune cells present mostly in the alveolar region of the lung. 
They are responsible for the initial clearance of deposited particles, thus, protecting 
against bacterial and viral infections. They are rich in lysozymes and various enzymes, 
hence, can engulf and digest invading organisms. The rate of particle clearance by this 
mechanism depends on the site of particle deposition in the respiratory tract, and total 
amount, shape, surface properties and size of particle (Stuart, 1976). 
1.20. Liposomes for pulmonary delivery 
Pulmonary delivery gives a rapid onset of action for the delivered drug. It gives the drug 
a direct access for the treatment of respiratory diseases and also has large surface area 
for drug absorption to the systemic circulation. The level of enzymatic activity in the 
pulmonary system is also low compared to that in the gastro-intestinal tract, hence 
delivery via inhalation can be particularly advantageous for drugs susceptible to 
enzymatic degradation such as peptides and proteins (Labiris and Dolovich, 2003). 
However, one limitation of pulmonary delivery is that the drug may leave the lung 
rapidly because of rapid absorption to the systemic circulation owing to the thinness of 
the pulmonary epithelium. Hence, designing novel delivery systems that can prolong the 
retention of the drug in the lung following inhalation is greatly needed (Zeng and 
Chong, 1995). Liposomes have been established as a drug delivery system that can 
entrap drugs and prolong the drug residence in the lung, resulting in enhanced local 
therapeutic effect in the lung and reduced potential of systemic adverse effects (Chrai et 
al., 2001, Thomas et al., 1991). Liposomes are made of materials similar to lung 
surfactants and are biodegradable and non-toxic (Huang et al., 2010a). Thus, extensive 




1.20.1. Liposomes for acute lung injuries 
Acute lung injury is caused by the presence of reactive oxygen species (ROS) which are 
chemically reactive molecules containing oxygen. They are formed by metabolism of 
oxygen in the body and known to have important roles to play such as haemostasis and 
cell signalling. However, over-production of ROS may disrupt cell membranes and 
cause oxidative stress. Anti-oxidants are required to decrease the number of ROS in the 
body. Liposomes can be used to entrap and deliver anti-oxidant enzymes to the lung. 
Some studies show that using liposomes for entrapping antioxidants may provide 
enhanced prophylaxis against oxidative lung injuries (Tanswell et al., 1990). It may also 
prolong the retention of the anti-oxidants in the pulmonary cells. Alipour et al in 2012 
studied the acute toxicity of a single dose of intravenously administered liposomal 
antioxidant formulation containing N-acetylcysteine (NAC) in rats was examined. This 
study showed no treatment-related toxicity in rats by a single bolus intervenous 
administration (Alipour et al., 2012). S. D. McClintock et al in 2005 published a study 
on rats with acute lung injuries using liposomes. In this study, 2-chloroethyl ethyl 
sulphide was installed into the lung to produce acute lung injury in rats in a manner that 
seems related to the loss of the redox balance in the lung. They concluded that the injury 
of rat lungs can be substantially diminished by the presence of reducing agents or anti-
oxidant enzymes delivered via liposomes (Abraham et al., 1999, McClintock et al., 
2006). J. G. Gaca did a study on treating acute lung injuries in swine using liposomal 
clodronate. Large number of pulmonary intravascular macrophages (PIMs) was found 
in swine which leads to physiological response in acute lung injuries. It was found that 
the use of liposomal clodronate significantly decreases the PIM population in the lung 
(Gaca et al., 2003). This is a promising treatment for acute lung injuries caused by 
endotoxins. 
1.20.2. Liposomes for asthma 
Asthma is the most common pulmonary disease. It is characterised by airway hyper 
responsiveness, chronic inflammation and airway remodelling. Asthma happens when a 
triggering agent like allergen induces the release of histamine from mast cells, which 
causes the attraction of many inflammatory cells along with pro-inflammatory cytokines 
and mediators (Saari et al., 2002). This chronic inflammation often causes an increase in 
airway hyper responsiveness that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing (Buist, 2003). The airway inflammation 
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and lung damage can be prevented by giving steroidal anti-inflammatory drugs such as 
beclometasone dipropionate (BDP) and budesonide and relieved using bronchodilators 
such as salbutamol sulphate (SBS). Chen et al in their experiment used SBS in liposome 
formulation to treat asthma using rat models. Effective distribution of liposomes with 
sustained release of the drug in the lung for 48 hours was reported.  Pharmacodynamic 
studies in guinea pigs where SBS entrapped in liposomes showed anti-asthmatic effect 
for 18 hours whereas free SBS solution showed only for 8 hours (Chen et al., 2012). 
Oberoi et al in 2012 worked to develop a liposomal dry powder inhaler using 
doxophylline. This study showed better retention of doxophylline in liposomal 
formulation as compared to the controlled release formulation (Oberoi et al., 2012).  In 
2003 K. S. Konduri used budesonide in stealth liposomes to treat asthma. They used 
mice models to conclude that weekly therapy of budesonide encapsulated in liposomes 
showed similar effects as daily dosage of budesonide on its own in conventional 
formulation. The liposomal budesonide proved most efficient of all formulations used in 
the experiment to decrease the lung inflammation, peripheral blood eosinophil levels 
and serum IgE levels (Konduri et al., 2003). 
1.20.3. Liposomes for Pneumonia 
Pneumonia is an inflammatory condition of the lung which is due to the infections 
caused by bacteria, fungi, parasites or viruses. Common syndrome includes chest pain, 
cough and difficulty in breathing. Antibiotics are normally useful for their treatment. 
This treatment can be complicated and less effective due to various factors like 
unfavourable location of infection, decreased immunity of the host or limited 
susceptibility of the applied antimicrobial agent (Schiffelers et al., 1999). Use of 
liposomes for carrying these agents could modify the pharmacokinetics of the drug 
along with proper tissue distribution. This helps to increase the drug concentration in 
the desired site and reduce the toxicity in undesired tissues away from the lung 
(Schiffelers et al., 1999). In various experiments of Schiffelers and co-workers, 
liposomes have been demonstrated to be an effective carrier of antibiotics (Schiffelers et 
al., 2000).  Liposome-encapsulated Gentamicin proved to be more efficient in the 
treatment of pneumonia in rat models than free Gentamicin. Liposomes with 
polyethanol glycol coating (i.e. PEGylated liposomes) have shown to be more beneficial 
for targeting antibiotics during pneumonia (Schiffelers et al., 2000). Ellbogen and co-
workers have shown that ciprofloxacin encapsulated sterically stabilized liposomes 
increased the pharmacokinetics of drug. They used rat models to conclude that the 
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efficiency of liposome encapsulated ciprofloxacin better than the free ciprofloxacin for 
treatment of pneumococcal pneumonia when injected intravenously (Ellbogen et al., 
2003). A new liposomal formulation is developed as a delivery system for antibiotics. 
“Arikace” is a new liposomal formulation of Amikacin for aerosol delivery with potent 
Pseudomonas aeruginosa killing and prolonged lung deposition. It’s a registered 
trademark word of Transave, Inc., Monmouth Junction, NJ. Arikace is being developed 
for inhalation treatment of gram negative bacteria using nebuliser (Li et al., 2008), 
(Drulis-Kawa and Dorotkiewicz-Jach, 2010). Recently a research was done to prove the 
tolerability, safety, biologic activity and efﬁcacy of Arikace in patients with Cistic 
Fibrosis with P aeruginosa infection with a dose of once daily for 28 days (Clancy et al., 
2013). 
1.21. Delivery of liposomes through nebulisers. 
Liposomes can be converted to aerosols in nebulisers before being delivered to the 
lungs. Various studies has been done to study the fate of liposomes after being delivered 
by this method 
Elhissi et al in 2007 studied the effect of nebulisation using vibrating mesh nebuliser on 
liposomes. They compared the delivery of non-extruded liposomes to the delivery of 
liposomes extruded through 1µm and 0.4µm using SBS as sample drug.  They observed 
that extrusion did not affect the delivery of drug through jet nebuliser. It was also 
observed that less disruption was caused by vibrating mesh nebuliser to the liposomes 
extrude through 1µm membrane than the non-extruded liposomes. However, liposomes 
extruded by 0.4µm membrane showed the least stability and were unable to withstand 
the sheer generated by the vibrating mesh (Elhissi et al., 2007). 
Ghazanfari et al compared the effect of passively and actively vibrating mesh nebuliser 
on liposomes. It was observed that vibrating mesh nebuliser was inappropriate for 
nebulizing highly viscous fluids. It was observed that passive vibrating mesh nebuliser 
was superior to actively vibrating nebuliser in generating very high total aerosol 
outputs. It was also observed that actively vibrating mesh nebuliser was better than 
passively vibrating nebuliser by providing shorter nebulisation time and reducing higher 
aerosol output rates for higher viscosity. Thus, vibrating mesh nebulisers were affected 
by the fluid properties of liposomal dispersion and nebuliser mechanism of operation 
(Ghazanfari et al., 2007).  
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Saari et al in 1999 studied that jet nebulisation reduces the liposome size and effectively 
delivers it to the lungs in human volunteers (Saari et al., 1999). Waldrep et al. in 1993 
studied the delivery of Ciclosporine A (CsA) to lungs via jet nebuliser using five 
different phosphotidylcholine formulations. He found that CsA-DLPC was the best 
formulation for aerosol delivery to the lung. It was also proved that liposomes prepared 
using phosphotidylcholine with low transition temperature were more efficient for 
nebulisation than those with higher transition temperature (Waldrep et al., 1993).   
Gasper et al in 2010 investigated the membrane integrity of liposomes encapsulating a 
florescent compound calcein using Aeroneb Pro nebuliser. He concluded that vibrating 
mesh nebulisers are well suited for the pulmonary delivery of drug (Gasper et al., 2007). 
1.22. Stability of liposomes to nebulisation 
Various studies are done to study the stability of liposomes on nebulisation. Liposomes 
are delicate vesicles, hence, the shearing forces generated during nebulisations may lead 
to the leakage of hydrophilic drug (Niven et al., 1991, Taylor et al., 1990b).  Taylor et al 
in 1990 observed the large loss of entrapped drug on passage of multilamellar vesicles 
through an air jet nebuliser due to vesicle fragmentation. He also observed that 
nebulisation of liposomes previously extruded through 1µm membrane decreased the 
drug loss (Taylor et al., 1990b). It is also studied that drug loss is less when the size of 
liposomes is smaller than the aerosols droplet size generated by nebulisations. This 
prevents the liposomes from breaking down into smaller vesicle to fit into the aerosol, 
thus, avoiding drug leakage (Niven et al., 1991). 
Bridges and Taylors in 1998 observed that smaller the liposomal size more efficient 
they are to be delivered from nebulisers. He also observed that the inclusion of 
cholesterol or DPPC in the liposome bilayers rendered them more resistant to the sheer 
forces to which they were exposed during nebulisation. This also suggests that inclusion 
of hign transition temperature lipid or cholesterol incleased the stability of liposomes by 
increasing the vesicle rigidity (Bridges and Taylor, 1998).   
Bridges and Taylor in 2000 studied the effect of freeze drying on the stability of 
liposomes for nebulisation. He observed that size of liposomes was larger and they 
aggregated without the addition of cryoprotectant trehalose. Freeze drying of liposomes 
without cryoprotectant trehalose were proved unstable to nebulisation. He also 
concluded that freeze drying provided liposomal preparation having long term physical 
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and chemical stabilitywhich maybe hydrated before its delivery through nebuliser 
(Bridges and Taylor, 2001). 
1.23. Hypothesis 
Liposomes are promising carriers for pulmonary drug delivery. However, conventional 
liposomes when used for pulmonary drug delivery via nebulisers are observed to leak its 
entrapped drug. This is due to the stress provided by the nebulisers during nebulisation 
and lack of liposome elasticity.  
Transferosomes made up of surfactants like Tween 80 have proven flexibility and they 
have structure similar to liposomes and useful for skin delivery.In this study it is 
hypothesised that a similar system can be useful for pulmonary delivery. Surfactosomes 
like transferosomes can be considered more elastic and flexible than liposomes, hence, 
expected to minimise the drug leakage during nebulisation. Surfactosomes would be 
more efficient than conventional liposomes for pulmonary drug delivery.  
Hence, surfactosomes made up of surfactant, Tween 80, in addition to liposomal 
components will be tested for its efficiency in pulmonary delivery. 
1.24. Aim of thesis 
The Aim of this thesis was to investigate the properties of an elastic vesicle called 
surfactosome, also termed as transferosome. The stability and efficiency of 
surfactosome was compared with the conventional liposome for pulmonary drug 
delivery. Hydrophilic model drug salbutamol sulphate (SBS) and hydrophobic model 
drug beclometasone dipropionate (BDP) were used for this purpose. The stability and 
efficiency was initially investigated using extruder of different polycarbonate 
membranes and later by nebulisers. The vesicles were prepared by thin film method as 
well as proliposome technology. Formulations with and without cholesterol were 
investigated to find if inclusion of cholesterol proved an advantage or disadvantage for 
pulmonary aerosol delivery. A novel formulation called prosurfactosomes was also 
investigated which on hydration forms surfactosome and compared with liposomes 
formed from hydration of proliposomes. Here Aeroneb Pro, Beurer iH50 and PARI LC 
sprint nebulisers were used to compare both the vesicles. The work focused on finding 
the best formulation for pulmonary drug delivery and to investigate if surfactosomes 
were better than liposomes to sustain the different forces applied on these vesicles 
before being delivered to the lungs. Effect of freeze drying and spray drying on these 
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vesicles were also investigated. This thesis also aimed to investigate the stability of 
liposomes and surfactosomes in different environment. 
The final outcome of this thesis was aimed at formulating a better vesicle for pulmonary 












                                                  Chapter 2 





Materials used are shown in Table 2.1 
Table 2.1 List of chemicals and their supplier used for the research 
Chemical 
Supplier 
Soya Phosphotidylcholine (Lipoid S-100) 
A gift from Lipoid, Switzerland 
NaCl (ACS, 99.0% min) 
 
 
Alfa Aesar, UK 
 
Salbutamol Sulphate (99%) 
Sodium 1-hexanesulfonate monohydrate (99%) 
Triton X -100 
Deuterium oxide (For NMR, 99.8% atom %D) 
Acros Organics, UK 





Fisher Scientific, UK 
Ethanol (99.8+% absolute duty free for HPLC 
certified HPLC 
Glacial acetic acid 99+% 
HPLC water (HPLC gradient grade) 
Methanol (HPLC grade) 
Beclometasone dipropionate (BDP) 
 
 
                Sigma, UK 
Cholesterol (Sigma grade, ≥99%) 
Mannitol ≥98% 






TAAB Laboratories Equipment Ltd., 
UK 
pH buffers (Phosphate), reference standard 
4 ± 0.01, 7± 0.01 and 10 ± 0.01 at 25°C 




2.2.1.  Preparation of conventional liposomes 
SPC and cholesterol were used in desired ratio as lipid phase. Different ratios of SPC 
and cholesterol were used in different studies and are specified precisely in the 
following chapters. The lipid phase was dissolved in ethanol or chloroform (20mg/ml) 
within a round bottom flask. The size of round bottom flask depended on the quantity of 
liposomes to be prepared. The organic solvents were removed using a rotary evaporator 
(R-215, Buchi, Swirzerland) under vacuum (V-700, Buchi, Switzerland) for 1 hour in a 
water bath (B-491, Buchi, Switzerland) at 38ºC at maximum rotation speed of 280rpm. 
After 1h the vacuum was turned off, negative pressure as released and the round bottom 
flask was detached. The resultant thin film was hydrated. Different hydration 
concentrations were used in different studies and are specified precisely in the following 
chapters.  
2.2.2. Preparation of proliposomes 
SPC and cholesterol were used in desired ratio as lipid phase. Different ratios of SPC 
and cholesterol were used in different studies and are specified precisely in the 
following chapters. The lipid phase was dissolved in chloroform (20mg/ml) within a 
round bottom flask. The size of the round bottom flask depended on the quantity of 
proliposomes prepared. Mannitol was used as the carbohydrate carrier and was added to 
the lipid phase in desired ratio for preparation of proliposomes with SBS or BDP. 
Different concentrations of mannitol were used in different studies and are specified 
precisely in the following chapters. The organic solvent was removed by evaporation 
using a rotary evaporator as described in section 2.2.1. After releasing the negative 
pressure and detaching the flask, the proliposomes were collected using a clean spatula. 
Proliposomes were then stored at room temperature and was used immediately.  
2.2.3. Preparation of surfactosomes 
SPC and cholesterol were used in desired ratio as lipid phase along with Tween 80 
(15% w/w of the total lipid) in a round bottom flask. . Different ratios of SPC and 
Cholesterol were used in different studies and are specified precisely in the following 
chapters. These were dissolved in ethanol or chloroform (20mg/ml) in a round bottom 
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flask. The organic solvent was evaporated as described in section 2.2.1 and the resultant 
thin film was hydrated in a concentration of 10 mg/ml.  
2.2.4. Preparation of prosurfactosomes 
SPC and cholesterol were used in desired ratio as lipid phase along with Tween 80 
(15% w/w of the total lipid) in a round bottom flask. SPC, cholesterol and tween 80 
were dissolved in chloroform (20mg/ml) in a round bottom flask. The size of the round 
bottom glass depended on the quantity of proliposome to be prepared. Mannitol was 
added to this lipid phase in desired ratios for SBS and BDP ultradeformable vesicular 
formulations respectively. The organic solvent was evaporated as described in section 
2.2.1. After evaporation of the solvent, the flask was detached and the proliposomes 
were collected using a clean spatula. The proliposomes were used immediately for the 
experiment. 
2.2.5. Addition of drug in the vesicular formulations 
Salbutamol sulphate (SBS) or and beclometasone dipropionate (BDP) were included 
within the liposomal, proliposomal, surfactosomal and prosurfactosomal formulations.  
2.2.5.1. Incorporation of salbutamol sulphate (SBS) 
For vesicles with salbutamol sulphate (SBS), 1 mg/ml drug was dissolved in isotonic 
sodium chloride solution (0.9% NaCl) before hydration. A two- step hydration method 
was used to maximise the drug entrapment. In this method, entire drug was dissolved in 
2ml of the isotonic NaCl solution and then added to the formulation for hydration. The 
preparation was vigorously hand-shaken and vortexed for 5min and was kept aside on 
the bench for 10 min. The remaining drug-free isotonic NaCl solution was then added to 
the concentrated vesicles and was left for 2 h at room temperature for annealing before 
conducting further experiments. 
2.2.5.2. Incorporation of beclometasone dipropionate (BDP) 
For vesicles with Beclometasone dipropionate (BDP), 2.5 mole% drug was added to the 
lipid components before addition of chloroform. After the removal of the organic 
solvent by rotary evaporation, the resultant formulation was hydrated with deuterated 
water (D2O) to give liposomes or surfactosomes. The preparation was vigorously hand 
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shaken for 5 min and left for 2 h at room temperature for annealing before conducting 
further experiments.  
2.2.6. VMD analysis of vesicles 
VMD of liposomes and surfactosomes was analysed using laser diffraction via the 
Malvern Mastersizer 2000, Malvern Instruments, UK. The stirring speed was set at 
1,360 rpm and the polydisperse mode of analysis was chosen. The 50% undersize of 
particles (i.e. volume median diameter) was recorded to represent the size of vesicles. 
The vesicles were mixed up using vortex (Stuart, SA8) to avoid vesicular aggregation. 
2.2.7. Zeta potential (Surface charge) analysis 
Zeta potential (surface charge) of liposomes and surfactosomes was analysed using 
electrophoretic light scattering via Malvern Zetasizer Nano ZS (Malvern instruments, 
UK). Three measurements each of ten runs were used to analyse the zeta potential of the 
vesicles. The particle suspension was injected into a "folded capillary cell" which is 
equipped with electrodes on both sides (supplied by Malvern Instruments Ltd, UK). The 
particle speed down the applied electric field was monitored with the laser beam.  
2.2.8. Separation of entrapped and unentrapped drug 
In order to quantify the drug in liposomes and surfactosomes using HPLC (1200 series, 
Agilent Technologies, UK), the separation of unentrapped drug from the vesicle-
entrapped fraction was necessary. The entrapped and unentrapped portions of the drug 
were separated from each other via centrifugation.  
2.2.8.1. Salbutamol sulphate 
Liposomes entrapping SBS were separated from the unentrapped drug in the continuous 
aqueous phase using ultracentrifugation. The centrifugation was performed at 55,000 
rpm (277,816 relative centrifugal force) for 35min at 6°C. Liposomal dispersion (7 ml) 
was loaded into the polycarbonate ultracentrifuge tube (Beckmann, USA) for this 
purpose. The free (unentrapped) drug in the aqueous phase was separated from the 
liposome pellet (entrapped drug) sedimented upon centrifugation via careful aspiration 
of the aqueous phase. Diluted Triton X-100 was added to the liposomal pellet to 
dissolve the liposome membranes, thus, disrupting the liposome vesicles and releasing 
the entrapped drug.  Analysis was conducted using HPLC which determined the 
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unentrapped and entrapped drug concentration to calculate the percentage entrapment of 
SBS. 
2.2.8.2. Beclometasone dipropionate 
For the separation of excess BDP from the liposomal and surfactosomal dispersions, a 
technique based on density difference between BDP crystals and liposomes was 
designed. Deuterated water (D2O) (density: 1.053g/ml) was selected as a vesicular 
dispersion medium for this purpose. Vesicles with BDP were separated from BDP 
crystals using D2O in a bench centrifuge (Jencons-PLS, Spectrafuge 24D, UK). The 
centrifugation was conducted at 13,000 rpm (15,300 relative centrifugal force) for 90 
min at room temperature. The vesicular dispersion (1 ml) was loaded into an eppendorf 
tube for this purpose. The vesicles containing entrapped drug and continuous D2O phase 
containing unentrapped (free) drug were separated using a Gilson pipette. A small 
deposition of the unentrapped crystalline BDP forming sediment in the bottom of the 
eppendorf tube was dissolved using methanol and aspirated via a Gilson pipette. 
Methanol was added to the separated layer to dissolve the vesicle membrane, thus, 
releasing the entrapped drug. This was, thus, ready for HPLC analysis to determine 
entrapped drug concentration. Methanol was also added to the BDP spot sediment and 
D2O containing unentrapped drug and were made ready for HPLC 
2.2.9. Drug entrapment studies  
2.2.9.1. Salbutamol sulphate (SBS) 
All samples were prepared and suspended in HPLC water. A concentration of 5mM 
aqueous solution of sodium 1- hexane sulfonate was mixed with methanol (75:25, v/v) 
to form the mobile phase. Glacial acetic acid (1%) was added to the mixture. HPLC 
instrument was set up using C18 column (HPLC column Eclipse XDB-C18, 4.6 x 
50mm, Agilent, UK) and UV detection at 276nm. The mobile phase flow rate was set at 
1ml/min and 40ºC (Elhissi et al., 2007). The assay was validated by using a calibration 
curve made by using solutions of different known concentrations of SBS from 5µg/ml 
to 70µg/ml. 
% 𝑆𝐵𝑆 𝑒𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑆𝐵𝑆 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑆𝐵𝑆 𝑎𝑑𝑑𝑒𝑑
 𝑥 100 
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2.2.9.2. Beclometasone dipropionate (BDP) 
All BDP samples for HPLC analysis were dissolved in methanol. HPLC-grades of 
Methanol and water (3:1 v/a) constituted the mobile phase. The mobile phase flow rate 
was set up at 1.7ml/min with a sample injection volume of 50µl and UV detection at 
238 nm. The assay was validated by using a calibration curve made by using solutions 
of different known concentrations of BDP from 5µg/ml to 40µg/ml. This HPLC method 
was adapted from that designed by Batavia and co-workers (2001). 
% 𝐵𝐷𝑃 𝑒𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐵𝐷𝑃 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐵𝐷𝑃 𝑎𝑑𝑑𝑒𝑑
 𝑥 100 
 
2.2.10. Drug loading  
Drug loading is calculated to understand the drug loaded per 100mg of lipid. 
2.2.10.1. Salbutamol sulphate (SBS) 
For SBS, for 100mg of lipid 6.67mg of SBS was used. Hence, 
 
𝑆𝐵𝑆 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =




2.2.10.2. Beclometasone dipropionate (BDP) 
For BDP, for 100mg of lipid 2.23mg of BDP was used (2.5 mole %). Hence, 
 
𝐵𝐷𝑃 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐵𝐷𝑃 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑙𝑖𝑝𝑖𝑑
 
2.2.11.  Quantification of phospholipid using Stewart   assay 
Stewart assay  is used to determine the quantity of phospholipid in samples prepared in 
organic solvents such as chloroform by exploiting the capacity of phospholipid 
molecules to develop colour on reaction with ammonium ferrothiocyanate (Stewart, 
1980). In this study, phospholipid concentration was determined in liposomal and 
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surfactosomal samples. Initially ammonium ferrothiocyanade solution was made by 
dissolving 27.03g of ferric chloride and 30.4 g of ammonium thiocyanate in 1000ml 
distilled water. A volume of 1ml vesicular dispersion was taken in a 15ml centrifuge 
tube. To this, 1ml ethanol was added in excess to form an ethanolic solution of 
liposomes and surfactosomes. This solution was kept at 90ºC overnight in an oven to 
evaporate the solvent, thus, forming a dry lipid film on the inner walls of the tube. To 
the resultant dry film, 2ml of chloroform and equal quantity of ammonium 
ferrothiocyanate were added. The tube was then vortexed for 20 seconds and 
centrifuged at 4,000 rpm using the bench centrifuge (Jouan B4i, France) for 10 min at 
4ºC. Chloroform formed the lower layer in the centrifuge while ammonium 
ferrothiocyanate with dissolved phospholipid formed the upper layer. This was due to 
chloroform being heavier than ferrothiocyanate. The lower (i.e. chloroformic) layer was 
separated using a Pasteur pipette and the concentration of phospholipid was estimated 
using spectrophotometry (UV detector) (Jenway, 7315 Spectrophotometer, UK) at 
485nm. The standard calibration curve was used to find the lipid concentration in the 
test sample.  
2.2.12. Visualization of samples using light microscopy 
Light microscopy (Novex B-Range, Holland) was used to analyse different layer after 
centrifugation. Light microscopy was also used to study the behaviour of mannitol in 
water. A drop of sample was placed on a glass slide and covered with a cover slip. 
Eyepiece magnification of 10x and objective magnification of 10x and 40x were used. 
Total magnifications of 100x and 400x were used and samples were viewed and 
analysed using the software Imagefocus v 3.0.  
2.2.13. Scanning electron microscopy (SEM) 
Proliposomes and prosurfactosomes before and after spray drying and freeze drying 
were analysed using Scanning electron Microscopy (SEM) (FEI Quanta 200, USA) and 
vacuum pump (Edwards PV25MK, UK) was used for this purpose. Initially the 
carbontab (agar, UK) was attached to Aluminium specimen tub (agar, UK) and small 
amount of sample was carefully kept on specimen tub. Air duster was used to blow 
away the excess particles. Loaded aluminium stub was sputter coated with gold sputter 
coater (Quorum technologies Emitech K550X, UK) and vacuum pump. The samples 
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were then placed on sample stage to be analysed. Samples were viewed and 
photographed in desired magnification using xT microscope control software. 
2.2.14. Transmission electron microscopy (TEM) 
A drop of SBS and BDP entrapped in liposome and surfactosome was placed on 
separate carbon coated grids (TAAB Laboratories Equipment Ltd., UK) and stained 
negatively using 1% phosphotungstic acid. It was observed and photographed using a 
Philips CM 120 Bio-Twin TEM (Philips Electron Optics BV, the Netherlands).  
2.2.15. Statistical analysis of data 
All data were processed using SPSS (statistical package for the social sciences) 
software by IBM. Data were presented as mean ±standard deviation (SD) with n=3 
observations or experiments. Data were processed using either the student t test or One-
way ANOVA to compare between 2 sets of groups or more than 2 respectively. A p 













                          Chapter 3 
 3.Comparison between liposomes and 
surfactosomes formed using thin film 
method for entrapment of drug before 





In this chapter liposomes and surfactosomes are prepared using thin film method.  Their 
VMD (size), span (size distribution), drug entrapment and drug retention after extrusion 
was studied. Formation of liposomes using thin-film method is the classic method of 
liposome preparation which was first described by Bangham et al (Bangham et al., 
1965). In this method all the lipid components (lipid, cholesterol and lipid soluble drug 
if any) were dispersed in an organic solvent (chloroform) which was evaporated in a 
round bottom flask using rotary evaporator and reduced pressure. For surfactosomes, 
Tween 80 was included in the lipid phase. A thin lipid layer was thus formed on the 
inner wall of the round bottom flask. This layer was hydrated using HPLC water (with 
dissolved drug SBS) for SBS formulations and D2O for BDP formulations and was 
agitated above the phase transition temperature for the thin film to disperse 
appropriately. The vesicles were formed after annealing for 2 h in room temperature. 
This is above the phase transition temperature of the lipid which is below 0°C.  
Multi-lamellar vesicles (1-5µm) were generated and were then reduced in size using 
mini-extruder. To obtain LUVs extrusion through polycarbonate membrane is preferred 
as extrusion decreases the lamellarity of the liposomes (Berger et al., 2001b). This gives 
uniformly sized vesicles. Thin film method is not considered appropriate for the large 
scale production of liposomes.  
In this study, liposomes and surfactosomes were produced using thin film method and 
characterised for VMD and drug entrapment. Extrusion of the produced vesicles was 
employed using Avestin mini-extruder and polycarbonate membranes having pore size 
of 5, 2, 1 and 0.4µm. This investigation was conducted to study and compare the effect 
of stress on liposomes and surfactosomes. This stress was compared to the shear stress 
provided by nebulisers during aerosol generation. Retention of the hydrophilic drug 
salbutamol sulphate (SBS) and the hydrophobic drug beclometasone dipropionate 
(BDP) in liposomes and surfactosomes with and without cholesterol was studied before 
and after extrusion. 
In this chapter, all four formulations were studied for their physical stability, drug 
retention and delivery characteristics. This study will help us conclude if surfactosomes 
are better than conventional liposomes in delivering hydrophilic and hydrophobic drug 
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to the pulmonary system. Extrusion will help us conclude if surfactosomes can entrap 
and retain more drug than liposomes after undergoing a stress similar to nebulisation. 
3.2. Methodology 
3.2.1. Preparation of liposomes for thin-film method 
SPC and cholesterol (1:1 mole ratio) were dissolved in ethanol or chloroform (20mg/ml) 
within a round bottom flask. The organic solvent was evaporated using rotary 
evaporator as described in chapter 2 (section 2.2.1). For liposomes with SBS, 1mg/ml 
drug was dissolved in the saline solution (0.9% w/v) before hydration. In case of BDP, 
2.5 Mole% drug was added to the lipid components before addition of chloroform. 
3.2.2. Surfactosomes 
Lipid phase (SPC and cholesterol, 1:1 mole ratio) along with Tween 80 (15% w/w of 
the total lipid) were placed in a round bottom flask. These were dissolved in ethanol or 
chloroform (20mg/ml) in a round bottom flask. The organic solvent was evaporated and 
the resultant thin film was hydrated as described in section 2.2.4. For liposomes with 
SBS, 1mg/ml drug was dissolved in the isotonic water before hydration. In case of BDP, 
2.5 mole% drug was added to the lipid components before addition of chloroform. 
3.2.3.  Extrusion 
Avestin Liposofast mini extruder was used to extrude the liposomes/ surfactosomes 
through different polycarbonate membranes. Ten ml of samples were extruded at a time. 
The different sizes of Nucleopore Track-etched membranes used were 5, 2, 1 and 
0.4µm.  The sample was passed through 5µm membrane 11 times and 5 times through 
2µm, 1µm and 0.4µm polycarbonate membranes. All samples were first passed through 
5µm membrane and then they were passes through the remaining smaller pore sized 
membranes. Sample extruded through 1µm polycarbonate membrane was extruded 
through 0.4µm.  
3.2.4. Solubility of BDP in presence and absence of Tween 80  
For checking the solubility of BDP in water, excess BDP (three times the normal 
concentration, 2.5 mole% to lipid, was used) was added to 1ml water within an 
Eppendorf tube. The mixture was shaken using a shaker water bath for 24 h at 40°C. If 
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the solution became clear after shaking for 24 h, more BDP was added to ensure that the 
amount added was in excess. BDP was added till the solution remained milky even after 
shaking it for 24 h. The eppendorf tube was centrifuged for 20 min and the supernatant 
was tested for drug concentration using HPLC as described in Chapter 2 section 2.2.9 
(b). The same procedure was repeated to analyse the solubility of BDP in the presence 
of Tween 80. One ml of Tween 80 and water (15:85 v/v) was used for this purpose. 
3.2.5. Stability of liposomes and surfactosomes upon extrusion  
To test the stability, all formulations including liposomes and surfactosomes with and 
without cholesterol were prepared. They were centrifuged using a bench centrifuge and 
the entrapped liposomal and surfactosomal part was separated as described in section 
2.2.8. The vesicular (floating) layer with entrapped drug was aspirated and re-suspended 
in fresh HPLC water. They were extruded 51 times using 1µm polycarbonate 
membranes as described in section 3.2.3. After extrusion, the drug entrapped in the 
vesicle was analysed using HPLC as described in section 2.2.8 and 2.2.9. The stability 
was further analysed by centrifuging the extruded samples using the bench centrifuge 
for 90 min at 13,000 rpm (15,300 relative centrifugal force at room temperature. The 
vesicular layer with entrapped drug was separated as described in section 2.2.8. This 
vesicular layer which contains the entrapped drug was again re-suspended in fresh 
HPLC water. These 1µm vesicles were further extruded 51 times through the extruder 
with 1µm polycarbonate membrane filters. Again the drug entrapped was analysed 
using HPLC as described in chapter 2 section 2.2.9. 
3.3. Results and discussion 
Liposomes and surfactosomes made from soya phosphotidylcholine (SPC) were 
measured for their VMD and span. In this study, thin film was formed by the 
evaporation of chloroform or ethanol in which the lipids were dissolved prior to 
evaporation using rotary evaporator. Hence, liposomes and surfactosomes prepared by 





3.3.1. VMD (size) and size distribution (span) of liposomes 
and surfactosomes with cholesterol prepared from following 
chloroform evaporation 
The median size and span values of liposomes and surfactosomes with cholesterol were 
studied as shown in Figure 3.1 and Figure 3.2 respectively. It was observed that VMD 
of liposomes prior to extrusion was around 6.5µm and for surfactosomes it was around 
4.8µm. Thus, VMD of surfactosomes was significantly smaller than that of liposomes 
(p<0.05). Following extrusion through 5µm polycarbonate membranes, the VMD of the 
liposome decreased to around 3.6µm and surfactosomes to around 3.2µm. There is no 
significant difference in the VMD of both types of vesicles (p>0.05). When the vesicles 
were further extruded through 2µm polycarbonate membranes, the liposomal VMD was 
decreased to 1.9µm and surfactosomal VMD to 1.95µm. On further extrusions with 
1µm and 0.4µm the VMD decreased to 0.89µm and 0.35µm respectively. Surfactosomal 
VMD was decreased to 0.97µm and 0.37µm respectively. There was no significant 
difference in the VMD of both formulations upon extrusion using the same VMD 
polycarbonate membrane (p>0.05). VMD reduction of the liposomes and surfactosomes 
on extrusion suggested that vesicles prepared from conventional components like SPC 
and cholesterol dissolved in chloroform followed by organic solvent evaporation and 
lipid hydration exhibited no apparent aggregation or fusion during extrusion. 
 
Figure 3.1 VMD of liposomes and surfactosomes with cholesterol made from solvent 
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It was observed that the span of liposomes prior to extrusion was around 2.06 and span 
of surfactosomes was around 1.54 with no significant difference between the two 
formulations. Following extrusion through 5µm polycarbonate membranes, the span of 
liposomes was reduced to 1.29 and surfactosomes to 0.86. The span of surfactosome 
was significantly lower than the span of liposomes (p<0.05). When the vesicles were 
further extruded through 2µm polycarbonate membranes, the span of liposome was 
reduced to 0.87 and span of surfactosome was reduces to 0.66. On further extrusions 
with 1µm and 0.4µm the liposomal span was reduced to 0.84 and 0.79 respectively, 
whilst for surfactosomal the span was reduced to 0.63 and 0.53 respectively. For each 
membrane VMD there was no significant difference in the span of liposomes and 
surfactosomes, suggesting that the behaviour of both types of vesicles after extrusions 
with 2µm, 1µm and 0.4µm membranes was similar. The reduced span values suggest 
that as the vesicles were extruded through the polycarbonate membranes, their size 
distribution has become more uniform (i.e. with lower polydispersity) and the standard 
deviation was decreased markedly.  
 
Figure 3.2 Span of liposomes and surfactosomes with cholesterol made from solvent evaporation 
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3.3.2. VMD (size) and span (size distribution) of liposomes 
and surfactosomes without cholesterol prepared following 
chloroform solution evaporation 
The median VMD and the span values of liposomes and surfactosomes without 
cholesterol were studied as shown in Figure 3.3 and Figure 3.4. It was observed that the 
VMD of liposomes prior to extrusion was around 5.82µm and for surfactosomes it was 
around 5.62µm, with no significant difference between the VMD of both types of 
formulations (p>0.05). Following extrusion through 5µm polycarbonate membranes, the 
VMD of the liposome decreased to around 3.46µm and surfactosomes to around 
3.87µm. When the vesicles were further extruded through 2µm polycarbonate 
membranes, the liposomal VMD was decreased to 1.74µm and surfactosomal VMD to 
2.08µm. On further extrusions with 1µm and 0.4µm the liposomal VMD decreased to 
0.89µm and 0.43µm respectively. Surfactosomal VMD was decreased to 1.15µm and 
0.38µm respectively. For each membrane size, there was no significant difference 
between the size of liposomes and surfactosomes (p>0.05). Size reduction of the 
liposomes and surfactosomes on extrusion suggests that vesicles prepared from 
conventional component like SPC in absence of cholesterol made by the solvent 
evaporation of chloroform had no apparent aggregation or fusion during extrusion. 
 
Figure 3.3 VMD of liposomes and surfactosomes without cholesterol made from solvent 
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It was observed that the span of liposomes prior to extrusion was around 2 and for 
surfactosomes it was around 1.68, with no significant difference between the two types 
of vesicles. Following extrusion through 5µm polycarbonate membranes, the span of 
liposomes was lowered to 1.2 and for surfactosomes it was reduced to 1.01. When the 
vesicles were further extruded through 2µm polycarbonate membranes, the span of 
liposome was reduced to 1.06 and for surfactosome it was lowered to 1.23. On further 
extrusions with 1µm and 0.4µm the span for liposomes was decreased to 0.86 and 0.98 
respectively. By contrast, for surfactosomes, the span was reduced to 0.93 and 0.97 
respectively. No significant difference was seen between the span values of liposomes 
and surfactosomes for each membrane size, indicating that both types of vesicles 
exhibited similar behavior upon facing the stress of extrusion through 5µm, 2µm, 1µm 
and 0.4µm membranes.  
 
Figure 3.4 Span of liposomes and surfactosomes without cholesterol made from solvent 
evaporation of chloroformic solution. Data are mean ±SD, n=3. 
 
Hence, from section 3.3.1 and 3.3.2 it can be concluded that inclusion of cholesterol has 
no significant effect on the VMD and span of liposomes and surfactosomes. This 
suggests that cholesterol inclusion can be desirable since it may give more vesicular 
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3.3.3. Liposomes and surfactosomes with cholesterol prepared 
following evaporation of ethanol 
After studying the characteristics of liposomes and surfactosomes prepared following 
the evaporation of chloroform, ethanol was used as an organic solvent instead of 
chloroform. The VMD and span of the resultant vesicles were recorded as shown in 
Figure 3.5 and Figure 3.6. The VMD of liposomes prepared following evaporation of 
ethanol without extrusion was 5.58µm and for surfactosomes it was 5.08µm, with no 
significant difference between the formulations (p>0.05). Here the VMD was consistent 
with that of vesicles prepared using chloroform as organic solvent, as discussed in 
section 3.3.1 and 3.3.2. When extruded with 5µm polycarbonate membranes, 
unexpectedly, the VMD was increased dramatically to 47.7µm for liposomes and to 
110.7µm for surfactosomes. When vesicles were further extruded using 2µm 
polycarbonate membranes, the VMD remained much larger than expected, being 
62.4µm 43.8µm for conventional liposomes and surfactosomes respectively. On further 
extrusion of liposomes with 1µm and 2µm membranes the VMD was markedly 
increased to 73µm and 92.3 respectively. Surfactosomes also exhibited very large VMD 
which was 64.3µm and 132.2µm respectively. For each membrane size, the size 
measured was formulation-dependent (p<0.05). This increase in VMD possibly 
indicates that liposomes and surfactosomes have undergone aggregation, which was 
attributed to the use of ethanol as organic solvent for the preparation of the lipid thin 
film used in manufacturing the liposomes and surfactosomes. The standard deviation for 
formulations was very large which indicated that the size varied with every repetition 
performed. This overall indicates that formulations were very unstable and extrusion 




Figure 3.5 VMD of liposomes and surfactosomes made from solvent evaporation of ethanolic 
solution. Data are mean ±SD, n=3. 
 
Size distribution study confirmed that formulations particularly surfactosomes exhibited 
aggregation or fusion. For instance, the span measurements of liposomes and 
surfactosomes prepared following evaporation of ethanol without extrusion were 
4.07µm and 7.4µm respectively. These values are too high when compared to those 
measured using chloroform as lipid solvent as shown in Figure 3.6. When extruded with 
5 µm polycarbonate membranes the span of liposomes was lowered to 1.9 and for 
surfactosomes it was reduced to 1.2, showing that extrusion through 5µm membranes 
has reduced the polydispersity of the formulations. However, on extrusion with 2µm 
polycarbonate membrane the span of liposomes was further reduced to 1.39 but for 
surfactosomes it was increased to 2.94. On further extrusion with 2µm and 1µm 
membranes the span of liposomes was 1.99 and 1.73 respectively. The span value of 
surfactosomes was 3.3µm and 4.38µm respectively. The surfactosomes had slightly but 
significantly larger span than liposomes (p>0.05). The standard deviation was very large 


































Figure 3.6 Span of liposomes and surfactosomes made from solvent evaporation of ethanolic 
solution. Data are mean ±SD, n=3. 
 
It can be concluded that ethanol was not appropriate at making a thin lipid film for 
subsequent hydration into stable liposomes. Compared to chloroform, the use of ethanol 
increased the size of liposomes and surfactosomes significantly, indicating aggregation 
and/or fusion of the vesicles with highly variable VMD and span measurements 
amongst the different batches investigated; this is evident by the high standard 
deviations. Hence, chloroform as an organic solvent has shown to be more appropriate 
than ethanol in preparation of liposomes using the thin film method. 
After studying the characteristics of liposomes and surfactosomes with regard to their 
VMD and span, it was concluded that ethanol is not suitable for the formation of thin 
films. Hence, further experiments employed chloroform in the preparation of liposomes 
and surfactosomes. It was also observed that there was no significance difference in the 
size of liposomes with and without cholesterol on using chloroform as solvent (p>0.05). 
Surfactosomes with cholesterol were slightly but significantly smaller than 
surfactosomes without cholesterol (p<0.05). Hence, inclusion of cholesterol can be 
considered useful in both liposomes and surfactosomes. 
After VMD and size distribution investigations of empty liposomes and surfactosomes 
were conducted, drug entrapment studies were carried out. Salbutamol Sulphate (SBS), 



























Liposomes using ethanol Surfactosomes using ethanol
68 
 
drug were used to evaluate the influence of drug solubility on the entrapment in 
liposomes and surfactosomes. 
To compare and study the characteristics of liposomes and surfactosomes, drug 
entrapment in these vesicles were studied using HPLC. These vesicles were also 
extruded through various polycarbonate membranes using the mini extruder to study the 
effect of stress and shearing on the drug retention. 
3.3.4. Entrapment efficiency of SBS by liposome and 
surfactosomes with and without cholesterol 
SBS entrapment was studied using HPLC and the results are shown in Figure 3.7. It was 
observed that there was no significant difference between the initial SBS entrapment 
efficiencies of all four formulations (p>0.05). The low entrapment of this drug in 
liposomes or surfactosomes may be due to the losses during the high rotational energy 
exerted during ultracentrifugation (Bendas and Tadros, 2007). It has been previously 
observed that the entrapment of hydrophilic drugs in liposomes is generally low (Taylor 
et al., 1990a, Shivhare et al., 2012). Stability of liposomes has been a concern since 
chemical decomposition of the lipid components and physical aggregation of the 
vesicles may alter the packing patterns of the bilayers, resulting in drug losses (Darwis 
and Kellaway, 2001). However, the entrapment values obtained in this study (Table 1) 
are higher than those found in other studies for the same drug using the thin film 
hydration method (Elhissi et al., 2006, Elhissi et al., 2007), which is possibly attributed 
to the two-step hydration protocol used in the present work.  
 
Figure 3.7  Entrapment of salbutamol sulphate in liposomes and surfactosomes before extrusion in the 

































3.3.5. Drug loading of SBS in liposomes and surfactosomes 
The drug loading of SBS in liposomes and surfactosomes were calculated. This was 
calculated to give the quantity of drug entrapped by 100mg of lipid. This study will help 
to analyse if formulation is economically feasible for drug entrapment. As shown in 
Figure 3.8 there was no significant difference in the SBS loading capacity in all four 
formulations (p>0.05). The highest loading of SBS was obtained using liposomes 
without cholesterol where the loading capacity was 2.38mg per 100mg of lipid. 
 
      Figure 3.8  Drug loading of SBS in liposomes and surfactosomes. Data are mean ±SD, n=3. 
3.3.6. Effect of extrusion on SBS entrapment in liposomes and 
surfactosomes prepared with or without cholesterol 
The liposomes and surfactosomes entrapping SBS were separated by centrifugation and 
were re-suspended in fresh drug-free HPLC water. The resultant dispersions were then 
extruded using various polycarbonate membranes which are 5µm, 2µm, 1µm and 
0.4µm. The stability of vesicles to the external stress was studied by measuring the drug 
entrapment following extrusion (Figure 3.9). It was observed that without any extrusion 
the drug leaked from both liposomes and surfactosomes. In surfactosomes, the 
proportion of drug leaked was greater than those using liposomes. Without any 
extrusion liposomes with cholesterol retained 88.6% while those without cholesterol 
retained 87.8% with no significant difference (p>0.05); suggesting that the large number 
of bilayers prior to extrusion has reduced the leakage of drug from the liposomes. By 
contrast, surfactosomes with cholesterol retained 54% whilst without cholesterol only 



































slight increase in BDP retention in formulation with cholesterol indicates that inclusion 
of cholesterol has reduced the leakage of drug from the surfactosomes. Thus, although 
formulations were not extruded they leaked certain proportions of SBS in a magnitude 
that was dependent on formulation. This is because during annealing the 
liposomes/surfactosomes may undergo physical and chemical changes which may lead 
to vesicle alteration leading to drug leakage via “burst effect” (Darwis and Kellaway, 
2001, Chandy and Sharma, 1996). When extruded through 5µm polycarbonate 
membranes, the SBS retention decreased further. Liposomes with cholesterol and 
without cholesterol retained 84.6 % and 72.9 % respectively with no significant 
difference (p>0.05); whereas surfactosomes with and without cholesterol retained 43.2 
% and 17.8 % respectively with the formulation with cholesterol retaining significantly 
more than the one without cholesterol. When extruded with 2µm polycarbonate 
membranes, the percentage entrapment continued to decrease. Liposome with 
cholesterol and without cholesterol retained 79.4 % and 60 % of SBS respectively 
which is significantly different (p<0.05) whilst surfactosomes with and without 
cholesterol retained 33.9 % and 16 % respectively without any significant difference 
(p>0.05). When these vesicles were extruded through 1µm polycarbonate membrane, 
there was further loss of the drug. Liposomes with cholesterol and without cholesterol 
retained 73.7 % and 58 % of SBS respectively with no significant difference (p>0.05) 
and surfactosomes with and without cholesterol retained 27.1% and 12.47% 
respectively which has a significant difference (p<0.05). Finally these vesicles were 
extruded through 0.4µm polycarbonate membranes. The final entrapment of SBS in 
liposomes and surfactosomes further decreased. Liposome with cholesterol and without 
cholesterol retained 64.8 % and 45.1 % respectively with a significant difference 
(p<0.05), whereas surfactosomes with and without cholesterol retained 20.9 % and 
12.11 % respectively with no significant difference (p>0.05).  
From Figure 3.9 it can be observed that as the pore size of polycarbonate membrane was 
smaller, the SBS retention decreased. It can also be observed that liposomes with 
cholesterol retained greater proportions of the drug than liposomes without cholesterol. 
The same trend was observed for surfactosomes. This observation shows that 
cholesterol makes the vesicles more stable since the drug leakage was decreased. Both 
the vesicles without cholesterol lost significant amount of the drug after being extruded 
through 0.4µm as compared to vesicles with cholesterol. Cholesterol has been reported 
to improve the in vivo and in vitro stability of liposomes (Kirby and Gregoriadis, 1980). 
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Previous studies have shown that cholesterol helped the phosphotidylcholine (PC) 
vesicles to withstand shear stress (Tseng et al., 2007b).  In the present study, it is shown 
that cholesterol enhanced the retention of drug in the vesicles. Moreover, it can also be 
observed that liposomes retained significantly greater drug proportions than 
surfactosomes (p<0.05). This suggests that liposomes have advantages over 
surfactosomes at entrapment of hydrophilic dugs like SBS. There is a significant 
decrease in the SBS entrapment percentage before extrusion and after extrusion though 
smallest pore size membrane used i.e. 0.4µm for all four formulations (p<0.05). The 
greater drug losses from surfactosomes upon extrusion might be attributed to the 
presence of surfactant which affected the bilayers packing and made them leakier. 
Surfactant increases the fluidity by increasing the gaps in bilayer through which SBS 
may leak to outside environment. Tween 80 may also increase the permeability of 
liposomes by interacting with the bilayers and affecting their packing (Young et al., 





Figure 3.9  SBS retention in liposomes and surfactosomes with and without cholesterol before and after passing the vesicles through various sized polycarbonate 
membranes: 5µm, 2µm, 1µm and 0.4µm. In this experiment the originally entrapped liposomes and surfactosomes are re-suspended in fresh HPLC water. Data are 
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Surfactosomes are more elastic than liposomes (Patel et al., 2009) which made the 
pressure required for extrusion very low. Surfactosomal formulations were forced 
though the polycarbonate membranes more easily with less effort in an air tight 
extruder. However, the leaky nature of surfactosomes indicates that they lack the ability 
to withstand pressure and tend to leak easily. The packing of phospholipid in 
transferosomal bilayers were possibly looser, resulting in larger pores for drug leakage 
from the vesicles. Inclusion of cholesterol enhanced the packing of the bilayers, hence, 
drug release decreased in vesicles with cholesterol.  When being extruded, the internal 
pressure physically destabilised the surfactosomes more than liposomes forcing them to 
release the drug entrapped in their internal aqueous spaces.  
Hence, these results suggest that for hydrophilic drugs like SBS liposomes with 
cholesterol are physically more stable than surfactosomes as they tend to retain greater 
drug proportions upon extrusion.  
3.3.7. Stability of SBS entrapped liposomes and surfactosomes 
using excessive extrusion 
The stability of liposomes and surfactosomes with or without cholesterol with SBS was 
studied. Formulations were extruded 51 times with the mini-extruded using 1µm 
polycarbonate membranes. This experiment was designed to simulate the shearing 
environment within the reservoir of a jet-nebuliser where the vesicles undergo stress 
multiple times during the generation of aerosols. From Table 3.1 it can be seen that 
when liposomes with or without cholesterol were extruded 51 times through 1µm 
polycarbonate membrane, liposomes with cholesterol retained significantly more SBS 
than liposomes without cholesterol (p<0.05). Similarly for surfactosomes, the vesicles 
with cholesterol retained significantly more drug than the vesicles made without 
cholesterol (p<0.05). It can also be observed that liposomes retained significantly more 
SBS than surfactosomes, thus, surfactants have contributed to make the vesicles less 
capable of retaining the hydrophilic drug originally entrapped (p<0.05).  
It can also be observed that when the 1µm vesicles after separation of the unentrapped 
drug (i.e. with theoretically 100% drug entrapment efficiency) were again extruded 
using 1µm polycarbonate membrane, SBS retention was better than the extrusion of un-
extruded sample. There was no significant difference in the drug retention in liposomes 
with and without cholesterol (p>0.05). Similarly in surfactosomes also there was no 
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significant difference in SBS retention by vesicles with and without cholesterol 
(p>0.05). However, the drug retention by surfactosomes was significantly low as 
compared to liposomes (p<0.05). 
When un-extruded vesicles were extruded 51 times through 1µm membrane, the 
leakage of SBS was significantly more than the leakage of SBS after 51 times extrusion 
of previously extruded vesicles (p<0.05). This applies for all four formulations. Hence, 
it can be observed that leakage of SBS is significantly more in larger vesicles than from 
small vesicles after excessive extrusion. When a small vesicle is extruded it undergoes 
fragmentation leading to leakage of SBS. During fragmentation only the external bilayer 
is destroyed while the internal core still has drug and water. Hence the leakage is less. 
However when a large un-extruded vesicles is extruded the vesicle is cut through 
leading to leakage of all drug. Similar observation was concluded by Niven in his 
studies (Niven et al., 1991). 
Hence it can be concluded that only small vesicles survive on extensive extrusion and 
size correlates to leakage for hydrophilic drug like SBS. 
Table 3.1 The stability of liposomes and surfactosomes using excessive extrusion through 1µm 
polycarbonate membrane. Data are mean ±SD, n=3. 
Formulations SBS retention after 
51 times extrusion 
through 1µm 
membrane (%) 
SBS retention after 51 
times extrusion of 
previously extruded 
vesicles through 1µm 
membrane (%) 
Liposomes with cholesterol 60.1  ±  3.67 67.27  ±  1.86 
Liposomes without cholesterol 45.06  ±  2.95 63.77  ±  1.65 
Surfactosomes with cholesterol 14.6  ±  1.04 52  ±  1.17 
Surfactosomes without 
cholesterol 
6.6  ±  0.98 47.9  ±  3.3 
Thus, it can be concluded that vesicles with cholesterol are more stable than the one 
without cholesterol for the retention of SBS. Liposomes are more stable than 
surfactosomes for SBS as sample drug. It can also be concluded that for hydrophilic 




To compare and study the characteristics of liposomes and surfactosomes, drug 
entrapment of these vesicles was studied using HPLC. These vesicles were also 
extruded through various polycarbonate membranes using the mini-extruder to study the 
effect of stress and shearing on the retained drug entrapment in liposomes. 
3.3.8. Entrapment of BDP by liposomes and surfactosomes 
with and without cholesterol 
To study the entrapment of BDP, deuterated water (D2O) was used instead of HPLC 
water. This is because on using HPLC water, BDP being insoluble in water was 
sedimented in the bottom of centrifuge tube upon centrifugation along with 
liposomes/surfactosomes-entrapped BDP. This made it impossible to separate 
unentrapped BDP from liposome-entrapped BDP. Hence, high density water (D2O) was 
used to separate the unentrapped BDP from the liposome-entrapped fraction of the drug. 
In this case, upon centrifugation, liposomes containing the entrapped drug will float at 
the top whilst the unentrapped (free) drugs will sediment as crystals (spot) at the bottom 
of the tube. The middle clear aqueous layer between the floating layer and the crystal 
spot adds to the fraction of unentrapped drug (Figure 3.10). 
 





3.3.9. Microscopic analysis of the creamy veicular layer and 
BDP spot in the eppendorf tube  
It was observed that in an eppendorf tube used for centrifugation, 3 layers were formed. 
These included the top thick layer containing liposomes/surfactosomes with entrapped 
BDP, a middle clear layer with unentrapped BDP and a spot at the bottom with BDP 
crystals (Figure 3.10). This was concluded after a microscopic analysis of all two layers 
in the eppendorf after 90 min centrifugation at 13,000 rpm and 15,300 relative gravity 
(Figure 3.11 and 3.12). BDP tends to crystallise due the incompatible steric fit between 
the steroid and the liposome bilayers, resulting in formation of large amounts of BDP 
crystals on storage (Batavia et al., 2001, Radhakrishnan, 1991). This crystallisation 
further leads to minimised incorporation of this drug into the bilayers, hence drug 
entrapment is reduced. 
 
Figure 3.11 A photograph showing liposomes suspended in the top layer of an eppendorf after 90 





Figure 3.12 A photograph showing BDP crystals deposited in the bottom of centrifuge tube after 
90min centrifugation observed under 40X magnification. This is typical of 3 such different 
experiments. 
3.3.10. Stewart assay 
Stewart assay was performed to analyse the quantity of phospholipid (SPC) present in 
each layer after centrifugation. Figure 3.13 and 3.14 graphically represent the amount of 
lipid in each layer of liposome and surfactosome, respectively. 
From Figure 3.13 and 3.14 it was possible to observe that the top layer (i.e. the layer 
containing liposomal suspension) had maximum amount of lipid. Thus, this top layer 
contained almost 93% of liposomes and 94% of surfactosomes in the centrifuged 
eppendorf. This confirmed that separation was highly efficient. Hence, by conducting 
HPLC of BDP from the top layer the drug entrapment percentage can be calculated. The 
middle layer had around 5.5% of the lipid and 2.3% in case of surfactosomes. As 5.5% 
and 2.3% was minimal amount of phospholipid, middle layer can be considered for 
calculating unentrapped BDP. The sedimented spot was confirmed to be mainly made 
of BDP crystals since it had less than 3% of the total lipid used. Hence, no appreciable 
presence of liposomes/surfactosomes was detected in the bottom spot.  
The amount of lipid in top layer is significantly more than lipid present in middle layer 
and spot sediment. Thus, Stewart assay made has confirmed that top layer contained 
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most of the vesicles; hence BDP present in this layer was quantified to calculate the 
entrapped drug proportion, while the middle layer and BDP spot were used to calculate 
the unentrapped proportion of the drug. 
 
Figure 3.13 Lipid present in each liposomal layer formed after centrifugation. Data are mean ± SD, 
n=3; for middle layer and spot compared to top layer 
 
 
Figure 3.14 Lipid in each surfactosomal layer formed after centrifugation. Data are mean ± SD, 
















































3.3.11.  Entrapment of BDP by liposomes and surfactosomes 
with or without cholesterol 
BDP entrapment was studied using HPLC and results were presented in Figure 3.15. It 
was observed that BDP entrapment in liposomes and surfactosomes with cholesterol 
was 31.6% and 30.6% respectively while those in liposome and surfactosome without 
cholesterol was 24.6% and 22.6% respectively. It was observed that there is no 
significant difference between the entrapment of BDP by all four vesicles (p>0.05). The 
difference in drug entrapment as a result of including cholesterol in the formulations 
was not statistically significant (p>0.05).  
This low entrapment is due to the geometric structure of BDP molecules which has 
possibly prevented them from robustly fitting within tahe lipid bilayers of liposomes 
and surfactosomes. It is also believed that some BDP may interact with lipid headgroups 
to form complexes (Darwis and Kellaway, 2001). Steroid drugs have limited solubility 
in phospholipid, hence the maximum entrapment is low (Fildes and Oliver, 1978). 
Hence, perhaps there is initial rapid release of BDP leading to low drug entrapment. 
BDP also tends to crystallise in liposomal formulations due to the incompatible steric fit 
of the drug with the lipid bilayers (Batavia et al., 2001). Hence, using light microscopy, 
large amounts of this crystalline steroid were observed after storage or upon 
centrifugation. Hence, cholesterol is important for providing stability and rigidity to the 
vesicle, thus reducing drug leakage from liposomes (Kirby et al., 1980). The relatively 
low drug entrapment may also be due to centrifugation, physical and chemical 





Figure 3.15  Initial entrapment of BDP in liposomes and surfactosomes in the presence and 
absence of cholesterol. Data are mean ± SD, n=3.  
 
3.3.12. Drug loading of BDP in liposomes and surfactosomes 
The drug loading of BDP in liposomes and surfactosomes was calculated as the quantity 
of drug present in 100mg of lipid. This study will help to analyse if formulations are 
economically feasible for drug entrapment. As shown in Figure 3.16 there is no 
significant difference in the BDP loading efficiency in all four formulations (p>0.05). 
The liposomes with cholesterol have the maximum loading efficiency of 0.43mg of 
drug per 100mg of lipid. 
 

































































3.3.13.  Saturation solubility of BDP in deionised water and 
Tween 80 solution 
Saturation solubility of BDP in water and Tween was studied. As shown in Table 3.2, 
solubility of BDP in water was 0.14µg/ml and in tween 80 solution (15:85 Tween 80: 
water v/v) was 12.67µg/ml. This shows that in presence of Tween 80 greater quantities 
of BDP became soluble. This means that formulations with surfactosomes had greater 
proportions of BDP solubilised in water and hence, less incorporation in the lipid 
bilayers was offered. This is thought to be responsible for the lower entrapment 
efficiency of BDP in surfactosomes compared to liposomes.  
Table 3.2 Table showing the solubility of BDP in water and Tween 80 
Solubility of BDP in water 0.14µg/ml 
Solubility of BDP in water + Tween 80 12.67µg/ml 
3.3.14. Effect of extrusion and cholesterol incorporation on 
drug entrapment in liposomes and surfactosomes  
The liposomes and surfactosomes entrapping BDP were separated from the dispersed 
D2O via centrifugation and were re-suspended in fresh D2O. The dispersions were then 
extruded using polycarbonate membranes with pore size 5µm, 2µm, 1µm and 0.4µm. 
Their reactions to this external stress caused by extrusion and the resultant retained 
entrapment of the drug were presented in Figure 3.17. It was observed that without any 
extrusion the drug leaked slightly from both liposomes and surfactosomes (Figure 3.17). 
Without extrusion the drug entrapment in liposomes with cholesterol and without 
cholesterol was 92.3% and 88% respectively. Similarly for surfactosomes with 
cholesterol and without cholesterol it was 89.33% and 83% respectively. There was no 
significant difference in BDP retention between all four vesicles (p>0.05). For the non-
extruded formulations it was expected that since no stress was applied, they separated 
vesicles should retain almost 100% of the originally entrapped BDP. However, this was 
not the case, possibly because the liposomes/surfactosomes have undergone physical 
changes during re-dispersion in D2O, leading to alterations in the bilayer properties and 
subsequent drug leakage. It has been previously reported that physical alterations in the 
liposome bilayers may cause the entrapped drug to leak (Darwis and Kellaway, 2001). 
When extruded with 5µm polycarbonate membranes, the percentage entrapment 
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decreased further as a result of some vesicle disruption and forced drug leakage while 
“squeezing” the vesicles through the membrane filters. Liposomes with cholesterol and 
without cholesterol retained 88.33 % and 73.66 % BDP respectively with a significant 
difference between both the formulations (p<0.05); whereas surfactosomes with and 
without cholesterol retained 80.66% and 78.66% BDP respectively with no significant 
difference (p>0.05). When extruded through 2µm polycarbonate membranes, the 
entrapment efficiency decreased further. Liposome with cholesterol and without 
cholesterol retained 82.66% and 67.66% of BDP respectively with a significant 
difference between both the formulations (p<0.05); whereas surfactosomes with and 
without cholesterol retained 74.66% and 73.33 % respectively with no significant 
difference (p>0.05). When these vesicles were extruded through 1µm polycarbonate 
membranes, there was further loss of the drug. Liposomes with cholesterol and without 
cholesterol retained 75% and 60.6% of BDP respectively with a significant difference 
between both the formulations (p<0.05); whereas surfactosomes with and without 
cholesterol retained 71% and 69.3% respectively with no significant difference 
(p>0.05).  Finally these vesicles were extruded through 0.4µm polycarbonate 
membrane. The entrapment of BDP in liposome and surfactosomes continued to 
decrease. Liposome with cholesterol and without cholesterol retained 68% and 56% 
with a significant difference between both the formulations (p<0.05); whereas 
surfactosomes with and without cholesterol retained 63.3 % and 62.66 % respectively 
with no significant difference (p>0.05).          
In Figure 3.17 it can be observed that as the pore size of polycarbonate membranes used 
was smaller, the BDP retention decreased. Moreover after statistical analysis it can be 
observed that liposomes with cholesterol retained significant more drug than 
cholesterol-free liposomes after extrusion through all pore sizes (p<0.05). This, 
however, was not a trend for surfactosomes since cholesterol did not significantly 
enhance the retention of the drug, suggesting that the presence of the surfactant in 
surfactosomes was responsible for counteracting the drug retention effect caused by 
cholesterol.  
The drug leakage in surfactosomes with cholesterol was slightly more compared to 
liposomes with cholesterol (p>0.05). This may be due to the reduced ability of 
surfactosomes to withstand the stress provided by the extruder or more likely the 
leakage rate of the drug from the bilayers was higher owing to the presence of surfactant 
in the surfactosomes. It was easier to extrude surfactosomes as compared to liposomes 
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because of their elasticity, but this, however, did not protect the drug from leakage. It is 
also possible that free Tween 80 molecules were present in the continuous phase of the 
surfactosomal formulation resulting in encouraging the steroid drug to partition between 
the bilayers and the continuous phase; this proposed behavior of the drug seemed to be 
further promoted by the stress exerted on the vesicles via extrusion. There is a 
significant decrease in the BDP entrapment before extrusion and after extrusion though 
smallest pore size membrane used i.e. 0.4µm in all formulations. This suggests that 





Figure 3.17  BDP retention in liposomes and surfactosomes with and without cholesterol before extrusion and after passing through various sized polycarbonate membranes 
























Liposomes with cholesterol Liposomes without cholesterol Surfactosomes with cholesterol Surfactosomes without cholesterol
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3.3.15. Stability of BDP entrapped in liposomes and 
surfactosomes using excessive extrusion 
Here, the stability of liposomes and surfactosomes with or without cholesterol, using 
BDP as model drug was studied. Formulations were extruded 51 times using 1µm 
polycarbonate membranes. This was expected to replicate the environment in nebuliser 
chamber where the vesicles undergo stress multiple times and are subjected to excessive 
shearing. From Table 3.3 it can be seen that when the liposomes with and without 
cholesterol was extruded 51 times, liposomes incorporating cholesterol retained 
significantly greater BDP proportions than liposomes prepared without cholesterol 
(p<0.05). For surfactosomes, there was no significant difference between the BDP 
entrapment regardless of cholesterol incorporation in the formulation (p>0.05). It was 
observed earlier that liposomes retained significantly more SBS than surfactosomes, 
thus, liposomes are physically more stable candidate carriers compared to 
surfactosomes   (p<0.05).  
It can be observed that when the 1µm vesicles after separation of the unentrapped drug 
(i.e. with theoretically 100% drug entrapment efficiency) were again extruded using 
1µm polycarbonate membrane, BDP retention was better than the extrusion of un-
extruded sample. There was no significant difference in the drug retention in liposomes 
containing cholesterol compared to liposomes free of cholesterol (p>0.05). 
Surfactosomes with cholesterol retained significantly more BDP than the one without 
cholesterol (p<0.05). The drug retention by surfactosomes was significantly lower than 
retained entrapment of the drug in liposomes (p<0.05). 
Thus, it can be concluded that vesicles with cholesterol are physically more stable than 
the ones without cholesterol. Liposomes retained significantly more BDP than 
surfactosomes. It is found similar to results with SBS as discussed in chapter 3 section 
3.3.7. Hence, it is presumed that liposomes would be more capable of tolerating the 
shear force generated by nebulisers.  This is investigated in further chapters of thesis 















BDP retention  after 
51 times extrusion of 
previously extruded 




65.8  ± 1.79 87.13  ±  1.8 
Liposomes without 
cholesterol 
55.27  ± 2.97 84.1  ±  1.1 
Surfactosomes with 
cholesterol 
55.3  ±  3.08 78.47  ±  1.45 
Surfactosomes without 
cholesterol 
49.5  ±  2.36 71.03± 2.15 
3.3.16. Comparison between liposomes and surfactosomes for 
hydrophilic and lipophilic drug  
As discussed in section 3.3.7 it can be concluded that liposomes are potentially better 
option than surfactosomes to deliver hydrophilic drugs like SBS to the lungs. 
Liposomes with cholesterol can help in maximising the retention of entrapped drug with 
minimum drug loss even if pressure is applied on the vesicles. As discussed in section 
3.3.14, it can be concluded that liposomes are better than surfactosomes for retention of 
lipophilic drugs like BDP. For surfactosomes, the entrapment efficiency was much 
higher for the lipophilic drug compared to the hydrophilic drug. Moreover, drug leakage 
was much less under pressure in surfactosomes when using the lipophilic drug. This 
may be due to the encapsulation of the lipophilic (hydrophobic) drug in the liposomal 
bilayers instead of the aqueous core (Figure 3.18). Hydrophobic drugs are expected to 
be associated with the hydrocarbon chain region of the lipid molecule (Batavia et al., 
2001). It is possible that the presence of Tween 80 in the surfactosomes has promoted 
the fluidity of the vesicle bilayers, resulting in enhanced localisation the steroid with the 
lipid composition of the vesicles. Hence, even after the fragmentation of 
surfactosomes/liposomes during extrusion, upon reassembly the drug can possibly 
associate itself within the bilayers of the downsized vesicles. However, in case of using 
the hydrophilic drug, fragmentation of the vesicles leads to the loss of drug which 
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cannot be again re-entrapped in the liposome aqueous spaces, rather the drug was 
present in the continuous aqueous phase outside the vesicles. 
 
Figure 3.18 Structure of a liposome and schematic representation of drug incorporation (Lembo 
and Cavalli, 2010) 
 
3.4. Conclusions 
After observing the VMD and span of liposomes and surfactosomes, it was decided to 
carry out the subsequent studies using chloroform rather than ethanol. Evaporation of 
ethanol to dissolve the lipids resulted in formation of lipid films that were difficult to 
hydrate, leading to aggregation or fusion of the vesicles, which, due to their large 
measured size, are unlikely to be appropriate for pulmonary drug delivery. It was also 
observed that there was no significance difference in the size of liposomes with or 
without cholesterol. Surfactosomes with cholesterol were slightly but significantly 
smaller than surfactosomes without cholesterol.  
After observing the behavior of liposomes and surfactosomes for drug entrapment, it 
was concluded that there was no significant difference in the SBS entrapment 
efficiencies of all four formulations. It can be concluded that liposomes with cholesterol 
are better for entrapping hydrophilic drugs as compared to surfactosomes. However, the 
use of surfactosomes resulted in excessive drug leakage when they were extruded with 
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5, 2, 1 and 0.4µm sized membrane in Avestin mini-extruder. The retention of SBS was 
better in liposomes than surfactosomes after passing through stress. After studying the 
loading efficiencies it was concluded that there was no significant difference between 
the loading efficiencies of all four formulations. On excessive extrusion (51 times) of all 
four vesicles through 1µm membrane, it was concluded that vesicles with cholesterol 
are more stable than the one without cholesterol for the retention of SBS. Liposomes are 
more stable than surfactosomes for SBS as sample drug. It can also be concluded that 
for hydrophilic drug like SBS smaller vesicles tend to retain more drug than larger 
vesicles after extensive extrusion.  
For lipophilic drug BDP it was found that, there was no significant difference in the 
initial BDP entrapment efficiencies of all four formulations. Both surfactosomes and 
liposomes were appropriate as they both retained significant drug even when they were 
placed under the pressure of extrusion through 5, 2, 1 and 0.4µm sized membrane in 
Avestin mini-extruder.  After studying the loading efficiencies it was seen that there was 
no significant difference between the loading efficiencies of all four formulations. On 
excessive extrusion (51 times) of all four vesicles through 1µm membrane it was 
concluded that vesicles with cholesterol are physically more stable than the ones 
without cholesterol. Liposomes retained significantly more BDP than surfactosomes. 
Hence, it is presumed that liposomes would be more capable of tolerating the shear 
force generated by nebulisers. It can also be concluded that smaller vesicles tend to 
retain more drug than larger vesicles after extensive extrusion. 
Hence in this chapter it is concluded that chloroform is a better solvent for lipids than 
ethanol while preparing liposomes and surfactosomes. It can also be concluded that for 
hydrophilic drug like SBS, liposomes are better than surfactosomes for drug entrapment 
and retention. For hydrophobic like BDP both liposomes and surfactosomes are equally 
good for drug entrapment and retention. Moreover, cholesterol is an important 
component to be incorporated in both types of vesicles as they may increase the stability 
and decrease the drug losses during extrusion. Loading efficiencies of all four 
formulations are similar for SBS and BDP. Liposomes are better than surfactosomes for 
retaining more drugs (both SBS and BDP) after excessive extrusion. Smaller vesicles 












                         Chapter 4 
 4.Entrapment studies of SBS and BDP 
for proliposomes and 
prosurfactosomes using particulate 





Liposomes made using thin film method were studied in the previous chapter. Thin film 
method is not appropriate for manufacturing liposomes on large scale. In addition to 
this, aqueous suspensions of liposomes may be subject to a variety of instability 
manifestations like aggregation, fusion and phospholipid hydrolysis which limit their 
stability. Hence an alternative approach to preparing liposomes was introduced by 
Payne et al in 1986; this was referred to as proliposome technology (Payne et al., 
1986a). This approach has been suggested as a convenient alternative to freeze- drying 
and spray drying. Ethanol based (Perrett et al., 1991) and particulate based 
proliposomes are the two types of proliposomes (Payne et al., 1986a) described in 
literature. In particulate based proliposome technology a carbohydrate carrier like 
sucrose, mannitol or lactose was used as core carrier particles to be coated with 
phospholipid. Addition of aqueous phase and shaking causes instant dissolution of the 
carbohydrate carrier and generation of liposomes. 
In this study, particulate based proliposomes were made using soya phosphotidylcholine 
(SPC), cholesterol (optional) and drug. Salbutamol sulphate (SBS) was used as a model 
hydrophilic drug and beclometasone dipropionate (BDP) was used as model 
hydrophobic drug. In this study a new type of vesicles called prosurfactosomes was 
prepared. In the preparation of prosurfactosomes, the surfactant Tween 80 was included 
within the lipid components. On hydration of prosurfactosomes, surfactosomes were 
formed which are presumed to be more elastic than conventional liposomes. Liposomes 
and surfactosomes prepared from proliposomes and prosurfactosomes respectively were 
studied for their VMD, size distribution (i.e. span), zeta potential (i.e. surface charge) 
and drug entrapment. Moreover, retention of the drug in liposomes after extrusion was 
investigated. Vesicles with different concentrations of cholesterol were considered. 
TEM was used to analyse the shape and lamellarity of liposomes and surfactosomes 









4.2.1. Preparation of proliposome 
SPC and Cholesterol were used in 1:1 and 2:1 mole ratio. The lipid phase was dissolved 
in chloroform (20mg/ml) within a round bottom flask as described in Chapter 2 section 
2.2.2. The carbohydrate carrier particles of mannitol were added to the lipid phase in 1:5 
w/w and 1:10 w/w for SBS and BDP formulations respectively. The organic solvent 
was removed using a rotary evaporator under vacuum for 1h with the flask being 
partially immersed in a water bath (38ºC at maximum) and a rotation speed of 280rpm. 
After releasing the vacuum and detaching the flask from the rotary evaporator, the 
proliposomes were collected using a clean spatula and then stored in room temperature 
to be used on the same day. The proliposomes were hydrated by addition of isotonic 
NaCl solution (0.9%) for salbutamol sulphate (5mg/ml) and deuterium oxide (D2O) for 
beclometasone dipropionate (BDP) (15mg/ml). Drug was incorporated into the 
formulations as described in chapter 2 section 2.2.5.1 and 2.2.5.2. 
4.2.2. Preparation of prosurfactosomes 
Lipid phase (SPC and cholesterol, 1:1 or 1:2 mole ratio) along with Tween 80 (15% 
w/w of the total lipid used) were loaded into a round bottom flask. These components 
were dissolved in chloroform (20 mg/ml) within the round bottom flask. Carbohydrate 
carrier particles of mannitol were added to the lipid phase in 1:5 and 1:10 w/w ratio for 
SBS and BDP formulations respectively. The organic solvent was evaporated and the 
resultant thin film was hydrated by addition of isotonic NaCl solution (0.9%) for 
salbutamol sulphate (5mg/ml) and deuterium oxide (D2O) for beclometasone 
dipropionate (BDP) (15mg/ml). Drug was added as described in chapter 2 section 
2.2.5.1 and 2.2.5.2. 
4.2.3. Analysis of cholesterol in BDP spot 
HPLC was used to analyse the concentration of cholesterol present in the BDP spot in 
the eppendorf after centrifugation. All samples for HPLC were diluted in a mixture of 
methanol before analysis. Methanol (HPLC-grade) was used as the mobile phase. HPLC 
instrument was set up using C18 column (HPLC column Eclipse XDB-C18, 4.6 x 
50mm, Agilent, UK). The mobile flow rate was 1.5ml/min with a sample injection 
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volume of 20µl and UV detection at 207 nm. The assay was validated by using a 
calibration curve made by using solutions of different known concentrations of BDP.  
4.2.4. Extrusion of formulations 
Avestin Liposofast mini-extruder was used to extrude the liposome/ surfactosomes 
samples through polycarbonate membranes having pore sizes 5µm and 2µm. 
(Nucleopore Track-etched membranes). The sample was passed through 5µm and 2µm 
membrane 11 times. All samples were first passed through 5µm membrane and then 
they were passes through the 2µm membranes. This technique may minimise drug loss 
as well as reduce the physical labour-force needed for extrusion. 
4.3. Results and discussion 
4.3.1. VMD (size) and span (size distribution) of SBS 
entrapped liposomes and surfactosomes. 
VMD of SBS entrapped liposomes and surfactosomes prior to extrusion were analysed 
using Malvern Mastersizer as shown in Figure 4.1. Formulations with cholesterol had 
1:1 molar ratio of cholesterol and SPC. Size of liposomes and surfactosomes with 
cholesterol was around 5.92µm and 5.93µm respectively. By contrast, VMD of 
liposomes and surfactosomes without cholesterol was around 6.32µm and 6.05µm 
respectively. It was observed that there was no significant difference between the VMD 
of vesicles (p>0.05).    
 
Figure 4.1 VMD of SBS entrapped liposomes and surfactosomes with (1:1 molar ratio) and 






























Span of SBS entrapped liposomes and surfactosomes prior to extrusion were analysed 
using Malvern Mastersizer as shown in Figure 4.2. Formulations with cholesterol had 
1:1 molar ratio of cholesterol and SPC Span of liposomes and surfactosomes with 
cholesterol was around 2.03 and 1.5 respectively. By contrast, span of liposomes and 
surfactosomes without cholesterol was around 1.96 and 1.94 respectively. It was 
observed that there was no significant difference between the span of vesicles for 
formulations used in this study (p>0.05).  
 
Figure 4.2 Span of SBS entrapped liposomes and surfactosomes with (1:1 molar ratio) and 
without cholesterol. Data are mean ±SD, n=3. 
 
4.3.2. Zeta potential of SBS liposomes and surfactosomes. 
Zeta potential (i.e. surface charge) of SBS liposomes and surfactosomes prior to 
extrusion were analysed using Malvern Zetasizer as shown in Figure 4.3. The zeta 
potential values of liposomes and surfactosomes with cholesterol was around -1.77mV 
and -3.25mV respectively. It can be observed that surface charge of surfactosomes were 
significantly more negative than that of liposomes (p < 0.05) (Figure 4.3). Charge of 
liposomes and surfactosomes without cholesterol were around -1.85mV and -2.28mV 
respectively, with no significant difference between the two formulations (p>0.05). 
Surfactosome with coleaterol appeared to have more negative zeta potential than 
liposomes. The presence of Tween 80 seems to increase the negative surface charge of 
vesicle.  Sorbitan esters, polyoxyethelene delivatives, are fatty acid esters of sorbitol 

























Polysorbate 80 (Tween 80) is an oleate ester (Remington et al., 2006, Rowe et al., 
2009). There is a possibility of by products like free fatty acids like linoleic acid, 
palmitic acid and stearic acid to be present as impurities as verified from Sigma Aldrich, 
UK. It is possible that these acids on dissociation on the surface of a particle gave rise to 
a negatively charged surface as discussed in section 1.7. Similar observation of increase 
in negative charge of solid lipid nanoparticle on addition of Tween 80 in the 
formulation was found by Prabhakar et al. in 2013 (Prabhakar et al., 2013).  Hence, 
surfactosomes are significantly more negative than liposomes.  
Zeta potentials of both liposomes and surfactosomes are tending towards zero with very 
minor differences in the negativity of formulations although statistic disagrees with it. It 
is stated that a higher absolute value of zeta potential indicates a more stable suspension 
and lower value indicates colloid instability, which could lead to aggregation of 
nanoparticles. 
 
Figure 4.3 Zeta potential of SBS entrapped liposomes and surfactosomes with and without 
cholesterol. Data are mean ±SD, n=3. 
 
4.3.3.  Entrapment of SBS in proliposomes and 
prosurfactosomes with and   without cholesterol 
Entrapment of SBS in liposomes and surfactosomes prepared from proliposomes and 


































with and without cholesterol entrapped 8.5% and 4.03% respectively while 
surfactosomes with and without cholesterol  entrapped 11.7% and 4.27% respectively. It 
can be observed that vesicles without cholesterol entrapped significantly lower amount 
of SBS than vesicles made with cholesterol (p<0.05). Hence, inclusion of cholesterol in 
formulation is desirable. It can also be observed that there is no significant difference in 
the entrapment efficiency of both liposomes and surfactosomes (p>0.05). Hence both 
the vesicles with cholesterol can be considered desirable for the entrapment of SBS. It 
is, however, important to note that entrapment of hydrophilic drugs in liposomes is 
known to be generally low since the aqueous spaces within liposome structures are 
limited compared to the aqueous phase outside the liposomes (Taylor et al., 1990, 
Elhissi et al., 2006).  
 
Figure 4.4  Initial entrapment of SBS in liposomes and surfactosomes with and without 
cholesterol. Data are mean ±SD, n=3. 
 
The entrapment of SBS in proliposomes and prosurfactosomes as compared to the 
vesicles prepared by thin film method in chapter 3 section 3.3.4 is very low. Maximum 
entrapment achieved was only 11.7% by prosurfactosomes with cholesterol. Hence, no 






























4.3.4. Drug loading of SBS in proliposomes and 
prosurfactosomes with and without cholesterol 
The drug loading of SBS in proliposomes and prosurfactosomes were calculated. This 
was calculated to give the quantity of drug entrapped by 100mg of lipid. This study will 
help to analyse if formulation is economically feasible for drug entrapment. As shown 
in Figure 4.5, vesicles with cholesterol loads significantly more SBS that the vesicle 
without cholesterol (p<0.05). Hence, inclusion of cholesterol is desirable. However, 
there is no difference between the drug loading of liposomes and surfactosomes 
(p>0.05).  
 
Figure 4.5  Drug loading of SBS in liposomes and surfactosomes with and without cholesterol. 
Data are mean ±SD, n=3. 
 
4.3.5. VMD (size) and span (size distribution) of BDP 
liposomes and surfactosomes. 
VMD of BDP liposomes and surfactosomes prior to extrusion were analysed using the 
Malvern Mastersizer as shown in Figure 4.6. Formulations with cholesterol had 1:1 
molar ratio of cholesterol and SPC. VMD of liposomes and surfactosomes with 
cholesterol was around 5.17µm and 7.46µm respectively. By contrast, when no 
cholesterol was included the VMD measurements of liposomes and surfactosomes were 
around 4.4µm and 5.53µm respectively. It was observed that, regardless of cholesterol 

































VMD of surfactosomes is may be due to the increase in fluidity of bilayer in the 
presence of Tween 80.  This increases the gaps in bilayers, thus, making them bigger 
than liposomes (Young et al., 1983, Tasi et al., 2003). It was also observed that addition 
of cholesterol had slight but significant effect on the VMD of vesicles (p<0.05) (i.e. 
cholesterol increased the size of vesicles). Similar findings were proved by Tseng et al. 
where increase in cholesterol concentration increased the vesicular size (Tseng et al., 
2007a). 
 
Figure 4.6 VMD of BDP entrapped liposomes and surfactosomes with (1:1 molar ratio) and 
without cholesterol. Data are mean ±SD, n=3. 
 
Span of BDP entrapped liposomes and surfactosomes prior to extrusion were analysed 
using Malvern Mastersizer as shown in Figure 4.7. Span of liposomes and 
surfactosomes with cholesterol was around 1.73 and 5.2 respectively. Span of liposomes 
and surfactosomes without cholesterol was around 1.66 and 6.8 respectively. It was 
observed that the span values of liposomes were significantly lower than those of 
surfactosomes. It was also shown that inclusion of cholesterol had no significant effect 
on the span of the vesicles (p>0.05). The large span values of surfactosomes indicate 
that they have wide size distribution (i.e. low uniformity in size). Aggregation of 
vesicles was possibly the reason for this wide size distribution, which may indicate that 
Tween 80 has promoted the aggregation of vesicles. Overall, liposomes had narrower 































though to enhance formulation stability, it actually reduced stability by promoting the 
interaction between the adjacent vesicles. 
 
Figure 4.7 Span of BDP entrapped liposomes and surfactosomes with and without cholesterol. 
Data are mean ±SD, n=3. 
 
4.3.6. Zeta potential of BDP liposomes and surfactosomes 
Zeta potential of BDP liposomes and surfactosomes prior to extrusion were analysed 
using Malvern Mastersizer as shown in Figure 4.8. The surface charge of liposomes and 
surfactosomes with cholesterol were around -4.15mV and -6.74mV respectively. Size of 
liposomes and surfactosomes without cholesterol was -2.3mV and -8.4mV respectively. 
It was demonstrated that the surface charge of liposomes were significantly less 
negative than that of surfactosomes (p<0.05). The surfactosomes were slightly more 
negative than liposomes may be due to the presence of Tween 80. Sorbitan esters, 
polyoxyethelene delivatives, are fatty acid esters of sorbitol and its anhydrides 
copolymerised with a varying number of moles of ethylene oxide. Polysorbate 80 
(Tween 80) is an oleate ester (Remington et al., 2006, Rowe et al., 2009). There is a 
possibility of by products like free fatty acids and their dissociation as discussed in 
section 1.7 and section 4.3.2. It was also seen that inclusion of cholesterol had no 



























Figure 4.8 Zeta potential of BDP entrapped liposomes and surfactosomes with and without 
cholesterol. Data are mean ±SD, n=3. 
 
4.3.7.  Evaluation of mannitol behaviour in aqueous 
environment 
In this study mannitol was used as the carbohydrate carriers for the manufacture of 
proliposomes. Mannitol has been previously proved to be the most promising candidate 
for pulmonary drug delivery (Steckel and Bolzen, 2004). Mannitol is a sugar alcohol 
which acts as an osmotic agent by improving the hydration of airways. This leads to the 
easy clearance of sputum by coughing and ciliary action (Jaques et al., 2008). Mannitol 
inhalation leads to long term improvement to lung function (Chan et al., 2011).  E. 
Daviskas had made several studies on the inhalation of mannitol. In one of the study, 
inhalation of mannitol for 2 weeks improved the lung function in patients with cystic 
fibrosis. The change in sputum’s physical property in favour of patients after treatment 
with mannitol was also observed. Mannitol increased the hydration of the airway 
surface by creating an osmotic gradient for water efflux into the airway lumen, thus, 
improving the mucus clearance (Daviskas et al., 2010). In another study, mannitol 
improved the health status of the patient with bronchiectasis by improving the hydration 
of mucus, thus, improving the clearance of mucus (Daviskas et al., 2005). Mannitol also 
has a positive effect on asthmatic patients (Daviskas et al., 2007). Mannitol inhalation 
reduced the viscoelasticity, surface tension, contact angle and the solids content of 






































and efficient in asthmatic and non-asthmatic patients (Brannan et al., 2005). Mannitol 
along with other sugar alcohols exhibit reduced caloric value. They are metabolised 
independently of insulin, thus, can be safely used by diabetic people (Schiweck et al., 
2000). Hence, Mannitol was selected as carbohydrate carrier for liposomes and 
surfactosomes in this study. 
However, during the studies, it was observed that mannitol formed needle-like 
filaments/crystals when stored in water for more than one hour, forming a gel-like 
product. The crystallization of mannitol in water was monitored using light microscopy 
as shown in Figure 4.9. The resultant samples became no longer suitable for HPLC 
analysis. Thus, immediate usage of these mannitol-based proliposomes in HPLC was 
recommended. Moreover, if this formulation will have a future clinical application, the 
proliposomes should be used immediately after hydration with aqueous phase. 
Mannitol is a naturally occurring sugar alcohol commonly used as a pharmaceutical 
excipient due to its compatibility with drugs and safety. It has different polymorphic 
forms like alpha (α), beta (β) and delta (δ) forms (Yoshinari et al., 2002, Raut et al., 
2011).  It has been previously reported that mannitol has a strong tendency to crystallise 
(Yu et al., 1998). Thus, when mannitol is exposed to high relative humidity this usually 
results in moisture-induced polymorphic transition followed by changes in morphology 
of the particles.  It is also observed that transition from δ form to β form is manifested 
by formation of filament-like crystals. It has also been demonstrated that prolonged 
contact with moisture can decrease the surface area and increase the size of mannitol 
particles. With the increase in the amount of water added, the SEM images have 
revealed the greater percentage of needle like β form (Yoshinari et al., 2003). This 
transformation of an amorphous material to become crystalline is referred to as glass 
transition (Yu et al., 1998). These crystals cannot revert back to their original form at 
room temperature (Raut et al., 2011). This polymorphic property of mannitol had 
adverse effects on outcomes of freeze drying products and shelf stability of drugs 




Figure 4.9 Light microscopy image showing the formation of mannitol crystals on hydration of 
mannitol based proliposomes. Magnification used is 400x. This is a typical of three images 
4.3.8. Initial entrapment of BDP in proliposomes and 
prosurfactosomes 
Initial entrapment of BDP in liposomes and surfactosomes were analysed. For this 
purpose vesicle with SPC only (no cholesterol), SPC with cholesterol (1:1) or SPC with 
cholesterol (2:1) were studied. As shown in Figure 4.10 it can be observed that in the 
formulation without cholesterol, BDP entrapment was 95.7% and decreased 
significantly to 40.3% and 48.3% on addition of cholesterol in the ratio 1:1 and 1:2 ratio 
respectively (p<0.05). Moreover, entrapment in liposomes made from SPC and 
cholesterol (1:1) was slightly but significantly lower than the entrapment in liposomes 
made from SPC and cholesterol (2:1). Entrapment significantly reduced from 48.3% to 
40.3% (p<0.05). This shows that addition of cholesterol decreases the entrapped 
percentage of BDP in liposomes. This is due to the similarity between the structures of 
cholesterol and BDP leading to a competition for entrapment. This competition leads to 
decrease in BDP entrapment. Hence, increase in cholesterol tends to decrease the BDP 
entrapment in the bilayers (Tsotas et al., 2007, Ali et al., 2010). 
For surfactosomes, the formulation without cholesterol entrapped 86.33% of BDP while 
the formulation with SPC and cholesterol (2:1) entrapped 92% of the drug with no 
significant difference in BDP entrapment between the two formulations (p>0.05). For 
the formulation made from SPC and cholesterol (1:1), BDP entrapment was reduced 
significantly to 25.67% (p<0.05). This shows that surfactosomal formulations with no 
102 
 
cholesterol or low cholesterol content (i.e. 2:1 SPC to cholesterol ratio) are superior 
than corresponding formulations made with greater cholesterol proportion (i.e 1:1 SPC 
to cholesterol). This may be due to the similarity in structures of cholesterol and BDP 
which increases the competition to be incorporated in the vesicular bilayer.  
It was also observed that there is no significant difference in the BDP entrapment by 
liposome and surfactosome with only SPC (p>0.05). Similarly there was no significant 
difference between liposomes and surfactosome with 1:1 cholesterol to SPC ratio 
(p>0.05). However, surfactosomes entrapped significantly more BDP than liposomes in 
2:1 SPC to cholesterol ratio (p<0.05).  
Hence, surfactosome has good entrapment of BDP in no or low cholesterol 
concentration, but liposome has good entrapment only in formulation with no 
cholesterol. 
 
Figure 4.10  Initial entrapment of BDP in liposomes and surfactosomes with different 
concentrations of cholesterol. Data are mean ±SD, n=3. 
 
4.3.9. Initial drug loading of BDP in proliposomes and 
prosurfactosomes  
The drug loading of BDP in proliposomes and prosurfactosomes were calculated. This 
was calculated to give the quantity of drug entrapped by 100mg of lipid. This study will 
help to analyse if formulation is economically feasible for drug entrapment. As shown 
in Figure 4.11, BDP loading in liposome without cholesterol was significantly more that 
in liposomes with cholesterol (p<0.05). Moreover, loading of BDP in liposomes made 



























made from SPC and cholesterol (2:1) (p<0.05). This shows that the addition of 
cholesterol decreases the loading of BDP in liposomes 
In surfactosomes, there was no significant difference in the BDP drug loading of 
formulation with only SPC and with SPC and cholesterol (2:1) (p>0.05). However, the 
BDP loading decreased significantly in surfactosomes with SPC and cholesterol (1:1) 
(p<0.05). This shows that as discussed in section 4.3.8, the surfactosomal formulations 
with no cholesterol or low cholesterol content (i.e. 2:1 SPC to cholesterol ratio) are 
superior than corresponding formulations made with greater cholesterol proportion (i.e 
1:1 SPC to cholesterol). 
 
Figure 4.11  Drug loading of BDP in liposomes and surfactosomes with different concentrations 
of cholesterol. Data are mean ±SD, n=3. 
 
4.3.10. Entrapment of BDP in vesicles (i.e. top layer) upon 
centrifugation using cholesterol-free or cholesterol-enriched 
formulations 
The entrapment of BDP in liposomes and surfactosomes was evaluated with a focus on 
formulations that are free from cholesterol. When no cholesterol was incorporated in 
both formulations and when low cholesterol content was used in surfactosomes 
formulation, no BDP sediment was formed upon centrifugation using D2O as dispersion 
medium (described in chapter 3 sections 3.3.8 and 3.3.9).  Hence, the entire amount of 
the drug was suspended in the aqueous phase or incorporated into the vesicle structures. 
The top liposomal layer was studies under light microscope to detect the presence of 
BDP crystals, if any. In Figure 4.12 (a) top suspended liposome layer of formulation 





























enriched with BDP. When no drug was included, the liposome layer was devoid of any 
crystals, indicating that crystals that might be seen in drug-containing formulations are 
BDP crystals. In Figure 4.12 (b) top layer of liposomal formulation without cholesterol 
was observed. This layer had a few scattered BDP crystals floating amidst liposomes; 
these crystals did not form a spot on the bottom of the eppendorf and their appearance 
in the liposome layer possibly indicates they were either adsorbed onto vesicle surfaces 
or leaked from the bilayers under the experimental conditions. In Figure 4.12 (c) top 
layer of liposomes with cholesterol (1:1 molar ratio) was observed. Here there no BDP 
crystals were seen, thus confirming their sedimentation in the bottom of the eppendorf 
or the ability of cholesterol to prevent leakage of the drug under experimental 
conditions.  
In liposomal formulations without cholesterol, the entrapment of BDP was more as 
compared to the ones with cholesterol. This is due to the similarity in structure of 
cholesterol and BDP, resulting in competition for entrapment in the liposomal bilayers. 
Thus, displacement of the lipophilic drug from the liposomal membranes that 
cholesterol has occupied is likely, resulting in lower entrapment efficiency of the drug 
in the liposomal bilayers. Similar effect of cholesterol was observed for the steroid drug 
dexamethasone due to its similarity in structure to cholesterol (Tsotas et al., 2007). In 
other studies, loading of drugs such as diazepam, ibuprofen, midazolam and propofon in 
liposome bilayers was shown to be inﬂuenced by the cholesterol content in the 
formulations; increasing cholesterol content was shown to reduce drug incorporation 
into liposomes. Another report confirmed the presence of a trend of decreasing drug 
loading with increasing cholesterol content in liposomes (Ali et al., 2010). It has also 
been reported that high levels of cholesterol interferes with the close packing of lipids in 
vesicles by modifying the membrane fluidity. This increases the distribution of aqueous 
phase within the liposomal vesicles, hence, reducing the entrapment of hydrophobic 
drug  (Ramana et al., 2010). 
On placement of formulation in a release medium, an initial large bolus of drug is 
released before achieving a stable controlled release profile. This phenomenon is termed 
as “burst effect” (Chandy and Sharma, 1996). Such burst happens in a very short time 
compared to the entire release process. Burst release is also unpredictable and the 
amount of drug leakage cannot be robustly controlled (Huang and Brazel, 2001).  The 
appearance of floating BDP crystals in the vesicle samples (Figure 4.12 b) is possibly 
due to the burst release phenomenon. Hence it can be likely that the entrapment of BDP 
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in vesicles without cholesterol is overestimated since rapid drug leakage will not count 





Figure 4.12  Light microscopy picture showing the top liposomal layer in formulations with (a) 
no drug. There are no crystals present and only vesicles floating (40x magnification). (b) No 
cholesterol. There are BDP crystals present (40x magnification).  (c) With cholesterol. There are 










4.3.11. Cholesterol assay for analysis of cholesterol in BDP 
sediment spot 
Cholesterol assay was performed to study if there is any cholesterol present in the BDP 
spot sedimented at the bottom of eppendorf tube upon centrifugation. This experiment 
was conducted only for cholesterol-containing formulations because BDP spot was 
formed only when cholesterol was included in the formulation. HPLC analysis has 
revealed that the BDP spot had only 5% cholesterol whilst the remaining 90-95 % was 
BDP crystals. Hence, lipid bilayers had greater affinity to incorporate cholesterol which 
displaced BDP from the bilayers, causing it to sediment as a spot, resulting in reduced 
drug entrapment. Formulations without cholesterol had more BDP entrapment and thus, 
no BDP sediment spot was observed. This study has confirmed the “competitional” 
affinity of cholesterol towards liposome bilayers.  
4.3.12. Effect of extrusion on BDP entrapment 
Effect of extrusion on the retention of BDP was studied using a mini-extruder with 
polycarbonate membranes having pore sizes of 5µm and 2µm with 11 cycles of each 
and HPLC for BDP retention studies as shown in Figure 4.13. Vesicles with SPC, SPC 
and cholesterol (2:1) and SPC and cholesterol (1:1) were studied after they were re-
suspended in fresh drug-free D2O. It was seen that liposome with SPC retained 90% 
BDP, vesicle with SPC and cholesterol (2:1) retained 94.3% and vesicle with SPC and 
cholesterol (1:1) retained 93.5% of BDP It was observed that without extrusion there 
was no significant difference in the entrapment of BDP (p>0.05), regardless of 
formulation.  When 5µm polycarbonate membrane was used for extrusion, the drug 
started to leak and entrapment decreased. There was no significant difference among the 
formulation with regard to drug retention by the liposomes (p>0.05). This indicates that 
when stress was applied using 5µm membranes, all formulations behaved similarly and 
were unaffected by the shearing effect, indicating that the stress exerted on the vesicle 
was insufficient to cause marked leakage of BDP from liposomes. On further extrusion 
of 5µm with 2µm polycarbonate membranes, it was observed that liposomes made from 
SPC and cholesterol (1:1) retained significantly lower proportion of BDP than the other 
two liposomal formulations (p<0.05). 
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Similar observation was found for surfactosomes. Vesicles with only SPC and vesicles 
with SPC and cholesterol (2:1) had no significant difference in terms of drug retention 
in the vesicles (p>0.05). 
It can be concluded from this study that inclusion of more cholesterol leads to excessive 
leakage of drug and decreases the ability of vesicles to tolerate stress of extrusion. Thus, 
with less or no cholesterol the vesicles were more stable. Cholesterol has been proved to 
give stability to the liposomes but in this study it was observed that high cholesterol 
levels may displace the BDP from vesicular bilayer. Hence, it is possible that stress has 
encouraged this displacement.  
It can also be observed that there is no significant difference between the retention of 
BDP by liposomes and surfactosomes without extrusion in all three formulations 
(p>0.05). Similar observations with no significant difference were found for retention of 
BDP by liposomes and surfactosomes on extrusion with 5µm and 2µm in all three 
formulations (p>.05). Hence, it can be concluded that liposomes and surfactosomes 




Figure 4.13  Retention of BDP in liposomes and surfactosomes with different concentrations of cholesterol after extrusion with 5µm and 2µm polycarbonate 


































without extrusion 5 µm extrusion 2 µm extrusion
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4.3.13. TEM analysis of liposomes and surfactosomes 
TEM analysis of liposomes and surfactosomes prepared from proliposomes and 
prosurfactosomes respectively were studied in Figure 4.14 (a) and (b). It is observed 
that the vesicles were unilamellar.  
 
 
Figure 4.14 (a): TEM image of liposomes prepared from hydration of 







From this study it was concluded that for hydrophilic drug like SBS or hydrophobic 
agent like BDP, liposomes and surfactosomes had similar VMD and size distribution 
(span). It was observed that for both of the drugs the surface charge of surfactosomes 
was more negative than liposomes. This was attributed to the presence of surfactant 
Tween 80 in the formulation along with the impurities like linoleic, palmitic and stearic 
acids which has possibly affected the surface charge intensity on the vesicle surfaces. 
In the entrapment studies it was shown that liposomes and surfactosomes retained very 
low proportions of SBS. Vesicles without cholesterol entrapped significantly lower 
proportions of this drug as compared to vesicles with cholesterol. After studying chapter 
3 and chapter 4, it was found that the drug entrapment by proliposome technology was 
significantly low as compared the entrapment by thin film method. Therefore, this 
technology is proved to be inappropriate for hydrophilic drug like SBS. For this reason, 
no extrusion was carried out using SBS formulations.  
For BDP, three formulations: vesicles with only SPC, vesicles with SPC and cholesterol 
(2:1) and SPC and cholesterol (1:1) were studied. For liposomes, formulation with no 
cholesterol was proved to be the best because it provided the highest drug entrapment. 
In other formulations with cholesterol it was demonstrated that drug entrapment was 
lower, suggesting that cholesterol has displaced the drug from the lipid bilayer due to 
the similar chemical structure of BDP and cholesterol, resulting in low drug entrapment 
in cholesterol-enriched formulations. For surfactosomes, formulations with no 
cholesterol and those with low cholesterol concentration (i.e. SPC and cholesterol; 2:1) 
proved to provide higher entrapment than formulation with high cholesterol 
concentration (i.e. SPC and cholesterol; 1:1). This is possibly due to displacement of 
BDP by cholesterol. In the presence of low concentration of cholesterol in the 
formulation BDP was not displaced in surfactosomes. Formulation with SPC only was 
analysed under light microscope BDP crystals were found floating on the top layer 
along with the vesicles. This was attributed to the “burst effect” shown by these 
vesicles.  
It can also be concluded that there was no significant difference between the entrapment 
of BDP by liposomes and surfactosomes prepared by proliposome technology in 
formulations with only SPC and those with 1:1 SPC to cholesterol ratio. However, 
111 
 
surfactosomes entrapped significantly more than liposomes in formulations with 2:1 
SPC to cholesterol ratio.  
When extruded with 5µm and 2µm polycarbonate membranes both liposomes and 
surfactosomes behaved similarly in terms of BDP retention in the bilayers. Vesicles 
with more cholesterol (i.e. SPC and cholesterol 1:1) retained lower proportions of BDP 
than the vesicles with no cholesterol or vesicle with less cholesterol (SPC and 
cholesterol 2:1) in both liposomes and surfactosomes. This is due to the excess rigidity 
provided by the cholesterol; hence it was difficult for BDP to locate within the bilayers. 
However, there was no significant difference between the BDP retention by liposomes 
and surfactosomes prepared by proliposome technology in all three formulations 
without extrusion and with extrusion through 5µm and 2µm polycarbonate membrane. 
TEM studies revealed that both proliposomes and prosurfactosomes form unilamellar 
vesicles on hydration.  
Hence, for proliposome formulation with SPC is more preferable over other 
formulations studied and for prosurfactosome formulation with SPC and cholesterol 
(2:1) is more preferable over other studied formulations due to their high BDP 












                         Chapter 5 
 5.Characterisation of particulate based 
proliposomes and prosurfactosome 






Liposomes and surfactosomes on nebulisation delivers drug to the respiratory tract. The 
liposomes and surfactosomes ensure a prolonged and localised drug delivery to the 
lungs (Huang et al., 2010a). These vesicles have the tendency of fragmentation on being 
nebulised due to the shear force generated by the nebuliser. Freeze drying and spray 
drying of liposomes using the cryoprotectant before nebulisation has shown an 
improved drug delivery (Lo et al., 2004, Lu and Hickey, 2005). Payne et al in 1986 
introduced proliposome technology which was more economical and easier to 
manufacture. These proliposomes on hydration with water above Tm of the phospholipid 
used produced liposomes (Payne et al., 1986b). The carrier particle dissolves in water 
and the lipids generate vesicles. 
In this chapter, four vesicular formulations were investigated for their drug delivering 
capacity using Aeroneb Pro, Beurer iH50 vibrating nebulisers and the standard air jet 
PARI LC sprint nebuliser. Proliposomes and prosurfactosome with or without 
cholesterol were investigated. On hydration they produced liposomes and 
surfactosomes. The VMD, span, zeta potential, initial entrapment, BDP delivered to 
both stages of twin impinger, BDP retained by vesicles after nebulisation and aerosol 
droplet sizes were all investigated. The aim of this study was to investigate the four 
formulations (Table 5.1) for its efficiency and stability on being nebulised by three 
nebulisers in both the stage of impinger. 
Table 5.1 List of formulations used for nebulisation 
Proliposomes with cholesterol (1:1 molar ratio SPC to cholesterol) 
Proliposomes without cholesterol 
Prosurfactosomes with cholesterol (1:1 molar ratio SPC to cholesterol) 







5.2.1. Preparation of proliposomes for nebulisation 
For proliposomes without cholesterol, only soya phosphotidylcholine (SPC) was used. 
For proliposomes with cholesterol, SPC and cholesterol were used in 1:1 molar ratio. 
The lipid phase was dissolved in chloroform (20mg/ml) within a round bottom flask. 
Carbohydrate based carrier particle mannitol was added to this lipid phase in 1:5 lipid to 
mannitol ratio for proliposomes with BDP formulations. BDP was added in 2.5 Mole % 
to lipid phase. The organic solvents were removed using a rotary evaporator as 
described in section 2.2.1. After detaching the flask, the proliposomes were collected 
using a clean spatula. The formulations were stored in room temperature and were used 
on the same day for nebulisation.   
5.2.2. Preparation of prosurfactosome for nebulisation 
For prosurfactosome without cholesterol, SPC and Tween 80 were used in the ratio 
85:15. For prosurfactosome with cholesterol, SPC and cholesterol were used in 1:1 
molar ratio with Tween 80 (15% w/w of the total lipid) in a round bottom flask. These 
were dissolved in chloroform (20 mg/ml) in a round bottom flask. Carbohydrate based 
carrier particle mannitol was added to this lipid phase in 1:5 lipid to mannitol ratio for 
prosurfactosome with BDP. BDP was added in 2.5 Mole % to lipid phase. The organic 
solvent was evaporated as described in section 2.2.1. After evaporation of the solvent 
the flask was detached and the proliposomes were collected using a clean spatula. It was 
stored in room temperature and was used on the same day for nebulisation. 
5.2.3. Hydration of vesicles for nebulisation 
Proliposomes and prosurfactosome were hydrated to form liposomal and surfactosomal 
dispersions. They were hydrated with 75% of HPLC water and 25% of NaCl isotonic 
water to a concentration 10mg/ml. This formed an isotonic vesicular dispersion ready 
for nebulisation. The isotonicity was contributed by mannitol and NaCl. 
5.2.4. Assembly of twin impinger  
Twin impinger, also called the two stage impinger, was assembled and isotonic NaCl 
solution was used as a collection medium in both stages of the impinger. Thus, 7ml and 
30 ml solution was placed in upper stage and lower stage of impinger respectively. Flow 
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rate through the impinger was set at 60 L/min for collecting the aerosols generated from 
nebulisers. Figure 5.1 shows the assembly of the twin impinger. 
 
Figure 5.1 Assembly of twin impinge 
 
5.2.5. Delivery of drug in vesicles via nebulisation   
Vesicular dispersion (liposomes/surfactosomes) of 20ml was placed in Aeroneb pro, 
Beurer iH50 and PARI LC sprint nebuliser. The mouthpiece of the nebuliser was 
directed towards the throat of twin impinger as shown in Figure 5.2. The vesicular 
dispersion was nebulised till it reached “dryness”. The liposomal and surfactosomal 
samples delivered were collected from upper stage and lower stage of twin impinger for 
further analysis. The residual concentration of BDP was also calculated by washing the 






Figure.5.2 Assembly of nebuliser with twin impinger (a) Aeroneb Pro vibrating mesh nebuliser (b) PARI 
LC sprint  air jet nebuliser and (c) Beurer iH50 vibrating mesh nebuliser. 
5.2.6. Retention of BDP in vesicles after nebulisation. 
To analyse the BDP retention in vesicles in both the stages, HPLC was carried out after 
centrifuging the samples collected from both stages. The BDP entrapped layer was 
separated from the unentrapped suspension as described in chapter 2 section 2.2.8(b) 
and HPLC analysis was carried out as explained in chapter 2 (section 2.2.9(b)). 
5.2.7. Spraytech experiments  
To detect the aerosol droplet VMD, Malvern spray tech laser diffraction size analyser 
was used. The aerosols generated from the nebuliser were directed perpendicularly to 






aerosols across it. The nebuliser was held 2.5cm away from the laser and VMD and 
span of aerosols were recorded.  
5.3.  Results and discussion 
5.3.1. Initial BDP entrapment 
Entrapment of BDP in liposomes and surfactosomes was analysed as shown in Fig 5.3. 
It was observed that there was no significant difference in the entrapment of BDP by 
both liposomes and surfactosomes with cholesterol (p>0.05). Similarly, there was no 
significant difference in BDP entrapment by both the vesicles without cholesterol 
(p>0.05). However, vesicles with cholesterol entrapped significantly lower amount of 
BDP than vesicles without cholesterol (p<0.05). This high entrapment in vesicles 
without cholesterol is due the excess entrapment of BDP in liposomal bilayer. This is 
due to the absence of competition from cholesterol which has a similar structure to BDP 
(Tsotas et al., 2007). This can lead to the displacement of the lipophilic drug from 
positions in the membrane that cholesterol may have occupied as explained in Chapter 4 
(section 4.3.10). However, some BDP crystals are trapped in the top vesicular layer in 
the eppendorf tube after centrifugation. This is possibly due to the “burst effect” as 
described in chapter 4 section 4.3.10. 
 
 
Figure 5.3  Entrapment of BDP in liposomes and surfactosomes with and without cholesterol 






































5.3.2. Initial BDP drug loading  
The drug loading of BDP in proliposomes and prosurfactosomes were calculated. This 
was calculated to give the quantity of drug entrapped by 100mg of lipid. This study will 
help to analyse if formulation is economically feasible for drug entrapment. As shown 
in Figure 5.4, it can be seen that there is no significant difference between the drug 
loading of liposomes and surfactosomes with and without cholesterol (p>0.05). 
However, significantly more drug is loaded in vesicles without cholesterol (p<0.05). 
Hence, exclusion of cholesterol from formulation is beneficial for better drug loading in 
proliposomes and prosurfactosomes due to lack of competition from cholesterol in 
incorporation of BDP in bilayers. 
 
Figure 5.4  BDP drug loading in liposomes and surfactosomes with and without cholesterol 
before nebulisation. Data are mean ±SD, n=3. 
 
5.3.3. VMD (size) and span (size distribution) of conventional 
liposomes and surfactosomes before nebulisation 
The VMD of liposomes and surfactosomes with and without cholesterol before 
nebulisation were analysed as shown in Table 5.2. It was observed that liposomes 
without cholesterol were significantly larger than the vesicles with cholesterol (p<0.05). 
Vesicles with cholesterol were slightly smaller than the ones without cholesterol. This 
concludes that inclusion of cholesterol decreases the VMD of liposomes and 

































increases the attraction between bilayer lipids, thus, decreasing the size (Wang et al., 
2006) 
The span of liposomes and surfactosomes with and without cholesterol before 
nebulisation was analysed. It was observed that there was no significant difference 
between the span of all vesicles. The size distribution of all vesicles was similar. 
Table 5.2  VMD and span of BDP entrapped liposomes and surfactosomes with and without 
cholesterol. Data are mean ±SD, n=3. 
Formulations VMD (µm)    Span 
Liposomes 6.376 ± 0.45 2.047 ± 0.13 
Liposomes with cholesterol (1:1) 5.38 ± 0.41 1.64 ± 0.48 
Surfactosomes 5.53 ± 0.2 1.47 ± 0.42 
Surfactosomes with cholesterol (1:1) 4.79 ± 0.22 1.7 ± 0.24 
5.3.4. VMD (size) and span (size distribution) of conventional 
liposomes and surfactosomes delivered to twin impinger using 
Aeroneb pro nebuliser 
Liposomes and surfactosomes with and without cholesterol were nebulised using 
Aeroneb Pro vibrating mesh nebuliser. The VMD and span of the vesicles collected in 
the upper and lower stage of twin impinger were analysed for their VMD and span as 
shown in Table 5.3. It was observed that there was no significant difference in the VMD 
of vesicles collected in the upper and lower stage of impinger (p > 0.05) except for 
surfactosomes without cholesterol. In surfactosomes without cholesterol, VMD of 
vesicles accumulated in upper stage was significantly larger than those in lower stage 
(p<0.05). The VMD of all the vesicles was less than 4µm and thus, can be easily 
incorporated into aerosol droplets with less leakage. As studied in chapter 3 sections 
3.3.7 and 3.3.15, small vesicles leak fewer drugs as compared to large vesicles when 
under stress of excessive extrusion.  Vesicles can, thus, possibly be incorporated into 
respirable aerosol droplets that may reach the lung with maximum drug retention on 
nebulisation.  
It was observed that VMD of all the vesicles after nebulisation decreased significantly 
(p<0.05). This size reduction was due to the vibrating mesh which acts as an extruder. 
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Span of all the vesicles deposited in both the stages of twin impinger were studied and 
compared with the initial span. It was observed that in upper stage span of liposomes 
were significantly lower than the span of surfactosomes (p<0.05). Size distribution of 
surfactosomes was more possibly due to its aggregation after nebulisation. In lower 
stage of twin impinger it was observed that the span of surfactosomes without 
cholesterol were significantly higher than that of liposomes without cholesterol 
(p<0.05). There was no significant difference in the span of liposomes and 
surfactosomes with cholesterol (p >0.05). There was no significant difference also 
between the span of vesicles deposited in upper stage and lower stage of twin impinger 
(p>0.05) with an exception of surfactosomes with cholesterol where there was a 
significant difference (p<0.05). Here the span of surfactosomes in lower stage was 
slightly but significantly higher than that in upper stage. In the previous studies, 
inclusion of tween surfactant in liposomal bilayers has resulted in increase in liposome 
interaction, resulting in aggregation. It was also studied by Tasi et al. that inclusion of 
Tween 80 into liposomes decreases the liposomal energy barrier of aggregation or 
fusion from the interaction potential. This aggregation is due to the increase in the 
hydrophobic interaction between the (CH2-CH2-O) of the tween surfactant headgroup 
and the liposomal bilayers.  (Tasi et al., 2003, Elhissi et al., 2012). It has also been 
studied that nebulisation  may increase aggregation by  increasing the fluid 
concentration during nebulization due to solvent evaporation (Muppidi et al., 2012). It is 
also studied that the air flow through the impinger leads to evaporation of water, thus, 
promoting to surfactosomal aggregation and fusion (Dua et al., 2012) 
Thus, it can be concluded that the overall span of surfactosomes is higher than 
liposomes which may be due to the tendency of surfactosomes to aggregate on 
nebulisation 
It was also observed that the span of liposomes remain unchanged after nebulisation but 
span of surfactosomes increased significantly after nebulisation in both the stages 
(P<0.05). This concludes that on nebulisation with Aeroneb pro vibrating mesh 
nebuliser with a mesh pore size 3µm, the size distribution of surfactosomes has 





Table 5.3 VMD and span of BDP entrapped liposomes and surfactosomes with and without cholesterol 
after nebulisation through Aeroneb Pro nebuliser. Data are mean ±SD, n=3. 
Formulations VMD (µm) Span 
 Upper stage  Lower stage Upper stage Lower stage 
Liposomes 2.98±0.75 1.93± 0.07 1.15±0.29  1.47 ± 0.78 
Liposomes with 
cholesterol (1:1) 
2.71±0.45 1.59± 0.27 0.87 ± 0.34 1.1 ± 0.82 




3.18 ± 0.58 1.41± 0.26 2.1± 0.18 2.97± 0.07 
5.3.5. VMD (size) and span (size distribution) of conventional 
liposomes and surfactosomes delivered to twin impinger using 
Beurer nebuliser 
Liposomes and surfactosomes with or without cholesterol were nebulised using Beurer 
vibrating mesh nebuliser. The VMD and span of the vesicles collected in the upper and 
lower stage of twin impinger were collected and were analysed for their VMD and span 
as shown in Table 5.4. It was seen that in upper stage liposome without cholesterol 
VMD was significantly larger than the vesicles with cholesterol (p<0.05). In lower stage 
it was observed that liposomes without cholesterol were significantly larger than the 
surfactosomes with and without cholesterol (p<0.05). It was also observed that liposome 
with cholesterol was significantly larger than the surfactosomes with cholesterol. Here it 
can be concluded that liposomes without cholesterol are larger than the other vesicles.  
Inclusion of cholesterol decreases the VMD of the vesicles. This may be due to the 
close packing of phospholipids due to the presence of cholesterol (Wang et al., 2006). 
VMD of vesicles in upper stage and lower stage of twin impinger were compared with 
the VMD before nebulisation with Beurer iH50. It was observed that the VMD of 
vesicles significantly decreased after nebulisation (p<0.05) with an exception of 
surfactosomes with cholesterol in upper stage. This shows that on nebulising with 
Beurer iH50 vibrating mesh nebuliser the vesicle size decreases and the mesh of the 
device has acted as an extruder. It was also observed that there was a significant 
difference in the size of vesicles without cholesterol in upper stage and lower stage of 
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twin impinger (p<0.05). VMD of vesicles without cholesterol in lower stage was 
significantly smaller than those in upper stage. Vesicles with cholesterol didn’t have 
much size difference between both stages. This may be due to the absence of cholesterol 
makes the vesicle less stable and more prone to fragmentation, thus, making it smaller 
in size. The VMD of all the vesicles was less than 4µm and as studied in chapter 3 
sections 3.3.7 and 3.3.15, small vesicles leak fewer drugs as compared to large vesicles 
when under stress of excessive extrusion. Hence, these vesicles can be incorporated in 
aerosols when nebulised with maximum drug retention. 
Span of all the vesicles deposited in both the stages of twin impinger was studied and 
compared with the initial span. It was observed that in upper stage of twin impinger 
liposomes with and without cholesterol was significantly smaller than the surfactosomes 
with and without cholesterol (p<0.05). There was no significant difference in the 
vesicles with and without cholesterol. Similar finding was found in vesicles collected in 
lower stage of twin impinger. This concludes that the span of surfactosomes was 
significantly higher than liposomes. This is due to the tendency of surfactosomes to 
aggregate and decrease the uniformity of vesicles after nebulisation as discussed in 
section 5.3.4. 
It was also observed that for liposomes without cholesterol, after nebulisation the span 
decreased significantly (p <0.05).  For other vesicles span deceased significantly only in 
upper stage of twin impinger. In the lower stage the decrease in span was not 
significant. This decrease in span after nebulisation with Beurer iH50 suggests that after 
nebulisation the size distribution of vesicles decreases and they become more uniform 
in size. This vibrating mesh nebuliser acts as an extruder to vesicles via forcing the 
vesicles through apertures with defined pore dimensions. Pore dimension of Beurer 
iH50 was between 3.8µm and 4.8µm as confirmed by the company’s technical team. 
Except for liposomes without cholesterol, for all other vesicles there was no significant 
difference between the span of upper and lower stage of twin impinger (p>0.5). This 








Table 5.4 VMD and span of BDP entrapped liposomes and surfactosomes with and without cholesterol 
after nebulisation through Beurer iH50 nebuliser. Data are mean ±SD, n=3. 
Formulations VMD in µm Span 
 Upper stage Lower stage Upper stage Lower stage 
Liposomes 4.07±0.27 3.33 ± 0.28 0.84 ± 0.22 0.68 ± 0.2 
Liposomes with 
cholesterol (1:1) 3.03 ± 0.17 2.52 ± 0.11 0.75 ± 0.22 0.92 ± 0.14 
Surfactosomes 3.72 ±0.3 2.33 ± 0.3   2.69 ± 0.59 1.80 ± 0.25 
Surfactosomes 
with cholesterol 
(1:1) 3.18 ± 0.48 1.52 ± 0.47 2.16 ±  0.17 2.24 ± 0.52 
5.3.6. VMD (size) and span (size distribution) of conventional 
liposomes and surfactosomes delivered to twin impinger using 
PARI LC sprint nebuliser 
Liposomes and surfactosomes with or without cholesterol were nebulised using PARI 
LC sprint air jet nebuliser. The VMD and span of the vesicles collected in the upper and 
lower stage of twin impinger were analysed for their VMD and span as shown in Table 
5.5. It was observed that in upper stage of twin impinger there was significant difference 
between the VMD of liposomes and surfactosomes (p<0.05). Liposomes were 
significantly smaller than surfactosomes with and without cholesterol. This may be due 
to the loose packing of phospholipids in the presence of Tween 80. However, there was 
no significant difference in the vesicular VMD with and without cholesterol. This shows 
that cholesterol does not significantly affect the VMD of liposomes and surfactosomes 
deposited following aerosolisation with the PARI LC sprint nebuliser. However in the 
presence of cholesterol the VMD of the vesicle was slightly decreased.  In lower stage 
there was no significant difference between VMD of all vesicles (p>0.05) with an 
exception of surfactosomes without cholesterol being significantly larger than 
liposomes with cholesterol. Here it can be concluded that cholesterol decreases the size 
of the vesicles, possibly because of the change of the bilayer packing patterns.  
VMD of vesicles in upper stage and lower stage of twin impinger were compared with 
the VMD before nebulisation with the PARI LC sprint nebuliser. Here it was observed 
that the VMD of all the vesicles significantly decreased after the nebulisation (p<0.05) 
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with an exception of surfactosomes without cholesterol in upper stage of the twin 
impinger. It was also observed that there was no significant difference in VMD between 
the vesicles in upper stage and lower stage (p>0.05). Similar finding were observed by 
Saari et al.in 1999 where nebulisation using air jet nebuliser reduced the VMD of 
liposomes due to shear force provided by continuous recycling of liposomes during 
nebulisation (Saari et al., 1999). Liposomal VMD reduction during jet nebulisation was 
also observed by Bridges and Taylor and Elhissi et al. due to shear force generated by 
the jet nebuliser during nebulisation. This leads to fragmentation of vesicle (Bridges and 
Taylor, 1998, Elhissi et al., 2007). 
This concludes that vesicles on being nebulised by PARI LC sprint nebuliser decreases 
in size due to its shear forces, leading to vesicle fragmentation. The VMD of all the 
vesicles was less than 5µm and as studied in chapter 3 sections 3.3.7 and 3.3.15, small 
vesicles leak fewer drug as compared to large vesicles when under stress of excessive 
extrusion. Hence, these vesicles can be incorporated in aerosol droplet on being 
nebulised with maximum drug retentions to be deposited in the lungs.  
Span of all vesicles deposited in upper stage and lower stage of twin impinger were 
analysed after nebulisation with PARI LC sprint nebuliser. It was observed that in upper 
stage there was no significant difference in the span of liposomes and surfactosomes 
with or without cholesterol (p>0.05). The uniformity of all the deposited vesicles was 
similar. Similar results were observed in the lower stage of twin impinger with an 
exception of surfactosomes without cholesterol which was significantly larger than the 
liposomes regardless of cholesterol incorporation within formulation (p<0.05). This was 
possibly due to the tendency of surfactosomes without cholesterol to aggregate on 
nebulisation as they lack the stability in the absence of cholesterol. 
It was also observed that the span of the vesicles changed significantly after 
nebulisation with PARI LC sprint nebuliser. After nebulisation the span of vesicles 
significantly decreased (p<0.05) with an exception of surfactosomes without cholesterol 
in lower stage where the there was a slight decrease in the size. This decrease in 
vesicular size distribution after nebulisation was due to the shear forces offered by the 
nebuliser which makes them more uniform in size. It was also observed that there was 






Table 5.5 VMD and span of BDP entrapped liposomes and surfactosomes with and without cholesterol 
after nebulisation through AirJet nebuliser. Data are mean ±SD, n=3. 
Formulations VMD in  µm Span 
 Upper stage Lower stage Upper stage Lower stage 
Liposomes 3.07± 0.24 1.74±0.35 2.59±0.35 2.76±0.22 
Liposomes with 
cholesterol (1:1) 2.83±0.33 1.53± 0.1 2.27± 0.32 1.82±0.11 
Surfactosomes 4.32±0.39 2.29± 0.26 2.83±0.32 4.08±0.96 
Surfactosomes with 
cholesterol (1:1) 3.8± 0.24 1.79± 0.36 2.73±0.17 2.95± 0.1 
5.3.7. Zeta potential of conventional liposomes and 
surfactosomes before nebulisation 
Zeta potential of liposomes and surfactosomes with and without cholesterol before 
nebulisation was studied as shown in Table 5.6. Surfactosomes appeared to have more 
negative zeta potential than liposomes. The presence of Tween 80 seems to increase the 
negative surface charge of vesicle. Tween 80 is a fatty acid ester made from fatty acid 
and sorbitol.This may be attributed by the presence of impurities/free fatty acids like 
linoleic acid, palmitic acid and stearic acid as discussed in section 4.3.2. It is possible 
that these acids on dissociation on the surface of a particle gave rise to a negatively 
charged surface as discussed in sections 4.3.2 and 1.7. Similar observation of increase in 
negative charge of solid lipid nanoparticle on addition of Tween 80 in the formulation 
was found by Prabhakar et al. in 2013 (Prabhakar et al., 2013).  Hence, surfactosomes 
are significantly more negative than liposomes.  
It is stated that that a higher absolute value of zeta potential indicates a more stable 
suspension and lower value indicates colloid instability, which could lead to 






Table 5.6  Zeta potential of BDP entrapping liposomes and surfactosomes with or without 
cholesterol before nebulisation. Data are mean ±SD, n=3. 
Formulation Zeta potential (mV) 
Liposomes -2.85± 0.17 
Liposomes with cholesterol (1:1) -2.82 ± 0.19 
Surfactosomes -3.44 ± 0.25 
Surfactosomes with cholesterol 
(1:1) -3.70 ± 0.24 
5.3.8. Zeta potential of conventional liposomes and 
surfactosomes delivered to twin impinger using Aeroneb pro, 
Beurer and PARI LC sprint nebulisers 
Following nebulisation directed towards the twin impinger impinger, zeta potential of 
liposomes and surfactosomes with or without cholesterol was determined using 
Aeroneb Pro, Beurer and PARI LC sprint nebulisers (Table 5.7).  
For Aeroneb pro it was observed that there was no significant difference between the 
zeta potentials of all vesicles in upper stage and in lower stage (p>0.05). Moreover, no 
significant difference between the zeta potential measurements of vesicles collected 
from upper stage and lower stage of the twin impinger. This indicates that the surface 
morphology of vesicles remains same in both stages of impinger. 
For Beurer iH50 similar findings as Aeroneb pro were observed. There was no 
significant difference in the zeta potential of vesicles in both upper and lower stage of 
twin impinger (p>0.05). There was also no significant difference between the zeta 
potentials of vesicles collected in upper stage and lower stage of twin impinger. Beurer 
iH50 changes the surface morphology of all the vesicles similarly irrespective of the 
vesicles and site of delivery.  
For PARI LC sprint nebuliser similar findings as Aeroneb pro and Beurer iH 50 were 
observed. There was no difference in the zeta potential of vesicles in both upper and 
lower stage of twin impinger (p>0.05). There was also no significant difference between 
the zeta potentials of vesicles collected in upper stage and lower stage of twin impinger. 
These findings indicate that the zeta potential of all vesicles is similar irrespective of the 
nebuliser and formulation used and regardless of the site of deposition within the twin 
impinger (i.e. upper stage or lower). Similar zeta potential of vesicles indicate that the 
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vesicle uptake by the cells will be similar irrespective of the site of delivery. Similar 
zeta potential also indicates similar pharmacokinetics of the vesicles after being 
delivered by nebuliser (Henriksen et al., 1994). 
However, the zeta potential of the vesicles significantly increased after nebulisation. 
This is possibly due to the reduction in VMD of vesicles after nebulisation. Reduction 
of size increased the surface area which in turn may increase the zeta potential. Similar 
trend was observed where the increase in liposomal VMD decreased the zeta potential 
when stored for 24 hours (Tseng et al., 2007a). Schubert et al in 2005 observed that 
when the particle size of solid-lipid nanoparticles (SLN) decreased with increase in 
emulsifier-lipid ratio, thus increasing zeta potential (Grahame, 1947). The negatively 
charged particles binds to the cationic sites of the cell in the form of cluster for 
adsorption (Henriksen et al., 1994).  
Table 5.7 Zeta potential of BDP entrapped liposomes and surfactosomes with and without cholesterol 
after nebulisation through all three nebulisers nebuliser. Data are mean ±SD, n=3. 



































































The efficiency of Aeroneb Pro, Beurer iH50 and PARI LC sprint nebuliser to deliver 
liposomes and surfactosomes with or without cholesterol to twin impinger was studied. 
This study may help at providing indications on which nebuliser and formulation are 
most desirable in terms of deposition in lower respiratory airways, if further in vivo 
studies are to be conducted in the future. 
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5.3.9. Delivery of BDP using conventional liposomes and 
surfactosomes to twin impinger using Aeroneb Pro nebuliser 
Aeroneb pro was used to study the efficiency of nebulisation using different vesicular 
formulations for pulmonary delivery as shown in Figure 5.5. Surfactosomes without 
cholesterol were delivered higher proportions compared to the other vesicles as 
measured from both the stages. In upper stage, 22% of surfactosomes without 
cholesterol was delivered which was significantly higher than liposomes and 
surfactosomes with cholesterol (p<0.05). Cholesterol-free surfactosomes were delivered 
slightly more than cholesterol-free liposomes (p>0.05). In lower stage, 38.5% of 
surfactosomes without cholesterol was delivered which was significantly more than the 
other formulations investigated (p<0.05). Liposome without cholesterol was also 
delivered in significantly higher proportions than liposome with cholesterol (p<0.05). 
These findings suggest that surfactosomes without cholesterol may offer the greatest 
potential in terms of pulmonary deposition profile using the Aeroneb Pro nebuliser. This 
is due to the high flexibility and lack of rigidity of surfactosomes when cholesterol is 
excluded (Benson, 2010, Samad et al., 2007). This helped the vesicle to squeeze 
through the mesh of the vibrating nebuliser without fragmentation. This may lead to less 
leakage of drug and more delivery. In vesicles with cholesterol, due to presence of 
cholesterol they become rigid. Hence, they are more liable to be broken/ to be 
fragmented when under stress during nebulisation due to excess rigidity. Vesicles were 
more ultradeformable and elastic in the absence of cholesterol. Similar findings were 
concluded by Zaru et al. where liposomes rich in cholesterol and with rigid liposome 
membranes were unable to efficiently retain amphiphilic drug Rifampicin during 
nebulization processes. Liposomes rich in cholesterol demonstrated very low 
nebulisation efficiency. It was also observed that addition of cholesterol at different 
concentrations had an impact on bilayer rigidity as well as on the interactions between 
the drug and the membrane components, influencing the stability of drug incorporation 
in the lipid membrane. This also affected the retention of the drug in the vesicles during 
nebulization (Prabhakar et al., 2013). Cholesterol can also lead to burst effect and 
excessive displacement of BDP from bilayer, thus, leading to excessive BDP leakage. 
It was also observed that BDP was delivered in significantly greater proportions to 
lower stage of twin impinger than upper stage (p<0.05) except with surfactosomes with 
cholesterol. Hence, it can be concluded that more BDP is likely to be delivered to the 
lower respiratory tract than upper tract using the Aeroneb Pro nebuliser. Lower 
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respitatory tract is the desired region for BDP delivery as corticosteroid (BDP) 
inhalation has adverse effects on upper respiratory tract. They include dysphonia, 
hoarseness of voice, cough and oral candiditis. Oral candiditis is rare and dose related 
and can be prevented by gargling, washing and spitting after taking inhaler or with local 
anti-fungal treatment. They are more common with patients sensitive to inhaled 
steroids. Hoarseness in voice is caused by the deposition of corticosteroid on the vocal 
cord. These can be avoided to some extent by gargling and washing after inhalation 
(Barnes, 2007). Hence, delivery of maximum BDP directly to the lower respiratory 
system via vesicles is more desirable. 
 
Figure 5.5 The delivery of BDP entrapped liposomes and surfactosomes with and without 
cholesterol after nebulisation through Aeroneb Pro nebuliser to both stages of impinger. Data are 
mean ±SD, n=3. 
 
5.3.10. BDP retained in conventional liposomes and 
surfactosomes in twin impinger following nebulization with 
the Aeroneb Pro Nebuliser  
BDP retained in vesicles after nebulisation was studied as shown in Figure 5.6. It was 
found that in upper stage vesicles with cholesterol retained significantly lower drug 
proportions than vesicles without cholesterol after nebulisation. Similar results were 
observed in lower stage. However, as studied and discussed in Chapter 4 (section 
4.3.10) there is competition between cholesterol and BDP for the entrapment in the 
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However, as discussed in chapter 4 section 4.3.10 burst release effect may lead to an 
over estimation of drug entrapped in vesicles without cholesterol. Overall in liposomes 
and surfactosomes with cholesterol the drug entrapped was 75.2% and 78.2% 
respectively in upper stage and 79.3% and 84.6% respectively in lower stage. In 
liposomes and surfactosomes without cholesterol the drug entrapped was 97.1% and 
96.2% respectively in upper stage and 98% and 98.1% respectively in lower stage.  
 
Figure 5.6 The retention of BDP in liposomes and surfactosomes with and without cholesterol 
after nebulisation through Aeroneb Pro nebuliser in both stages of impinger. Data are mean ±SD, 
n=3. 
 
5.3.11. Nebulisation of BDP in conventional liposomes and 
surfactosomes to twin impinger using Beurer nebuliser 
Beurer iH50 was used to study the efficiency of nebulisation using different vesicular 
formulations for pulmonary delivery as shown in Figure 5.7. It was observed that in 
upper stage, 23.2%   of BDP in surfactosomes without cholesterol was delivered which 
was significantly higher than other vesicles (p<0.05). It was also observed that 
surfactosomes with cholesterol were the least delivered vesicle with only 10.7% BDP 
being delivered. In lower stage, there was significant difference between the delivery of 
all the vesicles (p<0.05). Surfactosomes without cholesterol delivered more BDP than 
the other formulations which was 44%. Hence, it was concluded that surfactosomes 
without cholesterol was the best formulation to deliver BDP using Beurer iH50 












































upper impinger lower impinger
131 
 
and low rigidity of surfactosomes without cholesterol (Samad et al., 2007). This helped 
the vesicle to squeeze through the mesh of vibrating nebuliser without fragmentation. In 
vesicles with cholesterol, they tend to fragment more due to the rigidity provided by 
cholesterol. The vesicles are more elastic when they are cholesterol-free. Similar 
findings were found with Aeroneb Pro nebuliser in section 5.3.9. Similar findings were 
found in another study by Zaru  et al. where presence of cholesterol in the formulation 
increased the drug leakage (Prabhakar et al., 2013).  
It was also found that the vesicles delivered BDP significantly more in lower stage than 
in upper stage. Hence, it can be concluded that more BDP is likely to be delivered to 
lower respiratory tract than to the upper respiratory tract using Beurer iH50 vibrating 
mesh nebuliser. This is more desirable as BDP has many side effects in upper 
respiratory tract as discussed in section 5.3.9. 
 
Figure 5.7 The delivery of BDP entrapped liposomes and surfactosomes with and without 
cholesterol after nebulisation through Beurer iH50 nebuliser to both stages of impinger. Data are 
mean ±SD, n=3. 
 
5.3.12. BDP retained in conventional liposomes and 
surfactosomes following nebulization into twin impinger using 
Beurer nebuliser 
Drug retained in vesicles after nebulisation using Beurer iH50 vibrating mesh nebuliser 
was studied as shown in Figure 5.8. It was observed that in upper stage liposome 
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was no significant difference between other vesicle’s drug retention capacity (p>0.05). 
In lower stage, vesicles without cholesterol retained significantly more drug than 
vesicles with cholesterol (p<0.05). As studied and discussed in Chapter 4 section 4.3.10 
there is competition between cholesterol and BDP for the entrapment in the bilayers, 
hence, in vesicles without cholesterol higher drug retention was found. However, as 
discussed in chapter 4 section 4.3.10 burst release effect may lead to an over estimation 
of drug entrapped in vesicles without cholesterol. Similar results were observed while 
using Aeroneb pro as discussed in section 5.3.10. Overall in liposomes and 
surfactosomes with cholesterol the drug entrapped was 89.3% and 85.4% respectively in 
upper stage and 86% and 89% respectively in lower stage. In liposomes and 
surfactosomes without cholesterol the drug entrapped was 97.7% and 91.3% 
respectively in upper stage and 95.1% and 94% respectively in lower stage.  
It was also observed that there was significant difference in the drug retention by 
vesicles without cholesterol between upper stage and lower stage (p<0.05).Liposomes 
are delivered more to upper stage whereas surfactosomes are delivered more to lower 
impinger stage. This may be due to the elasticity of surfactosomes which make the 
aerosols reach to the lower stage more than upper stage. The mechanism of operation of 
Beurer iH50 is more specific to this characterisation. However, the percentage of BDP 
delivery is more than 85% for both the formulation in spite of the significant difference. 
 
Figure 5.8 The retention of BDP in liposomes and surfactosomes with and without cholesterol 
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5.3.13. Delivery of BDP using conventional liposomes and 
surfactosomes to twin impinger using PARI LC sprint 
nebuliser. 
PARI LC sprint air Jet nebuliser was used to study the potential of different vesicle-
based formulations for pulmonary delivery as shown in Figure 5.9. It was observed that 
in upper stage, 17.8% of BDP was delivered by surfactosomes with cholesterol which 
was significantly more than other vesicles (p<0.05). In lower stage there was significant 
difference in the drug delivery between all the vesicles (p<0.05). Surfactosomes without 
cholesterol delivered maximum BDP i.e.  62.8%. It was concluded that surfactosomes 
with cholesterol was the best formulation to deliver BDP using PARI LC sprint 
nebuliser to upper impinger while surfactosomes without cholesterol was the best 
formulation for lower impinger. This is due to the high flexibility of surfactosomes (El 
Maghraby et al., 2004). This helped the vesicle to squeeze through the mesh of vibrating 
nebuliser without fragmentation. In liposomes due to the absence of surfactant Tween 
80 they become rigid, hence, more fragmentation. 
It was also observed that there was significantly more BDP delivery in lower stage than 
in upper stage of twin impinger (p<0.05). Hence, it can be concluded that more BDP is 
likely to be delivered to lower tract than upper pulmonary tract using Air Jet nebuliser. 
This is more desirable as BDP has many side effects in upper respiratory tract as 
discussed in section 5.3.9. 
 
Figure 5.9 The delivery of BDP entrapped liposomes and surfactosomes with and without 
cholesterol after nebulisation through PARI LC sprint air jet nebuliser to both stages of 
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5.3.14. BDP retained in conventional liposomes and 
surfactosomes following nebulisation to the twin impinger 
using PARI LC sprint air Jet nebuliser 
BDP retained in vesicles after nebulisation was studied as shown in Figure 5.10. It was 
observed that in upper stage, surfactosomes without cholesterol retained significantly 
less BDP than other vesicles (p<0.05). Other vesicle retained similar amount of drug. In 
lower stage similar results were obtained where only 88.2% of BDP was retained by 
surfactosomes without cholesterol (p<0.05). Other vesicles retained similar amount of 
BDP. Overall in liposomes and surfactosomes with cholesterol the drug entrapped was 
98.6% and 98.1% respectively in upper stage and 98.7% and 97.4% respectively in 
lower stage. In liposomes and surfactosomes without cholesterol the drug entrapped was 
98.7% and 88.1% respectively in upper stage and 98.9% and 88.2% respectively in 
lower stage. This shows that surfactosomes without cholesterol retains least BDP when 
nebulised via air jet nebuliser. This may be due to the loose packing of lipids in 
surfactosomes (Young et al., 1983, Tasi et al., 2003). Mechanism of operation of this 
nebuliser may also have a huge impact. 
It was also observed that there was no significance difference between delivery of 
vesicles containing BDP in upper stage and lower stage of impinger (p>0.05). 
 
Figure 5.10 The retention of BDP in liposomes and surfactosomes with and without cholesterol 
after nebulisation through PARI LC sprint air jet nebuliser in both stages of impinger. Data are 
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Hence, the best formulation for all three nebuliser was analysed. It is expected that the 
delivery of BDP to the lung can be maximised by using the formulation delivering the 
maximum drug proportion through the selected nebuliser. 
Surfactosomes without cholesterol can be concluded as the best formulation after 
analysis of all the formulation. This was due to the elastic nature of these vesicles 
offered by the presence of Tween 80 and absence of cholesterol. Hence, the vesicles can 
easily squeeze through the meshed apertures of Aeroneb pro and Beurer iH50 and also 
sustain themselves without fragmentation upon shearing within the PARI LC sprint 
nebuliser. It can also be concluded that surfactosomes are better than liposomes for 
carrying higher BDP proportions to the twin impinger. 
The nebuliser suitable for each formulation was also analysed. It was observed that for 
liposomes with and without cholesterol, Beurer iH50 vibrating mesh nebuliser was the 
best among the three nebulisers studied. It was suitable for liposomal formulation for 
both upper and lower stages of the impinger. For surfactosomes without cholesterol 
Beurer and Aeroneb Pro both were suitable for BDP delivery to upper impinger while 
the PARI LC sprint nebuliser was better for BDP delivery to the lower impinger. PARI 
LC sprint nebuliser delivers significantly higher drug proportions to lower impinger 
(p<0.05). For surfactosomes with cholesterol, all three nebulisers were equally good for 
upper stage impinger, while for lower stage impinger air jet nebuliser is significantly 
preferable over other nebulisers (p<0.05). 
The aerosols generated for all there nebulisers were investigated for their VMD and 
span using laser diffraction. All four formulations were analysed for their stability and 
efficiency in their aerosol form. 
5.3.15. VMD (size) and span (size distribution) of aerosols 
generated from conventional liposomes and surfactosomes 
using Aeroneb Pro nebuliser 
VMD and span of aerosols generated from Aeroneb Pro vibrating mesh nebuliser were 
analysed as shown in Figure 5.11 and 5.12.  
The experiment showed that there was no significant difference in VMD of aerosols 
generated from all four formulations (p>0.05). Similar results were observed for span. 
All four formulation using Aeroneb pro nebuliser produces aerosols with similar VMD 
and size distribution. This concludes that Aeroneb pro generates similar aerosols 
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irrespective of the formulations. This proves that the physiochemical characteristics of 
liposomes and surfactosomes with and without cholesterol did not affect the size of 
aerosol produced by Aeroneb Pro. 
Hence, it can be concluded that the aerosol VMD and span are similar for all 
formulations generated from Aeroneb Pro nebuliser for all four formulations used in 
this study. 
 
Figure 5.11 The VMD of aerosols of liposomes and surfactosomes with and without cholesterol 
after nebulisation through Aeroneb Pro nebuliser. Data are mean ±SD, n=3. 
 
 
Figure 5.12 The span of aerosols of liposomes and surfactosomes with and without cholesterol 


















































5.3.16. VMD (size) and span (size distribution) of aerosols 
generated from conventional liposomes and surfactosomes 
using Beurer iH50 nebuliser 
VMD and span of aerosols generated from Beurer iH50 vibrating mesh nebuliser were 
analysed as shown in Figure 5.13 and 5.14.  
It was observed that there was no significant difference in VMD of aerosols generated 
from all four formulations (p>0.05).  Similar results were observed for span. All four 
formulation using Beurer iH50 nebuliser produces aerosols with similar VMD and size 
distribution. Similar to Aeroneb Pro, Beurer iH50 is a vibrating mesh nebuliser. As 
discussed in previous section 5.3.15, the properties of the aerosol generated from 
vibrating mesh nebuliser are independent of the physiochemical properties of the fluid 
nebulised. Hence, there is no difference in the VMD and size distribution of aerosols. 
 
 
Figure 5.13 The VMD of aerosols of liposomes and surfactosomes with and without cholesterol 
































Figure 5.14 The span of aerosols of liposomes and surfactosomes with and without cholesterol 
after nebulisation through Beurer iH50 nebuliser. Data are mean ±SD, n=3. 
 
5.3.17. VMD (size) and span (size distribution) of aerosols 
generated from conventional liposomes and surfactosomes 
using PARI LC sprint nebuliser 
VMD and span of aerosols generated from PARI LC sprint air jet nebuliser were 
analysed as shown in Figure 5.15 and 5.16.  
It was observed that the VMD of aerosols generated from surfactosomes with 
cholesterol was significantly more than liposome with cholesterol and surfactosomes 
without cholesterol (p<0.05) and slightly more than liposomes without cholesterol 
(p>0.05). Surfactosomes with cholesterol had the largest aerosol size. This may be due 
to the physiochemical properties of surfactosomes  which is particularly affected in Jet 
nebulisers (Bridges and Taylor, 1998). 
It was also observed that the span of liposomes without cholesterol was slightly but 
significantly greater than surfactosomes with and without cholesterol (p<0.05) and 
slightly more than liposome with cholesterol (p>0.05). This may be due the mechanism 

























Figure 5.15 The VMD of aerosols of liposomes and surfactosomes with and without 
cholesterol after nebulisation through PARI LC sprint nebuliser. Data are mean ±SD, n=3. 
 
 
Figure 5.16 The span of aerosols of liposomes and surfactosomes with and without 
cholesterol after nebulisation through PARI LC sprint nebuliser. Data are mean ±SD, n=3. 
 
It was observed that there was no significant difference in the VMD and span of 
aerosols generated using all the four formulations with Aeroneb pro, Beurer iH50 and 
PARI LC sprint nebuliser (p>0.05). All four formulations can be used with any of the 
























































It was also observed that the VMD of aerosols from all four formulations with all three 
nebulisers were larger than the VMD of liposomes and surfactosomes after nebulisation. 
Hence, the vesicle can easily be accumulated in the aerosol without being fragmented. 
This may minimise the drug leakage from vesicles during nebulisation. As all the 
vesicles are below 10µm in diameter they have the potential of being biologically active 
in susceptible individuals (Heyder, 2004, Hussain et al., 2011). 
5.4. Conclusion 
From this study it can be concluded that VMD and span of liposomes and 
surfactosomes with and without cholesterol decreases after nebulisation. This is due to 
the extrusion offered by meshes of Aeroneb Pro and Beurer iH50 nebuliser and sheer 
vibration by the PARI LC sprint nebuliser. The decrease in span also concludes that the 
uniformity of vesicles increase after nebulisation. It was found that zeta potential of all 
the vesicles after nebulisation were similar irrespective of the formulations, nebuliser 
used and the stage of impinger. This indicates that the vesicle may have similar 
pharmacokinetics after being delivered by nebulisation. However, zeta potential of the 
vesicles increased significantly after being delivered to impinger. This is may be due to 
the decrease in VMD of vesicles. 
On studying the initial entrapment of BDP on all four formulations it was observed that 
vesicles without cholesterol entrapped significantly more BDP than vesicles with 
cholesterol. This was due to the completion between BDP and cholesterol to be 
incorporated into the vesicular bilayer due to their similar structure. It was also 
concluded that surfactosomes without cholesterol is the best formulation to deliver BDP 
via nebulisers. Due to its high elasticity and flexibility it can easy squeeze through the 
meshes of vibrating nebulisers without being fragmented. Hence, maximum 
hydrophobic drug BDP was delivered to both the stages of impinger using 
surfactosomes as a carrier.  
All three nebulisers were analysed and compared for delivery of BDP using liposomes 
and surfactosomes with and without cholesterol. It was found that liposomes with and 
without cholesterol, Beurer iH50 was the better nebuliser for maximum delivery of BDP 
via liposomes to both lower and upper impinger when compared to Aeroneb pro and 
PARI LC sprint nebuliser. Hence, Beurer iH50 can be concluded as the better nebuliser 
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to deliver liposomes. Similarly, for surfactosomes with cholesterol PARI LC nebuliser 
was better than other two to deliver BDP to lower impinger. 
It was also studied that using all three nebulisers maximum BDP was delivered to the 
lower impinger stage as compared to upper impinger stage. This also concludes that for 
hydrophobic drug delivery, vibrating mesh nebulisers are better for upper stage whereas 
jet nebulisers are better for lower stage. Delivery of BDP is not much desirable for 
upper respiratory system as it has many side effects in upper respiratory tract as 
discussed in section 5.3.9. This study will, thus, help to choose the perfect nebuliser and 
vesicle for hydrophobic drug delivery. 
On studying the BDP retention in vesicles after nebulisation, it was concluded that 
using both vibrating mesh nebulisers, vesicles with cholesterol retained less BDP that 
those without cholesterol. This is due to the competition between cholesterol and BDP 
which displaces the BDP. In Air jet nebuliser, surfactosomes without cholesterol 
retained the least drug after nebulisation compared to other formulations. This may be 
due to the inability of surfactosomes to retain its stability in the presence of sheer force 
generated by the jet nebuliser. 
It can also be found that VMD of aerosols were bigger than the VMD of liposomes and 
surfactosomes after nebulisation. Hence, the vesicle can easily be accumulated in the 
aerosol without being fragmented. This may minimise the drug leakage from vesicles 
during nebulisation. 
Hence, from this study it can be concluded that an ultradeformable vesicle, 
surfactosome, is formulated and delivers more BDP to lower impinger than 
conventional liposomes due to improved elasticity. These surfactosomes can withstand 
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Various processes are available to make a dry powder formulation of vesicles to 
increase their stability. Freeze drying and spray drying are common techniques used for 
this purpose. 
Spray drying is a one-step process of drying that can have applications in designing dry 
powders of vesicle formulations. This process has the ability to produce spherical 
micro-particle powders with good flow properties, high porosity and low density. Thus, 
“respirable” dry powdered liposomes have been manufactured using the spray drying 
technology (Lo et al., 2004). Typical spray drying sequences that occur within fractions 
of a second are atomization of feed into a spray, spray-air contact, moisture evaporation 
of the sprayed droplets, and separation of the dried particles from the air (Lo et al., 
2004, Charnvanich et al., 2010). High temperature in spray drying may lead to thermal 
degradation of protein which is a major concern. This activity loss of proteins occurs 
due to protein’s sensitive structural alteration due to heat (Lo et al., 2004). 
Freeze drying is commonly known as “lyophilisation” and is considered a promising 
means of extending the shelf-life of vesicles. As freeze drying is a low temperature 
process it is unlikely to cause thermal degradation of liposomes and surfactosomes (Lu 
and Hickey, 2005, Pikal, 2006). Freeze drying can be viewed as a three-step process 
consisting of freezing, primary drying and secondary drying. Both freezing and drying 
may cause instability problems and stress to liposomes and surfactosomes as a result of 
the induced structural or functional damage to the vesicles during freezing and drying. 
This in turn leads to leakage of the encapsulated drug on rehydration, thus 
compromising integrity of vesicular formulations (Bridges and Taylor, 2001). Even the 
addition of lycoprotectants like mannitol may not prevent the destruction of vesicles.  
In this chapter, the stability of liposomes and proliposomes are analysed. Spray drying 
and freeze drying was performed on liposomal and surfactosomal dispersion to analyse 
their stability due to heat, freezing and drying. Stability of proliposomes and 
prosurfactosomes on being stored for a long time in different environments like room 
temperature, 2-8°C and 40°C were also analysed. The appearance of proliposomes and 
prosurfactosomes were analysed using Scanning electron microscopy (SEM) after and 
before spray drying and freeze drying. X-ray diffraction was performed for further 
analysis of the samples after freeze drying and spray drying. Transmission electron 
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microscopy was also used in this chapter to visualise liposomes and surfactosomes with 
SBS and BDP.  
6.2.  Methods 
6.2.1. Preparation of proliposomes  
For proliposomes with cholesterol, SPC and cholesterol were used in 1:1 molar ratio. 
The lipid phase was dissolved in chloroform (20mg/ml) within a round bottom flask. 
Carbohydrate based carrier particle mannitol was added to this lipid phase in 1:5 lipid to 
mannitol ratio for proliposomes with BDP formulations. BDP was added in 2.5 Mole % 
to lipid phase. The organic solvents were removed using a rotary evaporator as 
described in section 2.2.1. After detaching the flask, the proliposomes were collected 
using a clean spatula. They were stored in room temperature and used immediately.   
6.2.2. Preparation of prosurfactosomes  
For prosurfactosomes with cholesterol, SPC and cholesterol were used in 1:1 molar 
ratio with Tween 80 (15% w/w of the total lipid) in a round bottom flask. These were 
dissolved in chloroform (20 mg/ml) in a round bottom flask. Carbohydrate based carrier 
particles were made by using mannitol which was incorporated into the lipid phase in 
1:5 lipid to mannitol ratio for prosurfactosomes with BDP. BDP was added in 2.5 
mole% to the lipid phase. The organic solvent was evaporated as described in section 
2.2.1. After the evaporation of the solvent the flask was detached and the proliposomes 
were collected using a clean spatula. It was stored in room temperature and was used on 
the same day. 
6.2.3. Hydration of vesicles  
The proliposomes and prosurfactosomes were hydrated to form liposomal and 
surfactosomal dispersions. They were hydrated with HPLC water in the concentration 
10mg/ml. For entrapment studies formulations were hydrated with D2O in to make 
dispersions with lipid concentration of 10mg/ml. 
6.2.4. Spray drying 
Spray dryer was used to convert the liposomes and surfactosomes prepared by 
proliposome technology to dry powder form. BUCHI mini spray dryer B-290, 
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Switzerland, was used for this purpose. All parts of the spray dryer were assembled to 
ensure it was air tight. The temperature was set to 120ºC, Aspiration was 100% and 
pump was 15%. After the final assembly, aspirator and temperature were turned on. 
After reaching a stable input and output temperature, nitrogen inlet was turned on. The 
pressure of 8-9 bars was attained, and the pump was also turned on. Initially distilled 
water was spray dried to clean the instrument and tubes. Liposomal and surfactosomal 
dispersions (30 ml) were passed through the nozzle to be spry dried. The vesicular dry 
powder was collected from the collecting chamber after it was allowed to cool down 
and the powder was used for further characterisation.  
The yield of dry proliposomes and prosurfactosomes was calculated. 30ml of liposomal 
and surfactosomal formulation contained 1.8g of dry ingredients (lipid, BDP and 
mannitol). Hence, yield was the weight of dried liposomes and surfactosomes collected 
after spray drying in the collecting chamber.  
Percentage yield was calculated by comparing the collected weight of 
proliposomes/prosurfactosomes after spray drying and the original weight of 
proliposomes/prosurfactosomes used. 
% 𝑦𝑖𝑒𝑙𝑑 =  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑣𝑒𝑠𝑖𝑐𝑙𝑒𝑠  𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑 (𝑔)
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑖𝑛𝑔𝑟𝑒𝑑𝑖𝑒𝑛𝑡𝑠 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙𝑙𝑦 𝑢𝑠𝑒𝑑 (𝑔) 
× 100 
6.2.5. Freeze drying 
As an alternative to spray drying, freeze drying was used to convert the liposomes and 
surfactosomes prepared by proliposome technology to dry powder. The freeze dryer 
Scanvac Coolsafe 110-4, UK was used for this purpose. The liposomes and 
surfactosomes were initially kept in wide mouthed 30ml glass vials and frozen 
overnight to get a frozen sample. The vials were covered with parafilm having small 
holes to enable the frozen water to sublime during freeze drying. The freeze dryer was 
turned on and the temperature was set at -110ºC. Once this temperature was attained, 
the frozen samples were kept in the freeze dryer and the vacuum was turned on using a 
vacuum pump. This sample was kept in the freeze dryer for 24 hours till water sublimed 
leaving a dry sample. The vacuum was released and the samples were taken out. The 




6.2.6. X-ray diffraction 
X-ray diffraction was performed to check the crystallinity of proliposomes and 
prosurfactosomes before and after the process of spray drying and freeze drying. X-ray 
diffraction instrument (D2 Phaser, Bruker, UK) was used for this purpose. The 
powdered sample was placed on the dry shallow well of the sample holder having the 
diameter of 25mm. A densely packed flat and smooth surface was attained to get 
accurate results. A flat surface was used to press down the powder packing into the 
well. The sample holder was placed in the X-ray diffraction instrument. A range of 5-50 
theta was selected and the instrument was set for 30 min.  
6.2.7. Stability studies  
For the stability studies, proliposomes and prosurfactosomes were stored in different 
environmental conditions like room temperature, 40°C and in 5-6ºC. For room 
temperature, the samples were kept on the bench, whilst for 40°C the samples were kept 
in an incubator (Binder, USA), and for 2-8°C they were stored in the refrigerator 
(Labcold, Sparkfree Fridge Freezer RLFF13246, UK). Proliposomes/prosurfactosomes 
(600 mg) was hydrated to form 10ml of liposomal and surfactosomal dispersion once 
every 2 weeks for a period of 3 months. They were analysed for VMD, span, surface 
charge (i.e. zeta potential), pH and BDP entrapment. Only 1 repetition of experiment 
was considered in this particular study. 
6.2.8. pH test 
PH meter was used to test the acidity/basicity of the liposomal and surfactosomal 
dispersions. Hanna Instruments 2221 pH meter, UK was used for this purpose. Initially 
the instrument was calibrated using the standard pH buffers with pH values of 4 and 
then with pH value of 7. The desired samples were then tested for their respective pH 






6.3. Results and discussions 
6.3.1. Initial VMD, span and zeta potential of liposomes and 
surfactosomes 
VMD, span and zeta potential of liposomes and surfactosomes before spray drying and 
freeze drying were recorded as shown in Table 6.1. As discussed in chapter 5, there was 
no significant difference between liposomes and surfactosomes with regard to VMD, 
span ad zeta potential (p>0.05). The VMD, span and zeta potential after applying the 
drying procedures were compared with those before drying. 
Table 6.1  VMD, span and zeta potential of liposomes and surfactosomes before spray drying 
and freeze drying. Data are mean ±SD, n=3. 
Formulations VMD (µm) Span Zeta potential (mV) 
Liposomes 5.38 ±  0.41 1.64 ±0.49 -2.8± 0.19 
Surfactosomes 4.79 ± 0.22 1.7 ± 0.24 -3.7 ±0.24 
6.3.2. Spray drying of liposomes and surfactosomes 
6.3.2.1. VMD, span and zeta potential after spray drying 
The VMD, span and zeta potential (surface charge) of liposomes and surfactosomes 
after spray drying were analysed in shown in Table 6.2. It was observed that after spray 
drying there was no significant difference in the VMD of liposomes and surfactosomes 
(p>0.05). Similar results were found for span of liposomes and surfactosomes after 
spray drying (p>0.05). However, it was observed that there is significant difference 
between the surface charge of vesicles after spray drying (p<0.05). Surfactosomes 
appeared to have more negative zeta potential than liposomes (p<0.05). The presence of 
Tween 80 seems to increase the negative surface charge of vesicle. Sorbitan esters, 
polyoxyethelene delivatives, are fatty acid esters of sorbitol and its anhydrides 
copolymerised with a varying number of moles of ethylene oxide. Polysorbate 80 
(Tween 80) is an oleate ester (Remington et al., 2006, Rowe et al., 2009). There is a 
possibility of by products like free fatty acids like linoleic acid, palmitic acid and stearic 
acid to be present as impurities as verified from Sigma Aldrich, UK. It is possible that 
these acids on dissociation on the surface of a particle gave rise to a negatively charged 
surface as discussed in section 1.7 and 4.3.2. Similar observation of increase in negative 
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charge of solid lipid nanoparticle on addition of Tween 80 in the formulation was found 
by Prabhakar et al. in 2013 (Prabhakar et al., 2013).  Hence, surfactosomes are 
significantly more negative than liposomes.  
It can also be observed that there was no significant difference between the VMD and 
span of vesicles before and after spray drying as shown in Table 6.1 (p>0.05). However 
there was a significant difference between the charge of vesicles before and after spray 
drying (p<0.05). This leads to the conclusion that heat and stress generated during spray 
drying did not compromise the stability of liposomes and surfactosomes in terms of 
VMD and span. 
 
Table 6.2  Table showing the VMD, span and charge of liposomes and surfactosomes after spray drying. 
Data are mean ±SD, n=3. 
Formulations VMD (µm) Span Zeta potential (mV) 
Liposomes 4.42 ± 0.39 1.42 ± 0.08 -5.8 ±1.83 
Surfactosomes 6.36 ± 1.02 3.76 ± 2.27 -10.1 ± 1 
 
6.3.2.2. Retained entrapment of BDP after spray drying 
Entrapment of liposomes and surfactosomes before and after spray drying was analysed 
as shown in Figure 6.1. It was observed that there was no significant difference in the 
entrapment of BDP in both the vesicles before and after spray drying (Figure 6.1). 
Liposomes and surfactosomes retained 92.8% and 90.84% of BDP respectively after 
spray drying. Thus, surfactosomes and liposomes were stable after facing the heat and 





Figure 6.1 The entrapment of BDP before and after spray drying in liposomes and 
surfactosomes. Data are mean ±SD, n=3. 
 
6.3.2.3. Drug loading of BDP in liposomes and surfactosomes before 
and after spray drying 
The drug loading of BDP in proliposomes and prosurfactosomes before and after spray 
drying were calculated. This was calculated to give the quantity of drug loaded in 
100mg of lipid. This study will help to analyse if formulation is economically feasible 
for drug entrapment. As shown in Figure 6.2, there is no difference in the loaded BDP 
before and after spray drying in both vesicles (p>0.05). This shows that both 
surfactosomes and liposomes were stable after facing the heat and stress generated 



























Figure 6.2 The drug loading of BDP before and after spray drying in liposomes and 
surfactosomes. Data are mean ±SD, n=3. 
 
6.3.2.4. Yield after spray drying 
Amount of proliposomes and prosurfactosomes collected in the collecting chamber after 
spray drying was recorded as shown in Table 6.3. It was observed that there was no 
significant difference in the percentage yield of proliposomes and prosurfactosomes 
after spray drying (p>0.05). 73% of proliposomes was collected while 82% of 
prosurfactosomes were collected compared to the original amount of dry ingredients 
used in the vesicular dispersion. After spray drying 30ml (1.8g) of vesicular dispersion 
(lipid with mannitol), 1.3g of spray dried proliposomes and 1.4g of spray dried 
prosurfactosomes were collected. 
Hence, it can be concluded that surfactosomes have a trend for slightly higher yield than 
liposomes. 
After analysing the VMD and span, zeta potential, BDP retention and yield of 
liposomes and surfactosomes it was found that both liposomes and surfactosomes are 
equally stable to spray drying. They are not much affected by the heat and stress 
generated during the process. This may be due to the absence of heat sensitive materials 





























Initial entrapment Entrapment after spray drying
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Table 6.3 Yield and percentage yield of spray dried proliposomes and prosurfactosomes after 
spray drying. Data are mean ±SD, n=3. 
 Proliposomes Prosurfactosomes 
Yield 1.314g ± 0.46 1.480 g ± 0.08 
% yield 73% 82% 
6.3.3. Freeze drying of liposomes and surfactosomes 
6.3.3.1. VMD, span and zeta potential after freeze drying 
VMD, span and zeta potential of liposomes and surfactosomes after freeze drying was 
analysed as shown in Table 6.4. It was observed that there was significant difference 
between the VMD and span of both vesicles after freeze drying (p<0.05). 
Surfactosomes had significantly large VMD and span than liposomes. However, there 
was no significant difference between the zeta potential values of both formulations 
(p>0.05).It was also observed that there was no significant difference for VMD and 
span of liposomes after freeze drying when compared to the measured values before 
freeze drying (Figure 6.1) (p>0.05). However, VMD and span of surfactosomes 
increased significantly after freeze drying (p<0.05). This may indicate that liposomes 
are more stable to freeze drying than surfactosomes. Surfactosomes had physical 
instability like aggregation and fusion after freeze drying. Surfactosomes may be more 
fragile than liposomes due to its elastiticity. This may make it less resistant and more 
vulnerable during freeze drying. Concentration of cryoprotectant is an important factor 
determining its efficiency in protecting the nanoparticle (Abdelwahed et al., 2006).  As 
discussed in section 1.14.1.1, it is possible that the concentration of cryoprotectant 
mannitol used in formulation was not optimum for surfactosomes as the integrity of 
vesicle was not protected by mannitol. The used quantity of mannitol in the formulation 
did not help in vitrification and replacing water efficiently. This was observed by 
increased size and span after freeze drying. Further studies are required to optimise it. 
This may also be due to the presence of surfactant which increases the tendency of 





Table 6.4  VMD, span and zeta potential of liposomes and surfactosomes after freeze drying. 
Data are mean ±SD, n=3. 
Formulations VMD (µm) Span Zeta potential (mV) 
Liposomes 4.95 ± 0.3 1.91 ± 0.36 -10.7 ± 1.05 
Surfactosomes 7.88 ± 0.93 7.11 ± 1.59 -12.76 ± 0.4 
6.3.3.2. Retained entrapment of BDP after freeze drying 
BDP entrapment of liposomes and surfactosomes before and after freeze drying was 
analysed as shown in Figure 6.3. It was observed that there was no significant 
difference in the initial entrapment of BDP in proliposomes and prosurfactosomes. 
However, It was observed that there was significant loss of BDP in prosurfactosomes as 
compared to proliposomes after freeze drying (p<0.05). Liposomes and surfactosomes 
retained 91.3% ± 2.1 and 86.3% ±1.2 of the originally entrapped BDP respectively after 
freeze drying. Hence, surfactosomes are possibly less stable than liposomes, owing to 
the greater leakage of the originally entrapped steroid. It is likely that freezing followed 
by drying have caused structural damage to the surfactosomes, causing the bilayers to 
leak greater proportions of the originally entrapped BDP. Freezing may cause phase 
transition changes, osmotic stress and expansion of the bilayers due to ice formation 
(Bridges and Taylor, 2001). The stability of bilayers depends on hydrogen bonding 
between water molecules and the polar head groups of the phospholipid molecules in 
the bilayers. The process of drying may lead to loss of water which may lead to changes 
in the bilayer behavior and loss of vesicle integrity. like bilayer damage, or vesicle 
fusion or aggregation, ultimately causing loss of the originally entrapped material 
(Bridges and Taylor, 2001). Lyoprotectants like mannitol helps in stabilisation of 
nanoparticles by water replacement hypothesis where there is a formation of hydrogen 
bond between the lyoprotectant and the polar groups on the surface of nanoparticles. It 
also helps in vitrification as discussed in 1.14.1.1 (Grahame, 1947, Olton, 2008). 
Surfactosomes are possibly more fragile than liposomes due to presence of surfactant, 
Tween 80, and its elasticity. Concentration of mannitol in surfactosomal formulation 
used in this study also may not be optimum enough to preserve its native structure. 
Further studies are required to optimise it. 
Hence, surfactosomes were more unstable than liposome and less able to resist the 




Figure 6.3 Entrapment of BDP before and after freeze drying in liposomes and surfactosomes. 
Data are mean ±SD, n=3. 
 
6.3.3.3. Drug loading of BDP in liposomes and surfactosomes before 
and after freeze drying 
The drug loading of BDP in proliposomes and prosurfactosomes before and after freeze 
drying were calculated. This was calculated to give the quantity of drug entrapped by 
100mg of lipid. This study will help to analyse if formulation is economically feasible 
for drug entrapment. As shown in Figure 6.4, there is no significant difference in the 
BDP loading in liposomes and surfactosomes (p>0.05). However, after freeze drying 
there is significant loss of BDP from surfactosomes as compared to liposomes. This 
shows that surfactosomes are less stable that liposomes after freeze drying owing to the 
































Figure 6.4 Dug loading of BDP before and after freeze drying in liposomes and surfactosomes. 
Data are mean ±SD, n=3. 
 
6.3.4. SEM analysis of proliposomes and prosurfactosomes 
before and after spray drying ad freeze drying. 
6.3.4.1. SEM studies of mannitol, proliposomes and prosurfactosomes  
Morphology of mannitol, proliposomes and prosurfactosomes were studied in Figure 
6.5 (a) and (b) and Figure 6.6(a)-(d) using SEM analysis. It was observed that the 
surface of mannitol became smoother after coating with phospholipid and cholesterol 
for both proliposome and formulations. The porosity of mannitol was decreased because 
of coating with lipids on the outer surfaces of the mannitol carrier particles. According 
to the SEM images, prosurfactosomes appeared to be slightly smoother than 
proliposomes, which may be due to the presence of Tween 80 in prosurfactosomes. The 
VMD of proliposomes and prosurfactosomes ranged between approximately 100-
300µm while size of mannitol particles was less than 200µm. Thus, coating the carrier 
































Figure 6.5 (a) and (b). Structure of mannitol under SEM 
 
 
Figure 6.6 SEM of (a) proliposomes (200µm scale) (b) Proliposomes (20µm scale) (c) Prosurfactosomes 






6.3.4.2. SEM analysis of proliposomes and prosurfactosomes with 
cholesterol after spray drying 
Morphology of proliposomes and prosurfactosomes were analysed after spray drying in 
Figure 6.7 (a)-(d). It was observed that after spray drying proliposomes and 
prosurfactosomes became small in size and spherical in shape. They formed 
microspheres and their size was reduced significantly to less than 5µm. The particle size 
distribution was homogenous. There was also no apparent difference in the morphology 
when proliposomes were compared to prosurfactosomes.  
 
Figure 6.7 SEM of (a) proliposomes after spray drying (20µm scale) (b) Proliposomes after spray drying 
(200µm scale) (c) Prosurfactosomes after spray drying (20µm scale) and (d) Prosurfactosomes after spray 
drying (200µm scale) 
6.3.4.3. SEM analysis of proliposomes and prosurfactosomes after 
freeze drying 
Morphology of proliposomes and prosurfactosomes were analysed after freeze drying in 
Figure 6.8 (a)-(d). It was observed that after freeze drying, proliposomes and 
prosurfactosomes underwent a change in their smooth morphology to become needle 
157 
 
shaped and porous. The needle shaped structure may be due to the crystallisation of 
mannitol as discussed in chapter 4 (section 4.3.6). Yoshinari et al (2003) have shown 
that SEM images of mannitol had needle shaped structures due to the presence of β 
form of mannitol (Yoshinari et al., 2003). They had flake like structure. Porous 
structures can lead to fast reconstitution (Lee et al., 2007). The pores formed may be 
due to the vestige of sublimation of ice in the drying stage, leaving sharpness to the 
structure. They became sharper and smaller than those before freeze drying. The size 
decreased to approximately 20-50µm. It was observed that the morphology of 
prosurfactosomes after freeze drying was less porous than that of proliposomes. This 
may be due to the presence of the surfactant Tween 80 in the prosurfactosome 
formulation. 
 
Figure 6.8 SEM of (a) proliposomes after freeze drying (20µm scale) (b) Proliposomes after freeze drying 
(200µm scale) (c) Prosurfactosomes after freeze drying (20µm scale) and (d) Prosurfactosomes after 




6.3.5. X ray diffraction of proliposomes and prosurfactosomes 
before and after spray drying and freeze drying 
6.3.5.1. X-ray diffraction of spray dried proliposome and 
prosurfactosomes 
X-ray diffraction of proliposomes and prosurfactosomes were studied before and after 
spray drying as shown in Figure 6.9 and 6.10. As shown in Figure 6.9, peaks of 
proliposomes before and after spray drying resemble mannitol peaks as mannitol is the 
most abundant and dominating component of the formulation. Sharp peaks of mannitol 
show its crystallinity (Figure 6.9 a). BDP is semi-crystalline which is shown by the 
broad and less distinct peaks (disordered state) (Figure 6.9 c). Drug is in very small 
quantity as compared to other components; hence, they are not detected by X-ray 
diffraction. Drug peaks are not visible in the proliposomal formulations before and after 
freeze drying. The proliposomal formulation before spray drying is also crystalline 
which is shown by the sharp separated peaks (Figure 6.9 b). However, the peaks of 
proliposome with BDP, PM of proliposome and BDP and empty proliposome after 
spray drying did not show a highly crystalline structure (Figure 6.9 d-f). This is shown 
by the broad and less distinct peaks. An amorphous hump was also observed in the 
XRD graph obtained from the instrument software. Therefore, it can be concluded that 
proliposomes have lost their crystallinity as a result of spray drying and could possibly 
be described as semi-crystalline. Similar results of reduction in crystallinity after spray 
drying was observed by M. Dixit et al. when piroxicam nanocrystals were spray dried 
(Dixit et al., 2010).  Corrigan et al have also observed that spray drying may give 
increased amorphous content (Corrigan et al., 1984, Corrigan et al., 2004). The presence 
of crystallinity of proliposomes even after being spray dried  is possibly due to the 
crystallisation of mannitol as discussed in chapter 4 section 4.3.7 (Yu et al., 1998, 
Yoshinari et al., 2002). 
As observed in SEM images (Figure 6.7) of spray dried particles, they were spherical 
and porous. Porous materials could be amorphous as the particles are not in perfect 
repetitive order. The rapid solidification via rapid solvent removals also leads to 
increased amorphous content of the material (Dixit et al., 2010). Spray drying of 




The reduced crystallinity could lead to enhancement of solubility and dissolution of 
spray dried proliposomes. The tendency of amorphous materials to absorb moisture also 
leads to instability (Andronis et al., 1997).  
 
Figure 6.9 XRD of (a) Mannitol (b) Proliposomes before SD (c) BDP (d) PM of proliposomes and BDP 
after SD (e) Empty Proliposome after SD (f) proliposome with BDP after SD. 
 
Similar change in crystallinity was observed with prosurfactosomes after spray drying 
as observed with proliposomes in Figure 6.10. Crystallinity of prosurfactosomes 
decreased as a result of spray drying, thus, increasing their dissolution and decreasing 
their stability.  
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Figure 6.10 XRD of (a) Mannitol (b) Prosurfactosomes before SD (c) BDP (d) PM of prosurfactosomes 
and BDP after SD (e) Empty Prosurfactosomes after SD (f) Prosurfactosomes with BDP after SD. 
 
6.3.5.2. X-ray diffraction of freeze dried proliposomes and 
prosurfactosomes 
X-ray diffraction of proliposomes and prosurfactosomes were studied before and after 
freeze drying as shown in Figure 6.11 and 6.12. As shown in Figure 6.11 (a-f), peaks of 
proliposomes before and after spray drying resembled mannitol peaks as mannitol is the 
most abundant and dominating component of the formulation. Sharp peaks of mannitol 
show the crystallinity of the powder (Figure 6.11 a). Similar observations as discussed 
in section 6.3.5.1 were found for proliposomes before freeze drying, BDP, PM of 
proliposomes and BDP, empty proliposomes and proliposomes with BDP. The freeze 
dried proliposomes lost their crystallinity after freeze drying, thus, becoming semi-
crystalline. BDP being in very small quantity as compared to other components of the 
formulation is not visible in the proliposomal peaks. Being less crystalline may help 
freeze dried proliposomes to easily reconstitute on hydration (Andronis et al., 1997). 
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As observed in Figure 6.8, SEM of freeze dried particles revealed porous and flake-like 
needle shaped particles. Porous materials are amorphous as the particles are not in 
perfect repetitive order. Hence, an XRD study of freeze drying is supported by SEM 
images.  
 
Figure 6.11 XRD of (a) Mannitol (b) Proliposomes before FD (c) BDP (d) PM of proliposomes 
and BDP after FD (e) Empty Proliposome after FD (f) proliposome with BDP after FD 
 
Similar changes in crystallinity were observed with prosurfactosomes after freeze 
drying as observed with proliposomes as shown in Figure 6.12. Crystallinity of 
prosurfactosomes decreased upon freeze drying, thus, increasing their dissolution ability 
and decreasing their stability.  
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Figure 6.12 XRD of (a) Mannitol (b) Prosurfactosomes before FD (c) BDP (d) PM of prosurfactosomes 
and BDP after FD (e) Empty Prosurfactosomes after FD (f) Prosurfactosomes with BDP after FD. 
 
Hence, From XRD analysis it can be concluded that spray drying and freeze drying 
reduces the crystallinity of proliposomes and prosurfactosomes, thus making them semi-
crystalline. They tend to become more amorphous. Mannitol being the most abundant 
material in the formulations, all the peaks of proliposomes and prosurfactosomes 
resembled the peaks of mannitol. 
6.3.6. Stability studies of proliposomes and prosurfactosomes 
for 12 weeks 
The stability of proliposomes and prosurfactosomes were studied. For this study the 
vesicles were stored in different environment like 40ºC (in incubator), room temperature 
and 2-8°C. The important factors determining the stability of vesicles like pH, VMD, 
span, zeta potential and entrapment were studied. The comparison between 
proliposomes and prosurfactosomes was made to determine the best formulation and 
condition in terms of formulation stability. Readings were taken every 2 weeks for a 
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period of 12 weeks. The proliposomes and prosurfactosomes were hydrated before the 
experiment to form liposomes and surfactosomes respectively. 
This is preliminary research where only one reading of each week was taken. To 
confirm the result and to perform statistical analysis three readings for all vesicles and 
for all factors must be considered. Week 0 represents the freshly prepared samples. 
6.3.6.1. pH of liposomes and surfactosomes generated from 
proliposomes and prosurfactosomes respectively over 12 weeks 
To study the stability of proliposomes and prosurfactosomes in terms of pH, analysis of 
its acidity and basicity was performed. In Figure 6.13, the pH behaviour of 
proliposomes in different environments is shown. It was observed that in the initial 4 
weeks, the pH of liposomes made from proliposomes was neutral (between 6.5 and 7.5). 
From week 6 the acidity of liposomes started to increase (i.e. pH decreased). It was 
observed that liposomes stored in 40ºC were becoming acidic in a rapid rate. At the end 
of 12 weeks the pH decreased to 4.1. By contrast, for liposomes stored in room 
temperature (around 18-22ºC) the pH was 4.3. It was also observed that liposomes 
stored at 2-8°C were becoming acidic in a relatively slow rate, since after 12 weeks the 
pH became 5.2. Liposomes stored at refrigerator were more stable than the liposomes 
stored in 40°C and room temperature. The decrease in pH of the liposomal dispersion is 
due to the hydrolysis of phospholipid to form free fatty acids and lysophospholipids 
(Tseng et al., 2007a, Ravi and Singh, 2012). Fatty acids produced made the formulation 
acidic on storage. This results show that liposomes kept in 2-8°C slowed the breakdown 
of phospholipids. Hence, from this preliminary study it can be concluded that 





Figure 6.13 pH of liposomes prepared from proliposomes stored in room temperature, 2-8°C 
(refrigerator) and in 40°C (incubator) for 12 weeks. 
 
In Figure 6.14, the pH behavior of prosurfactosomes stored in different environments is 
shown.  It was observed that in the initial 2 weeks the pH of surfactosomes made from 
prosurfactosomes was between 7.5 and 6.5. From week 4 it was observed that the 
acidity of surfactosomes started to increase. It was observed that liposomes stored in 
40ºC were becoming acidic in a rapid rate. Vesicles stored in room temperature 
followed it. At the end of 12 weeks the pH of surfactosomes stored in 40°C decreased to 
3.8. This was followed by surfactosomes stored at room temperature (around 18-25ºC) 
where the pH was 4.2. It was also observed that vesicles stored 2-8°C was becoming 
acidic in a relative slow rate. After 12 weeks the pH was 5.2. It behaved relatively better 
than the vesicles stored in 40°C and room temperature. This is due to the breakdown of 
phospholipid into its components: glycerol, fatty acids and phosphate group. Fatty acids 
produced made the formulation acidic on storage. This results show that vesicles kept in 
2-8°C slowed the breakdown of phospholipids. Similar results were obtained in another 
stability study of liposomes where the pH of the liposomes lowered with decrease in 
temperature (Berg, 2010). Hence, from this study it can be concluded that 
prosurfactosomes remained the best when stored in refrigerator at 5-6°C.  
Hence, from this preliminary study it can be concluded that proliposomes and 



















vesicles stored in room temperature and 40°C. Both formulations started to become 
acidic on storage.  
It was also observed that prosurfactosomes became more acidic than proliposomes 
when kept in the incubator at 40°C. To check this behaviour of phospholipids, the 
proliposomes and prosurfactosomes were placed at 40°C for 24 hours to check the pH. 
The pH of liposomes dropped from 7.53 to 5.11 whereas the pH of prosurfactosomes 
dropped from 7.38 to 3.45. Hence, this shows that proliposomes are more stable than 
prosurfactosomes in terms of pH when stored in 40°C. 
 
Figure 6.14 pH of surfactosomes prepared from prosurfactosomes stored in room temperature, 2-
8°C (refrigerator) and in 40°C (incubator) for 12 weeks 
 
6.3.6.2. VMD of liposomes and surfactosomes in 12 weeks 
To study another parameter of stability of proliposomes and prosurfactosomes VMD 
analysis was conducted. In Figure 6.15 the VMD of liposomes prepared after hydration 
of proliposomes stored in different environments like 40°C, room temperature and 2-
8°C were analysed. Except for week 4 and 6, the VMD of all vesicles was less than 
6µm which was similar to the VMD of the freshly prepared samples. Hence, the VMD 
of liposomes remained unchanged in the end of 12 weeks. Thus, from this study it can 
be concluded that proliposomes are stable in all three conditions for the period of 12 



















Figure 6.15 VMD (size) of liposomes prepared from proliposomes stored in room temperature, 2-8°C 
(refrigerator) and in 40°C (incubator) for 12 weeks. 
 
In Figure 6.16 the VMD of surfactosomes prepared from prosurfactosomes in different 
environments like 40°C, room temperature and 2-8°C was analysed. It was observed 
that VMD of vesicle stored at room temperature started has increased from week 4. The 
trend for particle size increase for 2-8°C was less than that of vesicles stored at room 
temperature. VMD of vesicles became more than 10µm by this time for those stored in 
room temperature. By the end of 12 weeks, the VMD of surfactosomes at room 
temperature reached 19µm and for those stored at 40ºC the VMD was as large as 
21.1µm. It was also observed that surfactosomes stored in refrigerator were more stable 
and small in size than those stored in room temperature and 40°C as the size did not go 
beyond 13µm. However, the VMD of vesicles increased after on storage which is 
attributed to aggregation of vesicles due to their instability. Prosurfactosomes remains 
least unstable when they stored at 5-6°C. 
Hence, from this study it can be concluded that prosurfactosomes have more tendency 


























Figure 6.16 VMD (size) of surfactosomes prepared from prosurfactosomes stored in room 
temperature, 2-8°C (refrigerator) and in 40°C (incubator) for 12 weeks 
 
6.3.6.3. Span of liposomes and surfactosomes after 12 weeks of storage 
at different temperatures 
Span of surfactosomes and liposomes was determined in all 3 environments: Room 
temperature, 2-8°C and 40ºC. The span of proliposomes stored in all three environments 
were analysed as shown in Figure 6.17. It was observed that the span of vesicles started 
to increase after week 2. The span of proliposomes stored in 40°C increased rapidly 
from week 8 which was followed by liposomes in room temperature. The span of 
proliposomes stored in 2-8°C increased gradually till week 12. The span of liposomes 
by the end of week 12 increased largely as compared to week 0. The span of 
proliposomes stored in room temperature was 3.22. Proliposomes stored in 40ºC had a 
span value of 4.9 and of that stored in 2-8°C had a value of 3.88. Hence, from this 
preliminary study it can be concluded that proliposomes stored in 40°C had the largest 
span in 12 weeks. The span kept increasing due the tendency of liposomes to aggregate 




















Figure 6.17 . Span of liposomes prepared from proliposomes stored in room temperature, 2-
8°C (refrigerator) and in 40°C (incubator) for 12 weeks 
 
The span of surfactosomes prepared from prosurfactosomes was studied as shown in 
Figure 6.18. It was observed that span of vesicles increased after week 0. The span of 
surfactosome was high even in week 0 for prosurfactosomes stored in 40ºC. It was 
observed that from week 4 the span of vesicles increased to more than 5 in all 3 
environments. This indicates the instability of surfactosomes on being stored more than 
4 weeks and this is much higher than the span of liposomes. Similar results were 
observed in the previous studies in chapter 4 section 4.3.4 where surfactosomes showed 
higher span with more vesicular aggregation.  
Hence, it can be concluded that proliposomes produce more stable vesicles with lower 
span than prosurfactosomes on being stored for a long time. Uniformity in vesicles was 



















Figure 6.18 Span of surfactosomes prepared from prosurfactosomes stored in room temperature, 
2-8°C (refrigerator) and in 40°C (incubator) for 12 weeks 
 
6.3.6.4.  Zeta potential of liposomes and surfactosomes in 12 weeks 
The zeta potential (surface charge) of liposomes and surfactosomes prepared from 
proliposomes and prosurfactosomes respectively were analysed for stability by 
considering the zeta potential measurements. Proliposomes stored in room temperature, 
2-8°C and 40ºC for charge analysis as shown in Figure 6.19.  It was observed that zeta 
potential of vesicle increased with time when compared to that measured for the freshly 
prepared samples (i.e. week 0). The surface charge of liposomes increased more when 
the storage temperature was 40ºC than at room temperature and 5-6°C. By the end of 12 
weeks it was observed that the charge of liposomes stored in room temperature was -
9mV, liposomes stored in 2-8°C was -7.1mV whereas liposomes stored in 40ºC were -
13.9mV. Hence, from this study it can be concluded that liposome become least stable 
with its charge in 40°C and most stable in refrigerator at 5-6°C. In a study by Plessis et 
al.it is stated that the zeta potential alone cannot prove the instability of a vesicle and 
VMD should always be considered (Berg, 2010). He also concluded that liposomal 


















Figure 6.19 Zeta potential of liposomes prepared from proliposomes stored in room temperature, 
2-8°C(refrigerator) and in 40°C (incubator) for 12 weeks 
 
The charge of surfactosomes prepared from prosurfactosomes were analysed as shown 
in Figure 6.20. It was observed that the charge of surfactosomes from week 0 was more 
than that of liposomes in all three environments: room temperature, 2-8°C and 40°C. It 
was also observed that the surface charge of surfactosomes has changed throughout 12 
weeks. The surface charge gradually increased and by the end of 12 weeks, 
prosurfactosomes stored in 40°C had a zeta potential value of –17.6mV, 
prosurfactosomes stored in room temperature had a measurement of -14.32mV and that 
stored in 2-8°C had a value of -13.7mV. Hence, the zeta potential of surfactosomes has 
increased with time and with increasing the storage temperature. 
Hence, surfactosomes had more intensive surface charge than liposomes as discussed in 
chapter 4 section 4.3.5. It is stated that higher zeta potential indicates a more stable 
suspension and lower value indicates colloid instability which could lead to aggregation 
of vesicles (Ma et al., 2011). The negatively charges vesicles can easily bind to the 
cationic sites of the cell in the body in the form of cluster for absorption (Henriksen et 
al., 1994). For both type of vesicles the instability in terms of surface charge increases 



























Figure 6.20 Zeta potential of surfactosomes prepared from prosurfactosomes stored in room 
temperature, 2-8°C (refrigerator) and in 40°C (incubator) for 12 weeks 
 
6.3.6.5. Entrapment of BDP in proliposomes and prosurfactosomes 
over 12 weeks of storage 
The entrapment of BDP in proliposomes and prosurfactosomes for a period of 12 weeks 
was analysed. They were stored in three different environments: Room temperature, 2-
8°C and 40ºC. In Figure 6.21, the entrapment of BDP in liposomes prepared from 
proliposomes for a period of 12 weeks was analysed. It was observed that the 
entrapment of drug decreased with time. The leakage of drug was maximum in 
proliposomes stored in 40°C and was minimum in proliposome stored in 5-6°C. The 
initial entrapment of drug in liposome was 53%. By the end of 12 weeks, the 
entrapment of BDP in proliposomes stored in room temperature was 35%, stored in 
40ºC was 30% while that stored in 2-8°C was 40.8%. Hence, drug retention in 
proliposomes was maximised when proliposomes were stored at fridge temperature (i.e. 
5-6°C) and was least when storage was done at 40°C.It has been previously reported 
that liposomes are more stable when stared in 4-5°C as compared to any other 
temperature (Gregory, 2006) Muppidi et al also studied that liposomes stored at 4°C 
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increase in stability is due to the decrease in fatty acid breakdown at lower temperatures 
(HERNÁNDEZ‐CASELLES et al., 1990). There is inhibition of peroxide formation 
(oxidation) at low temperatures, thus, increasing liposome stability. 
  
 
Figure 6.21 BDP Entrapment% of liposomes prepared from proliposomes stored in room 
temperature, 2-8°C (refrigerator) and in 40°C (incubator) for 12 weeks 
 
The entrapment of BDP in surfactosomes prepared from prosurfactosomes for a period 
of 12 weeks was analysed as shown in Figure 6.22. It was observed that the entrapment 
of drug decreased with time. The leakage of drug was most in prosurfactosomes stored 
in 40°C and was minimum in prosurfactosome stored in 5-6°C. The initial entrapment 
of drug in surfactosome was 42%. By the end of 12 weeks, the entrapment of BDP in 
surfactosomes prepared from prosurfactosomes stored in room temperature was 23.8%, 
stored in 40ºC was 20.2% while that stored in 2-8°C was 29.3%. Hence, drug retention 
in prosurfactosomes was at maximum when formulation was kept in the refrigerator 
(i.e. 5-6°C) and minimum in 40°C. The leakage of BDP is due to the hydrolysis of 
phospholipids to free fatty acids and lysophospholipids. This can possibly disturb the 
phospholipid bilayer structure and may lead to leakage of encapsulated material (Tseng 
et al., 2007a, Ravi and Singh, 2012). 
Hence, it can be concluded that the stability of proliposomes and prosurfactosomes was 





























Figure 6.22 BDP entrapment % of surfactosomes prepared from prosurfactosomes stored in 
room temperature, 2-8°C (refrigerator) and in 40°C (incubator) for 12 weeks 
 
6.4. Conclusion 
In this chapter, the stability of proliposomes and prosurfactosomes were analysed using 
different methods. The VMD, span, charge and entrapment of BDP of these vesicles 
were analysed.  
After the study of spray drying, it can be concluded that there was no significant 
difference between the VMD and span of liposomes as compared to those of 
surfactosomes. However, the zeta potential of surfactosomes was significantly greater 
than that of liposomes after spray drying. It was also observed that there was no 
significant difference in the VMD and span of both the vesicles before and after spray 
drying. However, the zeta potential of both the vesicles increased significantly after 
spray drying.  It was found that there was no significant difference between the 
entrapment of BDP in liposomes and surfactosomes. This concludes that surfactosomes 
were as stable as liposomes after facing the heat and stress generated during spray 
drying. The mass output of surfactosomes after spray drying was slight but not 
significantly greater than liposomes. Hence, it can be concluded that both liposomes and 
surfactosomes are equally stable to spray drying. Thus, spray drying can be preferred to 
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After the study of freeze drying it can be concluded that the VMD and span of 
surfactosomes was significantly larger than the VMD and span of liposomes. The VMD 
and span of surfactosomes increased significantly after freeze drying as compared to 
that before spray drying. However, there was no significant difference between the 
VMD and span of liposomes before and after freeze drying. It was also observed that 
there was significantly more loss of BDP from surfactosomes than in liposomes after 
freeze drying. This concludes that liposomes are more stable to freeze drying than 
surfactosomes.  
The SEM studies revealed that mannitol lost its porosity after being coated by SPC and 
cholesterol in proliposomes and prosurfactosomes. Structure of prosurfactosomes was 
smoother than proliposomes. SEM revealed that after spray drying, proliposomes and 
prosurfactosomes were reduced in size and became spherical.  They formed 
homogenous microspheres with reduced surface area.  It was also observed from SEM 
that freeze drying produced small and needle shaped porous proliposomes and 
prosurfactosomes.  The flake-like structure of proliposome and prosurfactosome may be 
due to the vestige of sublimation of ice in the drying stage. 
X-ray diffraction (XRD) concluded that before spray drying and freeze drying 
proliposomes and prosurfactosomes were crystalline in nature. Mannitol is crystalline 
and dominated the peaks of proliposomes and prosurfactosomes as it forms the major 
component. BDP is semi-crystalline and being the minor component does not form the 
peak in XRD graph of proliposomes and prosurfactosomes.  Spray drying of 
proliposomes and prosurfactosomes decreased its crystallinity. Semi-crystalline 
structure was signified by broad and less distinct peaks and amorphous hump observed 
in the XRD. Rapid solidification via rapid solvent removals also leads to increase in 
amorphous nature. Similar observation was done for prosurfactosomes. Freeze dryer 
was also observed to decrease the crystallinity of proliposomes and prosurfactosomes. 
Porous materials as found after freeze drying are amorphous as the particles are not in 
perfect repetitive order. Similar observation was found for prosurfactosomes after freeze 
drying.  Hence, it can be concluded that spray drying and freeze drying decreases the 
crystallinity of proliposomes and prosurfactosomes, thus, making them semi-crystalline. 
Preliminary stability studies were performed for 12 weeks where the proliposomes and 
prosurfactosomes were stored in 40ºC (in incubator), room temperature and 2-8°C (in 
refrigerator). PH studies revealed that proliposomes and prosurfactosomes became 
acidic on storage after hydration. They were most stable in 2-8°C and least stable in 
40°C. This may be due to the breakdown of phospholipid into glycerol and fatty acid on 
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storage. It was also observed that proliposomes were more stable that prosurfactosomes 
when stored in 40°C. Study of VMD concludes that proliposomes on hydration are 
stable on all three conditions after 12 weeks. However, prosurfactosomes on hydration 
started to increase in VMD due to aggregation after 4 weeks. Prosurfactosome remain 
most stable when stored in 5-6°C. Study of span concluded that liposomes and 
surfactosomes formed from proliposomes and prosurfactosomes respectively were more 
stable when stored in 2-8°C and least stable in 40°C. It was also concluded that 
proliposomes maintained more uniformity than prosurfactosomes when hydrated after 
12 weeks. Zeta potential studies revealed similar results of being stable in 5-6°C. 
Prosurfactosomes increased their charge more than liposomes in the end of 12 weeks, 
thus, being less stable. The preliminary studies can also conclude that the stability of 
proliposomes and prosurfactosomes is best in 2-8°Cand worst in 40°C among the three 
environments used. Proliposomes were more stable that prosurfactosomes in all three 
conditions. Overall it can be concluded that proliposomes and prosurfactosomes were 
most stable in 2-8°C of refrigerator and least stable in 40°C of incubator. Proliposomes 
were more stable than prosurfactosomes in terms of maintaining pH, VMD, span, zeta 
potential and BDP entrapment in all three conditions. 
Hence this chapter concludes the stability of proliposomes and prosurfactosomes when 
spray dried, freeze dried and when stored in 2-8°C, room temperature and 40°C for 12 
weeks. SEM also reveals the structure of proliposomes and prosurfactosomes before 
and after spray drying and freeze drying and XRD reveals the degree of crystallinity of 
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The aim of this study was to investigate the efficiency of surfactant-enriched vesicles 
(i.e.surfactosomes) compared to conventional liposomes for potential use in pulmonary 
delivery via nebulisation. The properties of surfactosomes were investigated in terms of 
their drug delivery efficiency and stability. Salbutamol sulphate (SBS) and 
beclometasone dipropionate (BDP) were used as the model hydrophilic and 
hydrophobic drug respectively. Soya phosphotidylcholine (SPC) was used as the 
phospholipid with or without cholesterol to prepare liposomes and surfactosomes. The 
four formulations used in this study were 
Proliposomes with cholesterol (1:1 molar ratio SPC to cholesterol) 
Proliposomes without cholesterol 
Prosurfactosomes with cholesterol (1:1 molar ratio SPC to cholesterol) 
Prosurfactosomes without cholesterol 
Thin film method and proliposomes technology were both used to prepare liposomes 
and surfactosomes in this work. The vesicles’ efficiency to act as carriers for delivery of 
drug via nebulisation along with its stability was initially tested using a mini-extruded 
with polycarbonate membranes 5µm, 2µm, 1µm and 0.4µm. The amount of drug 
retained by all four formulations after extrusion was studied. These hydrated 
formulations were nebulised using Aeroneb Pro (vibrating-mesh), Beurer iH50 
(vibrating-mesh) and PARI LC plus (air-jet) nebulisers. Effect of cholesterol on 
liposomes and surfactosomes for drug entrapment and retention was also studied. 
Finally both liposome and surfactosome formulations were compared for their stability 
in different conditions like spray drying,  freeze drying and when stored for 3 months at 
different temperatures room temperature, 40°C (in oven) and 2-8°C(refrigerator). The 
structure of proliposomes and prosurfactosomes were also studied and visualised using 
SEM, and X-Ray diffraction. TEM was used to visualise structure of liposomes and 
surfactosomes. The work focused on finding the best formulation for pulmonary drug 
delivery and to investigate if surfactosomes are better than liposomes in sustaining the 




7.1. Comparison between liposomes and surfactosomes 
formed using thin film method for entrapment of drug 
before and after extrusion 
In Chapter 3, liposomes and surfactosomes with or without cholesterol were prepared 
using the thin film method. SBS and BDP were used as model drugs. They were studied 
for their size (VMD), span (size distribution) and entrapment efficiencies. They were 
even studied for their drug retention capacities on being extruded with different 
polycarbonate membranes like 5µm, 2µm, 1µm and 0.4µm. Effect of excessive 
extrusion (51 times) using 1µm polycarbonate membrane on all four vesicles were 
studied. There was a comparison between un-extruded vesicles and previously extruded 
vesicles with 1µm. 
Initially the VMD and span of vesicles were observed when they were prepared using 
two organic solvents: chloroform and ethanol. From the study it was concluded that 
evaporation of chloroform was better than ethanol since alcohol may lead to difficulty 
in hydration, thus, leading to aggregation or fusion of the vesicles. This resulted in 
vesicles with large size which are inappropriate for pulmonary drug delivery via 
nebulisation. Hence, chloroform was chosen for subsequent studies as it could be more 
appropriate for generating thin films that can be hydrated more readily to form less 
aggregated vesicles. All vesicles had VMD and span which were desirable to be used in 
pulmonary drug delivery.  
The entrapment studies using the hydrophilic drug SBS showed that all four 
formulations entrapped similar amount of SBS with vesicles having cholesterol being 
slightly better that those without cholesterol. This shows that cholesterol is an important 
component in liposomes and surfactosomes. Similarly the loading efficiencies were 
similar to all four formulations. However it was observed that liposomes were better 
than surfactosomes in retaining SBS when being extruded through all sizes of the 
polycarbonate membranes (5µm, 2µm, 1µm and 0.4µm). For hydrophilic drugs like 
SBS, liposomes are more resistant to drug leakage than surfactosomes when shearing 
via extrusion was applied. When the vesicles were extruded 51 times using the mini-
extruder with 1µm polycarbonate membrane, it was found that smaller vesicles tend to 




The entrapment studies of the hydrophobic drug BDP showed that similar to SBS there 
was no significant difference in the initial entrapment of BDP in all four formulations.  
Even the loading efficiencies were similar with no significant difference between the 
formulations. On extrusion through polycarbonate membranes it was observed that 
vesicles made using any of the four formulations have retained considerable proportions 
of BDP. It was noticed that as the pore size of polycarbonate membranes used was 
smaller, the drug entrapment was decreased. Liposomes with cholesterol retained 
greater drug proportions than liposomes made without cholesterol, indicating that 
cholesterol plays an important role in the stability of liposomes. However, for 
surfactosomes, cholesterol did not have an effect as surfactant was the dominating 
factor in making it less stable.  On being extruded 51 times with mini extruder using 
1µm polycarbonate membrane, it was observed that vesicles with cholesterol retain 
more BDP and liposomes are more stable than surfactosomes. It was also found that 
smaller vesicles tend to retain more drug than larger vesicles after extensive extrusion. 
In this study, chloroform was found to be a better organic solvent than ethanol for 
preparing liposomes and surfactosomes using thin film method. Ethanol made vesicles 
to aggregate when it was used as the organic solvent. For hydrophilic drug like SBS 
liposomes are more stable than surfactosomes while for hydrophobic drug like BDP 
both liposomes and surfactosomes are good with liposomes being slightly better. It was 
also concluded that cholesterol is an important component to be incorporated in the 
vesicular formulation as it increases formulation stability. Liposomes are better than 
surfactosomes for retaining greater drug proportions (SBS and BDP) after excessive 
extrusion (51 cycles). Smaller vesicles with size 1µm retained higher proportions of 
drugs after undergoing extensive extrusion than larger vesicles with size 4-7µm 
7.2. Entrapment studies of SBS and BDP for 
proliposomes and prosurfactosomes using particulate 
based proliposome technology 
In Chapter 4, liposomes and surfactosomes were prepared using particulate based 
proliposome technology. SBS and BDP were used as the model hydrophilic and 
hydrophobic drug respectively and mannitol was used as the carbohydrate carrier. 
Proliposomes and prosurfactosomes were hydrated to form liposomes and 
surfactosomes respectively. The vesicles were compared for size (VMD), size 
distribution (span), zeta potential (surface charge) and drug entrapment. Drug retention 
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on extrusion with polycarbonate membranes 5µm and 2µm was also studied. Effect of 
cholesterol concentration on drug entrapment and retention by liposomes and 
surfactosomes was also considered.  
The studies revealed a similar VMD and span for liposomes and surfactosomes 
regardless of cholesterol incorporation. However, it was observed that zeta potential of 
surfactosomes was more negative than that of liposomes. This is may be due to the 
presence of Tween 80 along with its impurities like linoleic, palmitic and stearic acids 
in the surfactosomal formulation. These acids may tend to dissociate on the surface of 
vesicles, thus, giving a negative surface charge. 
The entrapment of hydrophilic drug SBS was very low in all four formulations. It was 
also noticed that vesicles with cholesterol retained higher drug proportions than vesicles 
including no cholesterol. Hence, cholesterol is an important component in liposomes 
and surfactosomes for entrapping hydrophilic drugs like SBS. Proliposome technology 
unlike thin film method was not appropriate for the entrapment of hydrophilic drug like 
SBS. Hence, no extrusion was carried out using SBS formulations.  
The entrapment of the hydrophobic drug BDP was studied using proliposomes and 
prosurfactosomes. For both type of formulation (i.e. surfactosomes and liposomes), 3 
different formulations were compared: vesicles with only SPC, vesicles with SPC and 
cholesterol (2:1) and vesicles with SPC and cholesterol (1:1). For liposomes, 
formulation without cholesterol has shown to provide the highest BDP entrapment. This 
proves that due to the similar structure of BDP and cholesterol there is a competition for 
the incorporation of BDP in the lipid bilayers, thus, minimising the BDP entrapment. 
Increase in the concentration of cholesterol decreased the BDP entrapment. For 
surfactosomes, formulations with no cholesterol and those with low cholesterol 
concentration (i.e. SPC and cholesterol; 2:1) were better than vesicles with high 
cholesterol concentration at entrapping greater proportions of BDP. This may be due to 
the low competition between BDP and cholesterol to be incorporated in the bilayer and 
low displacement of BDP by cholesterol when low cholesterol concentrations were 
incorporated in the formulation. The low entrapment may also be due to the “burst 
effect” shown by these vesicles. It can also be concluded that there was no significant 
difference between the entrapment of BDP by liposomes and surfactosomes prepared by 
proliposome technology in formulations with only SPC and those with 1:1 SPC to 
cholesterol ratio. However, surfactosomes entrapped significantly more than liposomes 
in formulations with 2:1 SPC to cholesterol ratio.  
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It was also realised that when extrusion was performed using 5µm and 2µm 
polycarbonate membranes, liposomes and surfactosomes with or without cholesterol 
retained similar proportions of BDP. However, vesicles with cholesterol retained 
slightly lower BDP that those without cholesterol. This may be due to the excessive 
rigidity provided by cholesterol; hence making it difficult for BDP to locate within the 
bilayers. With regard to BDP entrapment, there was no significant difference in all three 
formulations of liposomes and surfactosomes before and after extrusion through 5µm 
and 2µm polycarbonate membranes. This indicates that for BDP retention with 
proliposome technology is good in all formulations with different concentrations of 
cholesterol in both proliposomes and prosurfactosomes. 
TEM studies revealed that liposomes and surfactosomes prepared from proliposomes 
and prosurfactosomes respectively formed unilamellar vesicles on hydration.  
Hence from this chapter it can be concluded that VMD and span of all formulations 
were similar whereas the zeta potential of surfactosomes were more negative than that 
of liposomes. It was also noticed that with particulate based proliposome technology 
there was very low entrapment of the hydrophilic drug SBS. Hence, no further extrusion 
studies were performed.  For entrapment of the hydrophobic drug BDP using particulate 
based proliposome technology, proliposomes with only SPC was the best formulation. 
Inclusion of cholesterol decreased the entrapment of BDP in liposomes. 
Prosurfactosomes with low cholesterol concentration (SPC to cholesterol 2:1) was best 
in entrapping BDP with low standard deviation as compared to surfactosome with no 
cholesterol at all or with high cholesterol concentration (SPC to cholesterol 1:1).  
7.3. Delivery and retention of BDP by liposomes and 
surfactosomes when delivered via nebulisation 
In chapter 5, liposomes and surfactosomes with and without cholesterol were used to 
deliver BDP to twin impinger via nebulisers. Aeroneb Pro (vibrating-mesh), Beurer 
iH50 (vibrating-mesh) and PARI LC sprint (air-jet) nebulisers were used for this 
purpose The twin impinger was used as an in vitro model where the upper stage may 
collect the fraction of aerosols that are likely to deposit in the upper respiratory tract 
while the lower stage is known to collect the “respirable” fraction of the aerosol (i.e. the 
fraction that is likely to deposit in the lower respiratory tract). The delivery and 
retention of BDP in the four formulations were studied in both stages of the impinger 
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using the three aforementioned nebulisers. VMD, span and zeta potential of the vesicles 
before and after nebulisation were also studied from samples collected from the 
impinger following nebulisation.  
From this study it was observed that the VMD and span of liposomes and surfactosomes 
with and without cholesterol decreased after nebulisation. Decrease in VMD suggests 
that the vesicles were fragmented due to the extrusion offered by the vibrating mesh 
nebulisers and the shear forces provided by the air jet nebuliser.  The decrease in span 
suggests the decrease in uniformity of vesicles after nebulisation (i.e. the narrower size 
distribution). It was found that zeta potential of all vesicles after nebulisation were 
similar irrespective of the formulation, nebuliser used and stage of the impinger. This 
indicates that the vesicles may have similar surface properties after being delivered by 
nebulisation, if these formulations would be considered for in vivo investigations. It was 
also seen that the vesicles became more negatively charged after nebulisation using all 
three nebulisers.  
On studying the initial entrapment of BDP on all four formulations, it was observed that 
vesicles without cholesterol entrapped significantly greater BDP than vesicles with 
cholesterol. This was due to the competition between BDP and cholesterol to be 
incorporated into the vesicular bilayers because of the similar structure of BDP and 
cholesterol. After this study it was concluded that surfactosomes without cholesterol 
was the best formulation to be delivered via all three nebulisers. This is due to the 
elasticity of the surfactosomes that has maximised the BDP proportioned delivered 
without considerable leakage. These vesicles fragmented less in the presence of forces 
generated by the nebulisers compared to other vesicles studied. The absence of 
cholesterol in the formulation decreased the rigidity and increased the flexibility, thus, 
delivering maximum BDP.  
After concluding surfactosomes without cholesterol to be the best formulation to deliver 
maximum BDP using all three nebulisers, the best nebuliser suitable to deliver the BDP 
via other 3 formulations was also analysed. It was concluded that for liposomes with 
and without cholesterol, Beurer iH50 was the most suitable nebuliser in this study. This 
was because the Beurer iH50 device delivered maximum BDP to both stages of the twin 
impinger using liposomes. For surfactosomes with cholesterol PARI LC sprint air jet 
nebuliser was proved to better than the other two devices at delivering BDP to lower 
stage of impinger.  
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This study also proved that using all three nebulisers, higher BDP proportions were 
delivered to the lower impinger as compared to the upper impinger. However, the air jet 
nebuliser delivered significantly greater BDP proportions than both vibrating mesh 
nebulisers to the lower impinger stage.  
The BDP retention studies concluded that vesicles with cholesterol retained less BDP 
than vesicles without cholesterol when nebulised via vibrating mesh nebulisers. This 
was possibly due to the competition between BDP and cholesterol to be incorporated in 
the vesicular bilayer. This displaced more BDP during extrusion via nebuliser, thus, 
retaining lower drug proportions in the vesicles having cholesterol. However, in air jet 
nebuliser, surfactosomes without cholesterol retained the least BDP after nebulisation. 
This was possibly due to the excessive fragmentation of this type of vesicles due to the 
shear force generated by the air jet nebuliser. Absence of cholesterol and presence of 
surfactant made the vesicles less stable, thus, increasing BDP leakage.  
On analysing the aerosol VMD generated by all three nebulisers it was concluded that 
the nebulisers generated aerosols with larger VMD than liposomes and surfactosomes 
regardless of cholesterol incorporation. This indicates that the vesicles can be 
incorporated in the aerosols with least fragmentation, thus, leading to less BDP leakage. 
Thus, this study helped to conclude the best formulation of all four formulation studied 
in this work to be used for maximum delivery of BDP via nebulisation. The 
formulations with surfactosomes were concluded to be ultradeformable in this study as 
it delivered maximum drug with less leakage. It also helped to conclude the most 
suitable nebuliser among the 3 used, for all four formulations and to deliver maximum 
BDP twin impinger representing the upper and lower respiratory tract. 
7.4. Characterisation of proliposomes and 
prosurfactosomes for stability 
In chapter 6, the stability of liposomes and surfactosomes prepared from proliposomes 
and prosurfactosomes respectively were studied.  
On studying the effect of spray drying on liposomes and surfactosomes, it was observed 
that the VMD and span of the vesicles and initial entrapment of the drug was similar for 
vesicles before spray drying and those after the drying was conducted. However, 
surfactosomes had higher zeta potential values than liposomes. After spray dying, there 
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was no difference in their VMD, span ad BDP entrapment and was similar to that of 
before spray drying. This shows that surfactosomes were as stable as liposomes to spray 
dying.  
On studying the effect of freeze drying, it was found that the VMD and span of 
surfactosome increased significantly whereas liposomes had similar VMD and span. 
BDP leakage was significantly more in surfactosomes compared to liposomes, 
indicating liposomes are more stable to freeze drying than surfactosomes. 
After SEM studies, it was seen that mannitol lost its porosity after being coated by SPC 
and cholesterol. After spray drying, proliposomes and prosurfactosomes were reduced 
in size and became porous microspheres. After freeze drying, they became very small 
needle shaped and had flake-like porous structures. It was also observed that 
prosurfactosomes apparently had slightly smoother surface than proliposomes, possibly 
due to the presence of the Tween 80 (surfactant) in prosurfactosomes. 
On studying the X-ray diffraction patterns, it was found that proliposomes and 
prosurfactosomes were more crystalline before spray drying and freeze drying. The 
crystallinity was dominated by mannitol as they formed distinct peaks. It was found that 
after spray drying proliposomes and prosurfactosomes became semi-crystalline (i.e. the 
amorphous content of the powders increased). This was shown by the amorphous hump 
and broad less distinct peaks. Similar observation was made after freeze drying which 
led to a decrease in the crystallinity of the formulations.  
The stability of proliposomes and prosurfactosomes were studied over 12 weeks where 
the samples were stored at 2-8°C (in refrigerator), room temperature and 40°C (in 
incubator). On studying the pH it was observed that the pH of both liposomes and 
surfactosomes decreased (became acidic) with time and 40°C was the most 
unfavourable temperature whilst 2-8°C was the most favorable.  On studying the VMD 
it was observed that proliposomes were more stable than prosurfactosomes in all three 
conditions. The VMD of surfactosomes made from prosurfactosomes increased after 4 
weeks whereas for liposomes made from proliposomes the size measurements remained 
consistent. On studying the span it was observed that the span of liposomes and 
surfactosomes prepared from hydration of proliposomes and prosurfactosomes 
exhibited the maximum increase at 40°C and minimum increase at 5-6°C.  However, it 
was demonstrated that proliposomes were more stable than prosurfactosomes in all 
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three temperatures investigated. Zeta potential studies revealed similar results of being 
stable in 5-6°C. Prosurfactosomes increased their charge more than liposomes towards 
the end of the 12 week period of investigation, thus, being less stable. These stability 
studies can also reveal that the stability of proliposomes and prosurfactosomes was at 
best at the fridge temperature (5-6°C) and exhibited the worst stability at 40°C. For each 
temperature, proliposomes were more stable than prosurfactosomes. However, the 
stability was studied over 12 weeks was only a preliminary study as the experiment was 
conducted only once. The experiment should be repeated at least 2 more times to 
validate the above results.  
7.5. Study limitations and future work 
In this study the characteristics of surfactosomes have been evaluated and compared to 
conventional liposomes. The efficiency of the vesicles at retaining SBS and BDP after 
extrusion and delivery of BDP via nebulisation was also studied. However, this study 
has many scopes to be improved and further testing and experiments are required to 
formulate a best formulation to deliver hydrophilic and hydrophobic drug to the 
pulmonary system.  
7.5.1. Use of different surfactants 
In this study Tween 80 was used as the primary surfactant. However, surfactosomes can 
be made using other Tw eens as well as Spans. On using other surfactants with different 
HLB values, there is a possibility of formulating a better surfactosome with high drug 
entrapment.  
7.5.2. Use of different carbohydrate carriers 
In this study mannitol was used as the model carrier in formulating particulate based 
proliposomes and prosurfactosomes. There are many other carriers available like 
sucrose, sorbitol and lactose. Formulations with these carriers may lead to different 
entrapment efficiencies of BDP and SBS along with their nebulisation efficiencies. 
Hence, the experiment can be repeated with other carbohydrate to validate the 





7.5.3. Use of different phospholipids 
In this work, soya phosphotidylcholine (SPC) was the primary phospholipid used. 
Different phospholipids like egg phosphotidylcholine (EPC), 
Dimyristoylphosphatidylcholine (DMPC) and dypalmitoylphosphatidylcholine (DPPC) 
are available and, thus, can be used to prepare liposomes and surfactosomes. 
7.5.4. PEGylation 
PEGylated liposomes have been studied extensively in drug delivery. PEGylation may 
increase the size and molecular weight of biomolecules, thus, improving their 
pharmacokinetics and pharmacodinamics, protecting molecules from enzymatic 
degradation, reducing renal clearance and limiting immunogenic reactions. Similarly, 
the surfactosomal formulation can be PEGylated and its effect can be studied. 
7.5.5. Use of different hydrophilic and hydrophobic drugs 
SBS and BDP were used as the model hydrophilic and hydrophobic drug respectively in 
this study. However, these findings can be validated by using different drugs available 
for treatment of diseases other than asthma. On studying the results with other 
hydrophilic and hydrophobic drug may give a clearer vision about the novel 
prosurfactosomes and their potential for pulmonary administration. 
7.5.6. In vivo studies 
In this study only in vitro experiments were conducted due to lack of time and the need 
for ethical approval if animals are to be used. However, a more robust conclusion on the 
efficiency and safety of the prosurfactosomes can be finalised only after conducting in 
vivo experiments using animal models and possibly human volunteers. 
7.5.7. Stability studies 
In this work the stability of proliposomes and prosurfactosomes was tested using freeze 
drying and spray drying. However, there can be more methods to compared and test 
stability of the formulations. The 12 weeks stability study in this work was conducted 
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